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ABSTRACT 
Polysaccharide conjugate vaccines are available to prevent disease caused by 
Neisseria meningitidis serogroups A, C, W and Y. Meningococcal vaccine efficacy is 
assessed in clinical trials using serum bactericidal assays (SBAs). Baby rabbit serum is 
usually used as the source of complement for SBAs as it lacks endogenous bactericidal 
activity compared to human serum. Previous studies have shown that SBA activities 
determined with rabbit (rSBA) and human (hSBA) complement correlate poorly, possibly 
due to different interactions between antibody subclasses and the complement source, 
and species-specific interaction of Neisseria meningitidis with complement regulators. 
The aim of this project was to investigate the mechanisms responsible for differential 
bactericidal activities of human and rabbit complement against Neisseria meningitidis. 
The serum concentration of polysaccharide-specific antibody subclasses was 
measured following vaccination with quadrivalent meningococcal polysaccharide 
vaccines; data showed that the concentration of polysaccharide-specific IgG1 antibody 
correlated most significantly with hSBA titres whereas the concentration of 
polysaccharide-specific IgM antibody correlated most significantly with rSBA titres. The 
interaction of human IgM and IgG subclasses with human and rabbit complement was 
compared at the level of C1q and C3 using both binding and functional assays. These 
data define important differences in the ability of human antibody subclasses to fix 
human and rabbit complement. Specifically, polysaccharide-specific IgM contributes 
significantly more to bactericidal titres in rSBAs compared to hSBAs. As a consequence, 
rSBAs produce misleadingly high titres in individuals with large IgM responses to 
vaccination. Using a series of pathway-specific inhibitors, it was shown that the 
alternative pathway contributes significantly more to the bactericidal activity of rabbit 
complement towards Neisseria meningitidis than human complement. 
This project provides significant insight into the difficulties and challenges 
associated with the interpretation of rSBA data, enhances the understanding of antibody 
responses to meningococcal vaccines and will support improvements in the 
development and testing of meningococcal vaccines. 
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Chapter One – Introduction 
 
1.1 Neisseria meningitidis 
Neisseria meningitidis is a species of Gram-negative, semi-commensal, diplococcus 
bacterium that can cause pathology in the nervous and circulatory systems of humans. Invasive 
infection can result in rapidly developing, life-threatening meningitis and meningococcemia. 
Serogroups of Neisseria meningitidis are categorised by different polysaccharides expressed on 
their outermost membrane. To date, 13 serogroups have been identified with A, B, C, W-135, X 
and Y responsible for the majority of infections throughout the world (Halperin et al., 2011). 
These serogroup-specific, carbohydrate structures are the antigens for many current 
meningococcal vaccines. 
Meningococcal vaccines are one of the most effective methods for the prevention of 
disease. Several correlates of protection have been developed to measure the efficacy of 
vaccination. Each is designed to assess the function of antibodies induced by vaccination in the 
clearance of Neisseria meningitidis. The serum bactericidal assay (SBA) measures the ability of 
antibodies in serum to kill Neisseria meningitidis through complement dependent cytotoxicity 
(CDC) (Goldschneider et al., 1969a; Goldschneider et al., 1969b; Maslanka et al., 1997). The 
dilution factor of an individual’s serum inhibiting 50% of bacterial growth is known as the SBA 
titre and titres greater than four are considered protective (Borrow et al., 2005). The SBA is the 
gold standard for the approval of new meningococcal vaccines (WHO, 1976, 2004, 2006). 
The SBA requires a source of complement from an individual lacking any pre-existing 
bactericidal activity towards each serogroup of bacteria being tested. High carriage rates and 
vaccination programmes often render finding a human donor of complement for SBAs fruitless 
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and standardisation difficult. As a result, baby rabbit serum (BRS) is recommended as the 
complement source to measure meningococcal vaccine efficacy (Maslanka et al., 1997). 
When a human donor is available, and comparisons between rabbit and human 
complement in SBAs have been made, titres correlate poorly questioning the validity of using 
rabbit serum as the source of complement (Findlow et al., 2009; Gill et al., 2011b). Variations in 
the ability of human antibody subclasses to activate human and rabbit complement and species-
specific differences in the interaction of complement regulatory proteins and Neisseria 
meningitidis are thought to be responsible for the poor correlation between SBAs with human 
(hSBA) and rabbit (rSBA) serum (Del Tordello et al., 2014; Gill et al., 2011b; Lewis et al., 2013; 
Santos et al., 2001; Zollinger and Mandrell, 1983). A much better understanding of the SBA and 
how titres correlate with protection against invasive disease is needed. 
 
1.1.1 Structure and Anatomy of Neisseria meningitidis 
 As previously stated, Neisseria meningitidis can be described as a Gram-negative, 
diplococcus bacterium. The descriptor ‘diplococcus’ refers to the spherical appearance of 
Neisseria meningitidis and that the bacterium typically forms pairs. Diplococcus is derived from 
the Greek ‘diploos’ meaning double and ‘kokkos’ meaning berry. The descriptor ‘Gram-negative’ 
refers to the fact that meningococci appear red (or pink) when Gram-stained as a result of their 
inability to retain the crystal violet dye used in this process. The counterstain safranin, which is 
also employed in this process, is responsible for the red colouring of the bacterium. Bacteria that 
retain the crystal violet dye and appear purple are known described as ‘Gram-positive’. 
 The technique of crystal violet dye to stain bacteria was developed by and subsequently 
named after the Danish bacteriologist Hans Christian Gram (1853–1938) in 1884 (Gram and 
Friedlaender, 1884). First devised as a method to make bacteria more visible in lung sections 
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from deceased pneumonia patients, Gram-staining is a commonly used technique to distinguish 
one type of bacteria from another and more specifically, the composition of their cell wall 
(Beveridge, 2001). 
 Typically, the cell wall of Gram-positive bacteria consists of a single lipid membrane 
surrounded by a thick peptidoglycan layer containing both lipoteichoic acid and teichoic acid. 
The cell wall of Gram-negative bacteria consists of a thin peptidoglycan layer contained within 
the periplasmic space which are sandwiched between an inner and outer lipid membrane 
(Beveridge, 1999; Shockman and Barren, 1983). This difference in the thickness of the 
peptidoglycan layer and the presence/composition of the outer lipid membrane of Gram-
negative bacteria is responsible for the ability of Gram-negative bacteria to leach the crystal 
violet dye while Gram-positive bacteria retain the crystal violet dye in the presence of ethanol 
(Salton, 1963). Additionally, the outer lipid membrane of Gram-negative bacteria often contains 
lipopolysaccharides, porins and other proteins (Beveridge, 1999). 
 As a Gram-negative bacterium, the outer lipid membrane of Neisseria meningitidis 
contains porins (such as PorA), lipoproteins (such as FHbp) and lipopolysaccharide, which can be 
released into the immediate environment by the bacteria in the form of ‘blebs’ (Devoe and 
Gilchrist, 1973; Jarva et al., 2005; Schneider et al., 2009). Often (and particularly by invasive 
isolates), Neisseria meningitidis can also express a polysaccharide capsule, which is antigenically 
unique to each serogroup and forms the basis of most current meningococcal vaccines (Armand 
et al., 1982; Artenstein et al., 1970; Gotschlich et al., 1972; Griffiss et al., 1981; Hankins et al., 
1982). Meningococcal polysaccharides are either homopolymer composed of mannosamine 
phosphate (serogroup A), glucosamine phosphate (serogroup X) or sialic acid (serogroup B and 
serogroup C) or heteropolymers composed of sialic acid with glucose (serogroup Y) or galactose 
(serogroup W135) (Bhattacharjee et al., 1975; Bundle et al., 1974; Lamb et al., 2005; Moore et 
al., 2007). Due to the similarities in structure of the polysaccharide capsules expressed by the 
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serogroups W135 and Y, cross-reactivity of serogroup-specific antibodies between these two 
serogroups has been shown (Reyes et al., 2013). The composition and size of these 
meningococcal polysaccharides have been shown to impact on their immunogenicity 
(Artenstein et al., 1970; Gotschlich et al., 1970; Gotschlich et al., 1972).  
 
1.1.2 Meningococcal Disease  
Neisseria meningitidis populates the mucosal lining of the nasopharynx of the host, 
often without causing noticeable pathology (Rake, 1934). Binding is mediated by type IV pili 
extruding from the surface of the bacterial body that express specificity for CD147 (Bernard et 
al., 2014). The major pilin PilE and the minor pilin PilV both interact directly with the second 
immunoglobulin domain of CD147. Neisserial type IV pili also bind and signal through the 
complement regulator membrane co-factor protein (MCP or CD46) and β2-adrenergic receptor 
(Coureuil et al., 2010; Källström et al., 1998). Carriage rates are high and range from 6% in infants 
to 25% in 18-19-year-olds after which rates decline to 8% in those aged 50 years and older 
(Christensen et al., 2010). Neisseria meningitidis is transmitted from person-to-person through 
respiratory and throat secretions. 
Meningitis is the inflammation of the meninges; a collective term for the dura mater, 
arachnoid, and pia mater membranes that surround the brain and spinal column. Once in the 
circulation, the bacterium colonises the meninges and cerebral spinal fluid (CSF) of the host. 
Subsequent inflammation increases the permeability of the blood-brain barrier (BBB) allowing 
entry of immune cells to combat the infection. The release of potent inflammatory cytokines by 
invading leukocytes and neutrophils into the CSF leads to an increase in intracranial pressure 
and ischemia (Sáez-Llorens and McCracken, 2003). 
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Typically, patients present with headaches, nausea, neck stiffness and fever (van de 
Beek et al., 2004). Only 22% of patients present with the characteristic purpura often associated 
with the disease. This purpura manifests from endotoxin release from lysed Neisseria 
meningitidis which activate clotting factors in the circulation leading to disseminated 
intravascular coagulation (DIC) (Colman et al., 1972). The resulting occlusion of peripheral blood 
vessels and subsequent ischemic tissue damage of skin and limbs may result in extensive scarring 
and amputation of the affected limb. Furthermore, the rapid depletion of circulating platelets 
and clotting factors increases the risk of haemorrhage (Levi and Ten Cate, 1999).  
If left unresolved, meningitis can lead to cardio-respiratory failure, seizures and death. 
Case fatality rates (CFR) for meningococcal disease average between 9-12% but can be as high 
as 50% with the addition of septicaemia. Around 20-25% of those patients who survive will 
develop a long-lasting morbidity. These morbidities commonly include seizures and epilepsy, the 
loss of hearing and sight, limb loss, and learning and behavioural difficulties in children (Sáez-
Llorens and McCracken, 2003; Van de Beek et al., 2006). Neisseria meningitidis infection is 
diagnosed by examination and bacterial culture of CSF or blood, although polymerase chain 
reaction (PCR) is now more commonly used (Gray et al., 2006; Stephens et al., 2007). PCR is 
often the preferred method of diagnosis as CSF cultures may provide false negative results if 
antibiotics are administered before testing (Kristiansen et al., 1991). CSF is aspirated by lumbar 
puncture between the vertebrae L3/L4 or L4/L5. CSF or blood samples from patients with 
suspected disease are cultured on blood agar and Gram-stained for identification. Positive 
cultures are seen as round, moist, Gram-negative, convex colonies (Figure 1. 1) (Gray and 
Fedorko, 1992). 
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Figure 1. 1 Neisseria meningitidis Colonies on Agar Plates 
Colonies of Neisseria meningitidis on blood agar (a) and chocolate agar (b) plates. Images taken 
from Laboratory Methods for the Diagnosis of Meningitis, Chapter 7: Identification and 
Characterization of Neisseria meningitidis published by Centres for Disease Control and 
Prevention. Website address: http://www.cdc.gov/meningitis/lab-manual/chpt07-id-
characterization-nm.html.  
Accessed 29/08/2016. 
  
a 
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1.1.3 Epidemiology 
Globally, the prevalence of each meningococcal serogroup varies significantly between 
countries and regions, with serogroups A, B, C and Y responsible for the majority of reported 
cases (Harrison et al., 2009; Lingani et al., 2015; Vyse et al., 2011). A summary table of disease 
rates and distribution of serogroups by region is shown in Table 1. 1. The greatest burden of 
disease occurs in Sub-Saharan Africa in an area known as the African Meningitis Belt. The African 
Meningitis Belt is formed of 18 countries with the majority of cases occurring in Burkina Faso, 
Chad, Ethiopia, and Niger. Unlike most regions where B, C and Y are the most commonly found 
serogroup, serogroup A is predominant in the African Meningitidis Belt (roughly 60% of all 
reported cases). The Meningitis Vaccine Project, created through the collaboration of The World 
Health Organisation and Program for Appropriate Technology in Health (PATH), is currently 
running a mass vaccination programme in an attempt to combat serogroup A disease in the 
region. Early reports suggest a significant reduction in rates of invasive serogroup A 
meningococcal disease (Lingani et al., 2015). 
In the UK, predominant serogroups include B, C W and Y with serogroup B accounting 
for more than 60% of all infections. Routine vaccination against serogroup C was introduced to 
the UK in 1999 following a significant increase in reported infections. Vaccination has been very 
successful with only 28 serogroup C cases reported in 2014/2015 compared to 883 in 
1998/1999. Recently, vaccines against serogroups B and A, C, W, Y were introduced into the 
vaccine schedule to reduce the large numbers of serogroup B infections and counter the 
worrying spike in serogroup W infections (Lucidarme et al., 2015). In Europe, case fatality rates 
remain between 5-10% for ages 0-44 years of age increasing to 20% of those aged >65. The 
variation in rates of meningococcal disease in the UK by year and age are shown in Figure 1. 2. 
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Table 1. 1 Worldwide Rates of Meningococcal Disease and Distribution of Serogroups 
Global incidence rates (per 100,000 people), case fatality rates (%) and distribution of serogroups (percentage of total isolates) for meningococcal disease. 
Region 
Incidence Rate (per 
100,000 population) 
Case Fatality 
Rate (%) 
Year of 
Study 
Distribution of Serogroups (%) 
A B C W Y X Other 
Australia 1.5 3.4 2005-2007 - 83.5 8.3 - - - 8.2 
South Africa 0.64 No Data 1999-2002 23 41 8 5 21 - 2 
New Zealand 2.3 5.9 2009-2013 - 52.6 29.8 8.8 7 - 2 
United States 0.53 11.3 1998-2007 - 29.9 28.8 2.5 34.8 - 4 
Japan 0.01 No Data 1990-2003 - 57 - 1 21 - 21 
Europe 1.44 7.75 1999-2004 0.7 75.4 17.6 2.7 2.2 1.3 0.1 
China 0.09 9.95 2005-2010 36.8 11.4 43.3 0.4 - - 8.1 
Canada 0.67 9.01 2002-2003 - 41.8 36.4 3.2 17.7 - 0.9 
Brazil 1.9 20 2006 - 38.2 55.2 5 1.6 - - 
Argentina 0.7 10 2007 - 68.8 11.4 13 6.8 - - 
Mexico 0.06 No Data 2000-2005 - 12 71 - 8 - 9 
African 
Meningitis Belt 
13.6 10.3 2004-2009 73.5 - - 13.6 2.8 8.2 1.9 
6.4 9.5 2010-2013 1.6 - - 38.4 - 59.3 0.8 
 
Table References: (Baethgen et al., 2008; Caugant et al., 2012; Chiu et al., 2010; Coulson et al., 2007; Dickinson and Pérez, 2005; Harrison, 2006; Harrison et al., 
2009; Ilyina et al., 2014; Laan et al., 2000; Li et al., 2015; Li, 2014; Lingani et al., 2015; Martin et al., 2007; Network, 2006; Rosenstein et al., 1999; Sáfadi and Cintra, 
2010; Takahashi et al., 2004; Vyse et al., 2011; Watkins et al., 2006) 
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Figure 1. 2 Cases of invasive Neisseria Meningitidis Infection in the UK 
a, Epidemiological data of confirmed invasive Neisseria Meningitidis infection by serogroup for 
epidemiological years 1998/1990 to 2014/2015. b, Cases and deaths per million population of invasive 
Neisseria Meningitidis infection by age for each serogroup between 2004 and 2014. Data collected 
from the Office of National Statistics and Public Health England. 
a 
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1.1.4 Treatment of Disease  
Meningococcal disease is classified by either the presence or absence of meningitis 
and/or meningococcemia (Feavers et al., 2015; McGill et al., 2016). If meningococcal disease is 
suspected immediate intravenous antibiotics (such as cefotaxime or ceftriaxone) and steroids 
(such as dexamethasone) are recommended to stem any further bacterial growth and reduce 
the symptoms of shock (Visintin et al., 2010). If meningitis and meningococcemia are both 
present, treatment of the meningococcemia will take priority due to its association with a much 
poorer prognosis (Van Deuren et al., 2000). 
Dissemination of Neisseria meningitidis infection into the bloodstream 
(meningococcemia) is often accompanied by septic shock and DIC. Intravenous fluid, inotropic 
drugs and oxygen are administered to maintain blood pressure, tissue perfusion and oxygen 
saturation (Carcillo et al., 1991). Mass consumption of clotting agents related to DIC is treated 
with vitamin K, plasma and platelet infusion to prevent bleeding and ischemia (Qu et al., 2011). 
Colonisation of the meninges by Neisseria meningitidis precedes meningitis (cerebral 
oedema) and is associated with increased intracranial pressure (ICP). Increased ICP can be 
combatted with intravenous infusion of either a saline or sugar solution (Wakai et al., 2013). 
However, it must be noted that the benefit of mannitol therapy in the treatment of increased 
ICP is under question and may even worsen ICP. All efforts are made to reduce any exacerbations 
in ICP by sedating patients, keeping patients cool and in an upright position and active 
prevention of seizures. 
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1.1.5 Meningococcal Vaccines 
Vaccination aims to produce immunological memory to a pathogen and to protect the 
host from disease if exposed to the same pathogen in the future. This can be achieved by 
introducing an antigen into the host initiating an adaptive immune response specific to the 
antigen (Boyd, 1946; Clem, 2011). An adequate immune response will activate both humoral 
and cell-mediated immunity on subsequent exposure. Long lasting memory B and T cells as well 
as circulating antibodies all provide a quick protective response if exposed to the pathogen post 
immunisation.  
The phenomenon of generating immunity to a disease by vaccination can be traced to 
Edward Jenner in his classical papers on Variolæ vaccinæ and smallpox (Jenner, 1801). Edward 
Jenner made the observation that individuals who had previously suffered from vaccinia virus 
infection were subsequently protected from smallpox. This observation eventually led to the 
production of an effective smallpox vaccine and successful eradication of the disease in 1969 
(Fenner et al., 1988).  
Vaccine antigens are generated and administered in many forms (Artenstein et al., 1970; 
Control, 1989; Donnelly et al., 1996; Sabin, 1985). Vaccines can comprise either dead or live 
attenuated pathogen (polio and measles vaccines, respectively), a subunit of a pathogen, a 
toxoid (tetanus vaccines), polysaccharides taken from the outer shell of the bacterial wall 
(meningococcal vaccines) or the DNA taken from the pathogen itself. The desired response to 
meningococcal vaccines is the production of high titres of protective antibodies. 
Much of today’s understanding of the protection against meningococcal disease and the 
effectiveness of capsular polysaccharides as a vaccine antigen was presented in a series of 
seminal papers entitled ‘Human Immunity to the Meningococcus I-V’ published in 1969 by 
Malcolm S. Artenstein, Emil C. Gotschlich and Irving Goldschneider of the Walter Reed Army 
Institute of Research, Washington. Artenstein et al., showed that in most cases the susceptibility 
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to meningococcal disease is related to a lack of meningococcal-specific bactericidal antibody and 
that antibody specific to the polysaccharide capsule of Neisseria meningitidis form a major part 
of the bactericidal titres of sera (Goldschneider et al., 1969a; Goldschneider et al., 1969b). 
Artenstein et al., also showed that natural immunity to the meningococcus could be acquired 
through either asymptomatic carriage of meningococci in the nasopharynx or due to 
transplacental passage of meningococcal-specific IgG antibodies from mother to foetus and that 
bactericidal antibodies could be induced by vaccination with the capsular polysaccharide of 
Neisseria meningitidis (Goldschneider et al., 1969b; Gotschlich et al., 1969c). The first vaccines 
were developed against serogroups A and C in the 1960s and 70s following the successful 
purification of high molecular weight (>100kDa) polysaccharides from the bacteria (Gotschlich 
et al., 1969a; Gotschlich et al., 1969c). These preparations induced significant bactericidal titres 
in humans; a vast improvement on previous studies using low molecular weight (<50kDa) 
(Gotschlich et al., 1969a, b; Kabat et al., 1944). Further investigations on the immunogenicity of 
these high molecular weight polysaccharides showed that responses are serogroup-specific and 
not cross-reactive to other serogroups, and that vaccination can reduce serogroup-specific 
nasopharyngeal acquisition but not the overall carriage of meningococci due to replacement by 
other serogroups (Gotschlich et al., 1969a, b; Gotschlich et al., 1969c). Soon after, vaccines 
composed of the polysaccharides isolated from serogroups W and Y were introduced (Armand 
et al., 1982; Griffiss et al., 1981; Hankins et al., 1982).  
Until recently, efforts to produce a protective serogroup B vaccine by the same process 
have been unsuccessful due to similarities between serogroup B polysaccharides and brain 
glycoproteins (Finne et al., 1983; Wyle et al., 1972). The genome of a serogroup B isolate was 
sequenced in the hope to identify alternative antigens suitable for vaccination (Tettelin et al., 
2000). Genes coding for 570 potential vaccine antigens were identified. A total of 330 of these 
were successfully expressed in Escherichia coli and used to immunise mice in the goal of 
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determining those antigens most appropriate for vaccination (Pizza et al., 2000). Seven of these 
antigens were shown to be highly expressed by Neisseria meningitidis and able to generate 
bactericidal antibody in mice. Individually, these antigens did not produce bactericidal antibody 
to all strains tested due to inter-strain variability of these antigens (Giuliani et al., 2006); 
however, a combination of five of these antigens did generate a broad bactericidal response and 
now form the basis of one of the new serogroup B vaccines, Bexsero™ (Gorringe and Pajon, 
2012). It was later discovered that one of these antigens specifically binds the soluble 
complement regulator factor H (FH), now known as factor H binding protein (FHbp) (Madico et 
al., 2006). Another serogroup B vaccine, composed of two FHbp subfamily members, is in 
development (Jiang et al., 2010). 
Characteristic of T cell-independent B cell activation, responses to meningococcal 
polysaccharide vaccines are weakly immunogenic and short-lived (Gold et al., 1975). To improve 
the immunogenicity of meningococcal vaccines in young children, polysaccharide antigens are 
often covalently linked to protein conjugates (Costantino et al., 1992; Findlow and Borrow, 2016; 
Pichichero, 2005). Common conjugates include tetanus toxoid (TT), non-toxic mutant of 
diphtheria toxin (CRM197) and diphtheria toxoid (DT). Protein conjugates of meningococcal 
polysaccharides show superiority over plain polysaccharides by inducing immunological memory 
and higher SBA titres (Leach et al., 1997; Li et al., 2014; Richmond et al., 1999a). Conjugate 
proteins have the potential to both boost or suppress the immune response to polysaccharide 
antigens (Findlow and Borrow, 2016). The process where prior immunity to a conjugate protein 
decreases the immune response to a polysaccharide antigen conjugated to the same protein is 
known as carrier induced epitopic suppression (CIES). CIES has been described for a TT-
conjugated MenC vaccine when administered to individuals previously vaccinated with another 
vaccine containing TT (Burrage et al., 2002). The exact mechanism behind CIES is unknown but 
thought to occur when either antibody specific to the conjugate protein sterically hinder B cell 
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access to the polysaccharide antigen, when the immune response to the carrier protein is 
prioritised over the response to the polysaccharide antigen and/or when conjugate protein-
specific regulatory T cells dampen the response to the polysaccharide antigen. 
 
1.1.6 Correlates of Protection 
Neisseria meningitidis infection is cleared by both CDC and phagocytosis (Granoff, 2009; 
Lo et al., 2009). Deficiencies in opsonins and complement proteins are associated with increased 
susceptibility to invasive meningococcal disease (Bathum et al., 2006; Hellerud et al., 2010). 
These mechanisms of protection are enhanced by bacteria-specific antibody acquired either by 
natural exposure to Neisseria meningitidis, vaccination or passively by placental transfer 
(Goldschneider et al., 1969a; Goldschneider et al., 1969b; Gotschlich et al., 1969a, b). Correlates 
of protection examine these mechanisms of immunity to assess whether an individual is 
protected against a specific pathogen. Several correlates of protection exist for Neisseria 
meningitidis which are used to evaluate the efficacy of meningococcal vaccination, including the 
SBA, opsonophagocytic assay and ELISAs to measure the concentration of anti-meningococcal 
antibody (Borrow et al., 2005; Domnich et al., 2015; Humphries et al., 2015). The SBA is the gold 
standard correlate of protection used for the approval of new meningococcal vaccines and will 
be the main focus of this project. 
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1.1.5.1 Serum Bactericidal Assay 
The SBA is a standard laboratory technique used to measure the efficacy of 
meningococcal vaccines and is a suitable measurement for regulatory approval (Maslanka et al., 
1997). The SBA measures the bactericidal activity of an individual’s serum towards Neisseria 
meningitidis. Briefly, serum from an individual is heat inactivated and serially diluted before 
mixing 1:1 with a source of active complement. Heat inactivation of the test sample removes 
complement activity without significantly altering the level of antibody. Sources of complement 
include human serum and BRS. Live Neisseria meningitidis bacteria, of a specific serogroup, is 
then added to this mixture, plated out and incubated overnight. The number of colonies is then 
counted and compared to the negative control (no sample present and heat-inactivated 
complement source). The dilution of the test sample where 50% bacterial growth is inhibited is 
known as the SBA titre. Susceptibility to meningococcal disease significantly correlates with SBA 
titre and titres greater than four to eight are considered protective (Borrow et al., 2001a; Borrow 
et al., 2005; Goldschneider et al., 1969a; Goldschneider et al., 1969b; Gotschlich et al., 1969a; 
Rezaei et al., 2007). 
 
1.2 Immunoglobulins 
Antibodies are a secreted form of the B cell receptor (BCR). The very first description of 
an antibody [fragment] has been attributed to Dr Henry Bence Jones; while examining the urine 
of a patient suffering from multiple myeloma in 1848 he noticed that heating the urine provoked 
a precipitate (Jones, 1848). Named after its originator, the Bence-Jones protein has since 
undergone extensive analysis and been identified as the disassociated light chain of an antibody 
(Delman and Gally, 1962). However, the first real description of antibodies is credited to Emil 
von Behring and Shibasaburo Kitasato in 1890 (Von Stabsarzt, 1890). Behring and Kitasato 
discovered a substance in serum able to neutralise tetanus toxin and convey immunity to 
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disease. This substance could be transferred in serum from immune animals into non-immune 
animals, generating passive protection against disease. This soluble serum protein with antitoxin 
properties was first referred to as antibody or ‘antikörper’ by Paul Ehrlich in 1891, although this 
term was not used commonly until several years later (Ehrlich, 1891; Lindenmann, 1984). 
In humans, antibodies can be separated into five distinct classes: IgG, IgM, IgA, IgD and 
IgE (Black, 1997). Initially known as the 7S γ-globulin (or variations thereof) as a result of 
sedimentation and mobility studies, IgG was first discovered and is the most studied of the 
immunoglobulins (Cohen, 1965; Tiselius, 1937; Tiselius and Kabat, 1939). The immunoglobulin 
IgM was identified soon after; followed by IgA, IgD and finally IgE (Grabar and Williams, 1953; 
Heremans et al., 1959; Ishizaka et al., 1966; Kabat, 1939; Rowe and Fahey, 1965; Waldenström, 
1944). The nature of B cell activation dictates the subclass of antibody secreted into the 
circulation (Nutt et al., 2015). 
 
1.2.1 Antibody Structure  
The core antibody unit is formed of four chains (two heavy chains and two light chains) 
held together with multiple disulphide bonds. Studies by Rodney Porter in the 1950s and 1960s 
on the antigenic similarities and functions of IgG fractions, generated through papain digestion 
and reduction of the disulphide bonds, led to the basic model of antibody structure that is still 
used today (Porter, 1962, 1963) (Figure 1. 3).  
Papain digestion of IgG produces three fractions, first assigned the names I, II and III 
based on their mobility through a carboxymethylcellulose matrix (Petermann, 1946; Porter, 
1950, 1958, 1959). Fractions I and II both bind antigen and inhibit antigen precipitation by the 
intact antibody. Fraction III does not bind antigen but does fix complement (Ishizaka and 
Campbell, 1958; Ishizaka et al., 1962). These factions were later termed Fab and Fc based on 
their antigen-binding (ab) function and tendency to crystallise (c) out of solution (Cohen, 1965). 
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Reduction of the disulphide bonds that holds IgG together with β-mercaptoethylamine and urea 
produced two sub-units of differing molecular weights (Edelman and Poulik, 1961; Edelman, 
1959). Based on their respective molecular weights (50kDa and 25kDa), these sub-units were 
termed heavy (H) and light (L) chains of antibody (Cohen, 1965; Pain, 1963). Two H chains and 
two L chains form a complete IgG molecule at a size of roughly 150kDa (Kabat, 1939). 
Immunisation of rabbits with the different subunits and fractions of human IgG and subsequent 
investigations on the cross-reactivity of the resultant antisera with these components showed 
that the H chain contained elements of both Fab and Fc fragments and the L chain contained 
only elements of the Fab fragment (Cohen, 1963). These data along with chemical composition 
investigations led to the well-known basic primary protein structure of IgG as shown in Figure 
1. 3 (Porter, 1962). 
The first complete amino acid sequence of an IgG[1] molecule was published in 1969 by 
Gerald M. Edelman et al., revealing several regions of homology throughout the heavy and light 
chains (Edelman et al., 1969). These finding supported the hypothesis that both the heavy and 
light chains of immunoglobulins are split into two and four domains, respectively. These 
domains are known as the variable light chain (VL) and constant light (CL) chain domains of the 
light chain and variable heavy chain (VH), CH1, CH2 and CH3 domains of the heavy chain. In 
1968, the first x-ray crystallography structure of an intact IgG molecule (hinge deletion IgG1 
‘Dob’ antibody) was achieved (Terry, 1968), enabling the solution of  the complete quaternary 
structure of this IgG1 antibody and confirming previous predictions of the multi-chain, multi-
domain arrangement of IgG (Sarma et al., 1971; Silverton et al., 1977; Terry, 1968).  
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Figure 1. 3 Immunoglobulin Structure 
The core antibody unit consists of two heavy and two light chains held together with multiple 
disulphide bonds. IgM is formed of five of these antibody units. The heavy and light chains are 
split into several domains: variable light chain domain (VL), constant light chain domain (CL), 
variable heavy chain domain (VH) and constant heavy chain domains (CH). The CH1 and CH2 
domains are connected via the hinge region, which varies in length between the subclasses. 
Papain digestion of the hinge region splits antibody into two fragments: Fc and Fab regions. A 
glycosylation site is contained within each CH2 domain of IgG antibody. Each IgM antibody unit 
has ten glycosylation sites: one on each CH1 domain, one on each CH2 domain, two on each CH3 
domain and one on each CH4 domain. 
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1.2.2 IgG Subclasses 
The IgG class of human antibody can be further divided into four subclasses: IgG1, IgG2, 
IgG3 and IgG4. These were first identified due to antigenic variation of their heavy chains (Grey 
and Kunkel, 1964; Terry and Fahey, 1964). The IgG subclasses were named in accordance to their 
abundance in plasma with IgG1 (66% of total IgG) the most and IgG4 (2%) the least abundant 
(French and Harrison, 1984; Kunkel et al., 1965). The IgG subclasses are similar in size (146 to 
170kDa) and share roughly 92-96% sequence similarity (Hamilton, 1987). Differences between 
the IgG subclasses are shown in Figure 1. 3 and Table 1.2. The most striking difference between 
the structure of IgG subclasses is the relative length of the hinge region that joins the CH1 and 
CH2 domains (Gregory et al., 1987; Hamilton, 1987). IgG3 possesses the longest hinge region at 
62 residues followed by IgG1 at 15 residues, IgG2 and IgG4 at 12 residues each (Edelman et al., 
1969; Michaelsen et al., 1977; Vidarsson et al., 2014). IgG subclasses significantly differ in their 
ability to activate complement and their affinities to Fc receptors. 
 
1.2.3 Antibody Function 
Antibodies express multiple effector functions once bound to their antigen. These 
functions result directly from or indirectly from binding antigen. As a consequence of differences 
in structure and composition, each subclass of antibody exhibits significant variation in their 
function.  
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Table 1. 2 Properties of Immunoglobulins 
Several structural and functional properties of rabbit IgG, human IgM and human IgG subclasses 
are shown. Rabbit immunoglobulin only consists of one subclass. The cytokines and antigens 
responsible for the upregulation or inhibition of each antibody subclass are also summarised. 
 
 
  
Property 
Antibody 
IgG1 IgG2 IgG3 IgG4 IgM IgG 
Species Human Human Human Human Human Rabbit 
Serum Concentration 
(mg/ml) 
8 4 0.8 0.4 1.3 13.6 
Complement Fixation ++ + +++ - +++ ++ 
Hinge Length (aa) 15 12 62 12 N/A 11 
Size (kDa) 146 146 170 146 970 144 
Specificity 
for 
Protein ++ +/- ++ +/- + + 
Polysaccharide + ++ - - + + 
Allergens + - - ++ - + 
Isoelectric Point 8.6±0.4 7.4±0.6 8.3±0.7 7.2±0.8 5.5 - 7.4 
 6.1–
6.5 
Stimulatory Cytokines 
IL-4;  
IL-10 
IFN-γ; 
TGF-β 
IFN-γ; 
IL-10 
IL-4; IL-
13; IL-
10 
IL-2; IL-5 N/A 
Inhibitory Cytokines IFN-γ IL-4 
TGF-β; 
IL-4 
IFN-γ 
IL-4; 
IFN-γ; 
TGF-β 
N/A 
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Antibodies can neutralise and aggregate pathogens and toxins reducing pathology and 
enhancing their clearance. The bivalency of an antibody means an antibody molecule can bind 
two antigens co-currently. Antigens with several epitopes allow the binding of multiple 
antibodies, each able to bind two antigens, creating an ever-growing cross-linked lattice 
structure (Dean and Webb, 1926). In this way, pathogens or toxins are concentrated, enhancing 
complement activation and increasing the speed and efficiency of clearance by phagocytes 
(Margni et al., 1980; Perdigón et al., 1982; Wright et al., 1980). Neutralising antibodies inhibit 
the biological actions of its antigen whether by preventing the transportation of a pathogen 
across a membrane or by directly blocking the actions of toxins (Davis et al., 1978). Introducing 
neutralising antibody to the meningococcal endotoxin LPS, which is responsible for the 
development of disseminated intravascular coagulation, into patients suffering from 
meningococcemia significantly reduced mortality rates (Ziegler et al., 1982). All antibody 
subclasses can aggregate and neutralise antigens. 
The Fc region of antibody bound to an antigen can activate complement, enhance 
phagocytosis and activate effector cells of the immune system, each activity aiding the clearance 
of pathogens. The first component of the classical pathway of complement activation, C1q, binds 
the CH2 domains of IgG and IgM antibody classes; the C1q binding site becomes exposed when 
the antibody is bound to antigen (Müller-Eberhard and Kunkel, 1961). Subsequent complement 
activation leads to CDC, opsonisation and chemotaxis. Human IgM and IgG3 antibodies are the 
best activators of complement followed by IgG1 and IgG2; IgG4 does not activate complement 
(Brüggemann et al., 1987; Gadjeva et al., 2008; Garred et al., 1989). The presence of 
complement activating antibody, or bactericidal antibody, and an intact complement system, 
significantly correlate with the susceptibility to invasive meningococcal disease (Figueroa and 
Densen, 1991; Goldschneider et al., 1969a; Goldschneider et al., 1969b; Gotschlich et al., 1969a; 
Granoff, 2009). 
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Fc receptors (FcRs) bind the Fc region of antibodies and are named according to their 
specificity (Anderson et al., 1989). For example, FcγRs bind IgG, FcεRs bind IgE and so on. FcRs 
are expressed on numerous cells types including dendritic cells (DCs), natural killer cells (NK 
cells) and mast cells (Daëron, 1997). FcR binding leads to either phagocytosis or antibody-
dependent cell mediated cytotoxicity (ADCC) of the targeted (opsonised) antigen (Aderem and 
Underhill, 1999). The IgE-binding FcR, FcεR1, is expressed by mast cells, basophils and 
eosinophils (Turner and Kinet, 1999). IgE antibody, cross-linked by antigen and bound to FcR, 
activates mast cells, basophils and eosinophils releasing stored histamine and other 
inflammatory mediators. In a similar vein, degranulation of NK cells occurs through FcγRIII 
signalling releasing preformed granules, containing cytotoxic enzymes such as perforin and 
granzyme A, killing the antibody labelled cell. Activation of FcRs expressed by macrophages and 
DCs drives phagocytosis of the targeted antigen. Macrophages and DCs don’t only help clear 
infection directly but link innate and adaptive immunity through antigen processing and 
presentation to cells of adaptive immunity. 
 
1.2.4 B Cell Activation 
Antigens able to activate B cells and induce secretion of immunoglobulin are separated 
into two distinct categories (Mond et al., 1995; Parker, 1993). Those dependent on the help of 
T cells for activation (TD) and those able to activate B cells in the absence of T cells (TI). The 
latter can be split further into TI-1 and TI-2 antigens (Vos et al., 2000). TD antigens, such as TT, 
are proteins able to both bind the B cell receptor (BCR) and engage with major histocompatibility 
complexes (MHC). TI-1 antigens, such as LPS or bacterial DNA, activate B cells without the help 
of T cells or engagement of the BCR. TI-2 antigens, such as bacterial polysaccharides, activate B 
cells by multivalent binding of the BCR (Dintzis et al., 1976). A second stimulatory signal, 
independent of the original antigen, is usually necessary for the production of secretory 
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immunoglobulins. This second signal is delivered by the engagement of additional B cell 
receptors by other immune cells (T cells, NK cells and macrophages), products of complement 
activation (C3d), damage associated molecular patterns (DAMPS) or pathogen-associated 
molecular patterns (PAMPS) (Abruzzo and Rowley, 1983; Dempsey et al., 1996; Pasare and 
Medzhitov, 2005).  
 
1.2.4.1 Antibody Class Switching 
 Sufficiently stimulated B cells will secrete antigen specific antibody into the circulation 
of the host (Stavnezer, 1996a). B cells are able to produce antibodies of nine different subclasses 
(IgM, IgD, IgG3, IgG1, IgA1, IgG2, IgG4, IgE and IgA2) differing primarily in their heavy chain and 
valency. The constant heavy chain region of an antibody is determined during B cell activation 
by a process known as class switch recombination (CSR) (Muramatsu et al., 2000). The constant 
heavy chain locus is made up of each heavy chain gene sandwiched between switch regions (Lee 
et al., 2001). CSR is driven by the activation-induced cytidine deaminase enzyme (AID) which is 
significantly upregulated when a B cell is activated (Stavnezer et al., 2008). AID converts cytosine 
bases to uracil by the process of deamination in and around switch regions. These regions are 
excised creating double-stranded breaks in the DNA. Double-stranded breaks in the S regions 
recombine creating a loop of DNA containing the constant heavy chain genes that will be deleted 
allowing the next constant heavy chain gene in the locus to be transcribed. A simplified model 
of CSR is shown in Figure 1. 4. Sufficient B cell activation also induces somatic recombination of 
the variable (V), joining (J) and diversity (D) regions, responsible for the specificity of an antibody, 
in a process known as affinity maturation (Alt et al., 1992). Affinity maturation selects antibodies 
with the highest affinities to antigen discarding B cells expressing BCRs with lower affinities.  
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Figure 1. 4 Class Switch Recombination 
Class switching of antibodies secreted by activated B cells occurs by a process known as class 
switch recombination. a, CSR is driven by the activation-induced cytidine deaminase enzyme 
(AID) which converts cytosine bases to uracil by the process of deamination in and around switch 
regions (S) flanking genes encoding the constant heavy chains for each class of antibody. 
Constant heavy chain genes include Cµ (IgM), Cδ (IgD), Cγ1-4 (IgG1-4), Cα1-2 (IgA1-2) and Cε 
(IgE). b, Deaminated S regions are excised creating double-stranded breaks in the DNA. Double-
stranded breaks in the S regions recombine creating a loop of DNA containing the constant heavy 
chain genes. c, This loop of DNA is then removed allowing the next constant heavy chain gene 
in the locus to be transcribed. In this case, IgM antibody is class switched to IgA1. Adapted from 
(Stavnezer et al., 2008).   
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Cytokines, secreted by helper T cells and other cells of the immune system, directly 
affects CSR and the class of antibody that is secreted (Kracker and Radbruch, 2004; Stavnezer, 
1996b). The initial antibody class secreted in response to an antigen is IgM. Class switching 
usually occurs within six days post initial activation of the B cell. The cytokines interferon gamma 
(IFN-γ), transforming growth factor beta (TGF-β), interleukin-4 (IL-4), IL-5, IL-13 and IL-10 each 
play a crucial role in determining the class of antibody secreted (Coffman et al., 1993). For 
example, stimulation with IL-4 induces class switching to the IgE, IgG1 and IgG4 subclasses whilst 
inhibiting IgG3 production (Lundgren et al., 1989; Pene et al., 1988b). In contrast, IgE and IgG1 
antibody production is inhibited by IFN-γ (Pene et al., 1988a). In addition, IgA antibody is 
produced in the presence of TGF-β (Cerutti, 2008). A summary of the role cytokines play in 
inhibiting or stimulating class switching in B cells is shown in Table 1.2. 
The co-stimulatory receptor CD40 and its ligand (CD40L) also play a pivotal role in class 
switching and B cell activation (Fuleihan et al., 1993; Wykes, 2003). Those lacking functional 
CD40L on their B cells suffer from a disease known as hyper-IgM syndrome characterised by 
normal to high levels of circulating IgM and very low concentrations of all other classes of 
antibody (Aruffo et al., 1993).  
Although able to produce antibodies of all classes, antibody responses to TD antigens 
are predominantly IgG1 and responses TI antigens are generally restricted to IgM, IgG2 and IgG1 
(Barrett and Ayoub, 1986; Stevens et al., 1983). TD antigens are strongly immunogenic 
producing high-affinity antibody and immunological memory whereas TI antigens are poorly 
immunogenic and produce relatively low-affinity antibodies and no immunological memory 
(Richmond et al., 2000). Meningococcal polysaccharides are TI-2 antigens and are poorly 
immunogenic inducing primarily IgM, IgG2 and IgG1 antibody (de Voer et al., 2011). Low-affinity 
antibodies are associated with lower SBA titres (Hetherington and Lepow, 1992). Additionally, 
IgG2 antibodies are poor activators of complement, an important mechanism in the protection 
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against meningococcal disease (Augener et al., 1971). As such, meningococcal polysaccharides 
are conjugated to proteins to drive the antibody response towards that exhibited by TD antigens 
(Pace et al., 2009). Indeed, meningococcal protein conjugate vaccines produce higher SBA titres 
and induce some immunological memory (Galson et al., 2015; Memish et al., 2011; Shao et al., 
2009). 
 
1.2.5 Complement Activation by Immunoglobulins 
 As previously discussed, IgG and IgM antibodies activate the complement system when 
bound to antigen. Both antibody subclasses activate complement by binding the complement 
protein C1q. The affinity of C1q for immunoglobulin and antigen density is thought to dictate 
the level of complement activation. 
 
1.2.5.1 Human C1q 
First assigned the nomenclature of 11S due to its sedimentation velocity, C1q was 
discovered based on its ability to bind aggregated IgG antibody and its role in complement 
activation (Müller-Eberhard and Kunkel, 1961). The 11S protein was found in complex with two 
proenzymes, later termed C1r and C1s (Lepow et al., 1963). Early studies on the structure of C1q 
showed it to be composed of two non-covalently associated subunits with molecular weights of 
60kDa (C1qI) and 42kDa (C1qII), respectively (Yonemasu and Stroud, 1972). C1qI was revealed 
as a disulphide-bonded, heterodimer formed of two subcomponents of 29kDa (C1qI-1) and 
27kDa (C1qI-2). C1qII was revealed as a disulphide-bonded, homodimer formed of a 22kDa 
subcomponent (Reid, 1976; Yonemasu and Stroud, 1972). The three subcomponents of C1q are 
present in equal concentrations and have subsequently been assigned the nomenclature of a-
chain, b-chain and c-chain of C1q (Reid et al., 1972). Electron microscopy experiments with 
negatively stained C1q revealed it to consists of six terminal subunits each joined to a central 
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core by connecting strands (Knobel et al., 1975; Shelton et al., 1972). Amino acid composition 
studies showed the abundance of hydroxyproline and hydroxylysine, typically found in collagen 
and not globular proteins (Reid et al., 1972). Inactivation of C1q by incubation with collagenase 
enzyme further pointed to a collagen-like region of the protein. Amino acid sequencing 
confirmed that each of the chains contains an N-terminal collagen-like region and C-terminal 
non-collagen-like or globular region (Reid, 1974). The collagenous region of each subunit 
(composed of an a-chain and b-chain dimer and one-half of a c-c-chain dimer) form a helical 
triple helix with each helix held together by the covalent bond between each c-chain dimers 
(Reid and Porter, 1976). The structure and organisation of C1q are shown in Figure 1. 5. 
 
1.2.5.2 C1q Affinity to Immunoglobulins 
The binding affinity of monomeric IgG to C1q is weak, reported to range between 1.1 
and 23.9 x 10-4M for the different human IgG subclasses (Hughes-Jones, 1977; Hughes-Jones and 
Gardner, 1979; Painter et al., 1982; Schumaker et al., 1976; Sledge and Bing, 1973). The affinity 
of C1q is in the order IgG3>IgG1>IgG2>>IgG4 (Schumaker et al., 1976). The binding affinity is 
significantly increased upon aggregation of IgG by heat treatment or clustering when bound to 
antigen. Binding of C1q to multiple IgG ligands increases the avidity by several logs of magnitude 
into the nanomolar scale (Bindon et al., 1988; Emanuel et al., 1982; Hughes-Jones, 1977; Moore 
et al., 2010; Painter et al., 1982; Patel et al., 2015; Quast et al., 2015). The binding affinity of 
fluid-phase IgM antibody to human C1q is in the micromolar range despite possessing five times 
the number of binding sites of IgG (Poon et al., 1985; Sledge and Bing, 1973); however, binding 
affinity markedly increases following interaction with antigen due to a conformational change 
of IgM from its planar to staple form (Burton, 1986; Swanson et al., 1988; Wright et al., 1990; 
Wright et al., 1988).  
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Figure 1. 5 Structure of C1q 
C1q is composed of 6 x 3 polypeptide chains (A, B and C chains) held together by covalent and 
non-covalent interactions. Each chain is formed of a short non-collagenous region at the N-
terminus of the protein followed by a longer collagen-like domain and globular domain. Chains 
A-B and C-C are covalently linked by a disulphide bond at the non-collagenous region at the N-
terminus. The collagenous region of each subunit (composed of an A-chain and B-chain dimer 
and one-half of a C-dimer) form a helical triple helix with each helix held together by the covalent 
bond between each C-chain dimers.  
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Contemporary studies of the binding affinity of C1q to immunoglobulins have been 
achieved with surface plasmon resonance (SPR) (Moore et al., 2010; Patel et al., 2015; Quast et 
al., 2015). Immobilisation of antibody for C1q binding studies has been conducted using three 
different methods: direct coupling, captured with Protein A or captured with Protein L. The C1q-
binding affinity (KD) of a human IgG1 antibody directly amine coupled to an SPR sensor chip was 
calculated as 3.5nM (Quast et al., 2015). The KD of a human IgG1 antibody captured by a Protein 
A coated SPR sensor chip was calculated as 48nM (Moore et al., 2010). Both these methods have 
been criticised as the alignment of the antibody is not optimal for interaction with C1q (Patel et 
al., 2015). Protein L binds to the light chain of immunoglobulins and thereby orientates 
antibodies for efficient interaction with C1q (Graille et al., 2001). Using a Protein L coated SPR 
sensor chip to capture antibody, the KD of human C1q to human IgG1, IgG2, IgG3 and IgG4 was 
calculated as 81nM, 191nM, 88nM and 223nM respectively (Patel et al., 2015). 
The flexibility of IgG antibodies is determined by the length of the hinge connecting CH1 
and CH2 domains (Feinstein, 1965; Valentine and Green, 1967). Specifically, the length of the 
upper hinge region is proportional to the degree of flexibility offered between the Fc and Fab 
regions of an antibody (Dangl et al., 1988; Oi et al., 1984). It is thought that the hinge length of 
an antibody also correlates with its ability to fix complement. For humans, IgG3 is the most 
flexible, followed by IgG1, IgG2 and IgG4. It is hypothesised that increased flexibility allows 
efficient organisation of multiple Fc regions to interact with C1q, a necessity for activation. A 
longer hinge also moves the Fab regions of an antibody far enough away from the C1q binding 
motif not to restrict binding. Indeed, immunoglobulins with their hinge region deleted are 
rendered inflexible and incapable of complement activation (Deutsch and Suzuki, 1971; Klein et 
al., 1981). Inflexibility and steric hindrance of the C1q binding motif by the Fab region were 
proposed as one of the main reasons for the inability of human IgG4 antibody to activate 
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complement. This was further strengthened when the Fc fragment of IgG4 was shown to bind 
C1q to a similar extent to the Fc fragment of IgG1 (Isenman et al., 1975).  
Additional investigations have shown that differences in hinge length and antibody 
flexibility do not fully account for variations in complement activation (Brekke et al., 1995; 
Michaelsen et al., 1994; Norderhaug et al., 1991; Tan et al., 1990). Chimeric human IgG3 and 
IgG4 antibodies, each with their hinge region replaced with the other, showed no significant 
difference in C1q binding compared to their native counterparts (Tan et al., 1990). For example, 
an IgG4 antibody with the hinge of IgG3 did not activate complement and vice versa. However, 
total deletion of the hinge region again removed the capability of IgG3 to activate complement. 
Further scrutiny of the hinge region of IgG3 showed that the hinge region was not necessary to 
bind C1q and fix complement (Brekke et al., 1995; Michaelsen et al., 1994). However, a 
disulphide bond, generated by mutation of the N-terminus of the CH2 domain correctly aligning 
the two CH2 domains of the antibody, was required for complement activation.  
A recent study, investigating the importance of antibody clustering and antigen density 
in classical pathway activation, described the ability of IgG1 antibodies to form hexamers by 
interacting through their Fc domains (Diebolder et al., 2014). Mutations in the CH2 and CH3 
domains, enhancing the interaction of multiple antibodies (Glu345 to Arg), increased complement 
activation for IgG1, IgG2, IgG3 and IgG4 to similar levels. It is hypothesised that antigen density, 
hinge length and flexibility play a role in hexamer formation. This phenomenon of the 
polymerisation of immunoglobulins at sites of high antigen density was previously predicted 
when comparing the differences in the ability of IgM and IgG antibody to activate complement 
(Burton, 1986; Watts et al., 1985). 
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1.2.5.3 C1q Binding Motif on Human Immunoglobulins 
The antibody fragment Fabc, containing the VH1, CH1 and CH2 domains, retains the 
ability to activate complement (Colomb and Porter, 1975). This, with the knowledge that Fab 
fragments (containing VH1-CH1 domains) do not fix complement, and that Fc fragments 
(containing CH2-CH3 domains) suggest that the C1q binding motif must be contained within the 
CH2 domain of IgG. This was further confirmed when the functional affinity of IgG sub-fragments 
to C1q was assessed (Painter et al., 1982). The functional affinity of the Fc fragment and CH2 
sub-fragment were both measured at 4 x 104M-1. In contrast, the IgG sub-fragment CH3 
expressed no affinity to C1q. 
 Mutational and sequencing studies of the CH2 domain have further scrutinised the C1q 
binding motifs on IgG. The first mutational study, investigating the C1q binding site on 
immunoglobulins, was performed with a mouse IgG2b antibody (Duncan and Winter, 1988). The 
amino acid residues Asparagine297, Glutamic acid318, Lysine320 and Lysine322 in the CH2 domain of 
mouse IgG2b were identified as essential for interaction with C1q. These residues are conserved 
in the immunoglobulins of multiple species, including all human IgG subclasses, and this region 
was predicted to be the C1q binding motif for all complement fixing immunoglobulins. 
Additional investigations, carried out to improve the understanding of the differences between 
human IgG subclasses and their interaction with C1q, have painted a more complex picture 
(Gaboriaud et al., 2003; Idusogie et al., 2000; Moore et al., 2010; Morgan et al., 1995; Schneider 
and Zacharias, 2012; Thommesen et al., 2000; Xu et al., 1994). 
Several reports investigating the binding site of C1q for IgG1 antibody showed that the 
previously predicted residues Lysine320 and Glutamic acid318 are not essential for interaction with 
C1q (Idusogie et al., 2000; Morgan et al., 1995; Thommesen et al., 2000). However, residues 
Aspartic acid270, Lysine322, Proline329, and Proline331 were all implicated. Not only have residues 
been identified that, when mutated, reduced C1q binding, but also other mutations described 
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that can enhance the interaction (Moore et al., 2010). A total of twelve residues within the CH2 
domain of IgG1 are predicted to interact with C1q (Schneider and Zacharias, 2012). These 
include the residues Aspartic acid270, Lysine322, Proline329 and Proline331 also shown to be 
important experimentally. The highly conserved glycosylation site at Asparagine297 also plays an 
important role in C1q binding (Nose and Wigzell, 1983; Quast et al., 2015). De-glycosylation or 
removal of this site significantly reduces C1q binding. Table 1. 3 shows the full sequence of the 
CH2 domains of the human IgG subclasses, residues identified as important for C1q binding and 
areas of variability between the subclasses. 
Whilst human IgG4 antibody shares many residues with IgG1 highlighted as essential for 
binding, including those originally identified on mouse IgG2b, it interacts poorly with C1q. The 
amino acid residue Serine331, which only occurs in IgG4, is thought to be partly responsible for 
this lack of affinity (Brekke et al., 1994; Tao et al., 1993; Xu et al., 1994). Replacing Proline331 in 
IgG1 and IgG3 antibodies for Serine abolishes C1q binding in these subclasses whilst a Serine331 
to Proline substitution in IgG4 can recover binding (Xu et al., 1994). 
 
1.2.5.4 Immunoglobulin Binding Motif on C1q 
C1q binds antibody through the globular heads at the C-terminus of the molecule, 
denoted by size as A, B and C (Duncan and Winter, 1988; Hughes-Jones and Gardner, 1979). 
When individually isolated, each of the globular heads show binding to IgG and IgM (Kaul and 
Loos, 1997). A more detailed analysis of individual globular head binding to antibody showed 
preferential binding of IgG to globular heads A and B over C whilst IgM showed preferential 
binding to globular heads A and C (Kishore et al., 2003; Kishore et al., 1998). 
As with the binding motif for C1q on IgG, mutations of the residues predicted as 
potential points of interaction have been performed with each globular head of C1q (Gadjeva et 
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al., 2008; Kojouharova et al., 2004; Roumenina et al., 2006; Zlatarova et al., 2006). These studies 
have revealed a bias in the contribution that globular head B makes in antibody binding. For 
IgG1, the residues ArginineA162, LysineA200, ArginineB108, ArginineB109, ArginineB114, HistidineB117, 
ArginineB129, LysineB136, ArginineB163 and ArginineC156 have all been implicated. A total of twenty 
residues from globular heads B and C are predicted to facilitate the binding to IgG (Gaboriaud et 
al., 2003; Schneider and Zacharias, 2012). The binding motif for IgM is less well studied. The 
amino acid residues TyrosineB175, ArginineB108, ArginineB109, LysineB136, LysineA200, HistidineC101 
and LysineC170 have each been indicated in IgM binding (Gadjeva et al., 2008; Zlatarova et al., 
2006). These residues, along with those highlighted for IgG, are detailed in Table 1. 4. 
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Table 1. 3 C1q Binding Motifs on Rabbit IgG and Human IgG Subclasses 
The amino acid sequences of the hinge and CH2 regions of rabbit IgG and human IgG subclasses is shown. Amino acid residues contained within the CH2 regions 
identified to reduce, facilitate or are not involved in the interaction with C1q are highlighted. The glycosylation site and residues that vary between antibodies are 
also highlighted.  
 
 
 
 
 
 
 
 
 
 
Table Key: A
1
 = Reduce interaction with C1q; N
297
 = Glycosylation site; D
2
 = Enhance interaction with C1q; D
3
 = Not involved in C1q binding; D = Areas of variation. 
Table References: (Brekke et al., 1994; Duncan and Winter, 1988; Gaboriaud et al., 2003; Idusogie et al., 2000; Moore et al., 2010; Morgan et al., 1995; Nose and 
Wigzell, 1983; Quast et al., 2015; Schneider and Zacharias, 2012; Tao et al., 1993; Thommesen et al., 2000; Xu et al., 1994). 
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Table 1. 4 IgG and IgM Binding Motifs on C1q 
The amino acid sequences of the A, B and C chains of human C1q. Residues indicated in binding IgG or IgM, IgG and IgM are highlighted. Residues underlined and 
emboldened are contained within the globular heads of each chain. 
 
 
 
 
 
 
 
 
 
Table Key: M
2
 = IgG binding only; Y
1
 = IgM binding only; R
+
 = IgG and IgM binding. Table References: (Gaboriaud et al., 2003; Gadjeva et al., 2008; Kishore et al., 
2003; Kishore et al., 1998; Kojouharova et al., 2004; Roumenina et al., 2006; Schneider and Zacharias, 2012; Zlatarova et al., 2006). 
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1.2.5.5 Complement Activation and Antigen Density 
Of the human antibody subclasses, IgM, IgG3 and IgG1 exhibit the greatest ability to 
activate complement (Bindon et al., 1988; Brüggemann et al., 1987; Dangl et al., 1988; Garred 
et al., 1989). The IgG subclasses IgG2 and IgG4 show very little complement activation (Davies 
and Sutton, 2015; Xu et al., 1994). In lower antigen densities, IgG3 shows better complement 
activation than IgG1 whilst at higher antigen densities it is IgG1 that shows better complement 
activation that IgG3 (Garred et al., 1989; Giuntini et al., 2016).  
It was thought that this apparent resilience of IgG3 to fix complement, even in areas of 
low antigen density, may be explained by its extended hinge region and resultant increased 
flexibility compared to the other human IgG subclasses (Edelman et al., 1969; Michaelsen et al., 
1977; Vidarsson et al., 2014). However, this hypothesis was recently challenged when the ability 
of IgG1, IgG3 and hinge-truncated IgG3 antibodies to fix C1q and activate complement on the 
surface of Neisseria meningitidis bacteria was assessed (Giuntini et al., 2016). As before, IgG3 
activated complement better that IgG1 when bound to a sparsely expressed antigen and IgG1 
activates better than IgG3 when bound to a densely expressed antigen. Unexpectedly, the IgG3 
hinge-truncated mutants had enhanced complement activation when compared to intact IgG3 
suggesting the long IgG3 hinge is not responsible for the superior complement activation 
compared to IgG1 with sparse antigens. These observations confirm previous findings that a 
hinge-truncated IgG3 antibody had superior complement activation capabilities compared to 
wild type IgG3 (Norderhaug et al., 1991). The exact mechanism behind this phenomenon is 
unknown although it is suspected that the long hinge of IgG3 keeps complement activation 
further from the antigenic surface than IgG1 reducing potency. 
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1.3 The Complement System 
The complement cascade is an ancient part of the innate immune system comprised of 
a series protein components found in the blood (Dunkelberger and Song, 2009). The 
complement system functions to clear pathogens from the host by several mechanisms 
including opsonisation, complement dependent cytotoxicity and chemotaxis (Frank and Fries, 
1991; Nuttall, 1888; Ward et al., 1965). Three pathways of complement activation, known as the 
classical, lectin and alternative pathways, have been described (Arlaud and Colomb, 2005; 
Thurman and Holers, 2006; Turner, 1996). Each of these pathways share many components but 
are activated by distinct mechanisms. An overview of complement activation for each pathway 
is shown in Figure 1. 6. 
The discovery of complement has been attributed to a number of scientists in the late 
19th and early 20th century who noted the bactericidal effects of serum. Élie Metchnikoff (1845-
1916), Russian zoologist and former pupil of Pasteur, was the first to describe the ability of 
phagocytic cells to clear infection by engulfing and digesting them (Gordon, 2008). At the time 
it was thought that phagocytosis was the main action of pathogen clearance until Hungarian 
scientist Josef Von Fordor (1843-1901), working on Anthrax, showed that the acellular fraction 
of blood alone could directly kill the bacteria (Tauber and Chernyak, 1989; Von Fodor, 1886). 
German bacteriologist Hans Buchner (1850-1902) who also noticed this phenomenon coined the 
term ‘alexin’ from the Greek ‘to ward off’ (Buchner, 1891; Buchner, 1889). Bacteriologists 
Richard Pfeiffer (1858-1945), George Nuttall (1862-1937) and Jules Bordet (1870-1961) showed 
the lytic properties of blood were enhanced with prior vaccination but inhibited when heated 
to 56⁰C suggesting that alexin was, in fact, two separate entities (Nuttall, 1888; Pfeiffer, 1894). 
Bordet proposed that bacteria were first sensitised by binding antibodies allowing the 
complement system to deliver the killer blow (Bordet, 1895; Bordet, 1900). Building on this work 
Professor Paul Ehrlich (1854-1915) noted in his 1899 work entitled ‘Zer Theorie der 
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Lysinwirkung’, or ‘On the theory of the action of lycin’, that the heat liable component of alexin 
complemented the action of antibodies in the destruction of bacteria (Ehrlich and Morgenroth, 
1899). As such, the term ‘complement’ is now used to describe the heat-labile component 
responsible for the bactericidal activity of blood. The idea of complement existing of multiple 
components was first demonstrated in 1907 by A. Ferrata and E. Brand (Brand, 1907; Ferrata, 
1907). Today, more than 30 components of complement have been described, and its 
importance in disease is well understood (Sarma and Ward, 2011). 
 
1.3.1 Pathways of Complement Activation 
 
1.3.1.1 Classical and Lectin Pathways 
 The classical pathway of complement was the first pathway of activation to be described 
following the experiments of Bordet, Ehrlich and Morgenroth (Bordet, 1895; Bordet, 1898; 
Ehrlich and Morgenroth, 1899; Ehrlich and Morgenroth, 1901). Whilst investigating the lytic 
properties of blood, they noted that complement dependent cytotoxicity of erythrocytes was 
only initiated once first sensitised by antibody. The classical pathway is triggered by binding of 
the C1 complex to its ligand (Cooper, 1985). The C1 complex is composed of a recognition 
domain, C1q, and a serine protease domain, comprising of two copies each of C1r and C1s 
(Lepow et al., 1963). The C1r and C1s tetramer interact with each of the six triple helical collagen-
like stems protruding from each globular head of C1q which is stabilised in the presence of Ca++ 
ions (Gregory et al., 2003). The immunoglobulins IgG and IgM are the most studied ligands of 
C1q, but many other ligands have been described (Gaboriaud et al., 2003). 
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Figure 1. 6 Pathways of Complement Activation 
The complement system is activated by three different pathways: classical, lectin and 
alternative. The classical and lectin pathways are activated by the serine protease associated 
pattern recognition molecules C1q and MBL/ficolins, respectively. The conformational changes 
in C1q and MBL that occur when bound to their respective ligands activate the associated serine 
proteases, which in turn cleave C4 and C4b-bound C2 forming the C3 convertase of the classical 
and lectin pathways, C4b2a. The alternative pathway is activated by spontaneous hydrolysis of 
C3 causing a conformational change that allows FB to associate. FD then cleaves FB to generate 
the C3 convertase of the alternative pathway, C3(H2O)3Bb. The C3 convertases of each pathway 
cleave C3 into C3a and C3b. The associated of C3b with each C3 convertases forms the C5 
convertase for each three pathways. The C5 convertase cleaves C5 into C5a and C5b. C5b further 
associated with C6, C7, C8 and C9 to form the membrane attack complex (MAC). Proteolytic 
fragments C4a, C3a and C5a function as anaphylatoxins whereas the fragments C4b, C3b and 
C5b function as opsonins.  
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The lectin pathway of complement activation is the most recent of the three pathways 
to be described following the isolation of mannose-binding lectin (MBL), the activator of the 
lectin pathway, in the late 1970s and 1980s (Ikeda et al., 1987; Kawasaki et al., 1983; Kawasaki 
et al., 1978). Noting the similarities between C1q and MBL, Y. Kozutsumi, T. Kawasaki and I. 
Yamashina postulated its ability to activate complement when bound to cell surfaces (Ikeda et 
al., 1987). Unlike the classical pathway where C1q is the only recognition protein, the lectin 
pathway consists of two distinct families of recognition proteins: ficolins and collectins 
(Holmskov et al., 2003). MBL is a member of the collectin family and the best characterised of 
the lectin pathway activators. Like C1q, MBL associates with a tetramer of serine proteases, two 
monomers each of MBL-associated serine protease-1 and 3 (MASP-1 and 3) and MASP-2 (Dahl 
et al., 2001; Matsushita and Fujita, 1992; Thiel et al., 1997). MBL monomers are formed of a 
short non-collagenous region at the N-terminus of the protein followed by a longer collagen-like 
domain, a neck region and carbohydrate recognition domain (Dong et al., 2007). Homotrimers, 
known as stalks, associate through the interaction of collagen-like regions between each 
monomer stabilised by disulphide bonds between the N-terminus regions (Thiel, 2007). Finally, 
two to six stalks assemble forming functional MBL. Only one dimer of MASP-1 or MASP-2 tends 
to associate with the collagen-like domain of MBL trimers and tetramers whereas MASP-2 and 
MASP-3 tend to associate with the collagen-like domain of higher oligomers of MBL (Dahl et al., 
2001). In serum, MBL predominantly exists as a trimers or tetramers. MBL binds 3- and 4-
hydroxyl groups in the pyranose ring carbohydrates, such as glucose, D-mannose and N-
acetylglucosamine, commonly expressed by pathogenic cells, in the presence of Ca++ ions (Endo 
et al., 2006).  
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 Multivalent binding of the C1 complex causes a conformational change bringing the 
activation and catalytic sites of both C1r proteases together (Gaboriaud et al., 2004). C1r is then 
auto-activated by the cleavage of the arginine–isoleucine bond in the activation site of one C1r 
monomer by a serine residue within the catalytic site of the other (Lacroix et al., 2001). Once 
activated, C1r then cleaves and activates C1s in the same fashion. Activated C1s shows specificity 
for both C4 and C2. C1s first cleaves C4, into C4a and C4b, and then cleaves C2, into C2a and 
C2b, but only when C2 is in complex with C4b (Müller-Eberhard et al., 1967; Polley and Müller-
Eberhard, 1968). Unlike C1r, MASP-1 dimers are not auto-activated but activated by a separate 
MASP-1 dimer when MBL complexes cluster (Kjaer et al., 2016; Kjaer et al., 2015). Activated 
MASP-1- cleaves and actives MASP-2 which can then cleaves C4 and C4b-bound C2 (Héja et al., 
2012). MASP-1 also shows serine protease activity towards C4-bound C2 (Møller-Kristensen et 
al., 2007). The larger fragments of proteolysis, C4b and C2a, remain together forming the C3 
convertase of the classical and lectin pathways, C4bC2a, whereas C4a and C2b are released. C4b, 
anchored to the surface of pathogens, is an opsonin targeting cells for phagocytosis (Krych‐
Goldberg and Atkinson, 2001). Upon the cleavage of C4, an internal thioester is exposed 
covalently linking C4b to amino or hydroxyl groups present on pathogenic surfaces (Dodds et al., 
1996). This same mechanism also tethers C3b to pathogenic surfaces (Sim et al., 1981). 
 The preferred substrate of C4b2a is C3 (Pangburn and Rawal, 2002). However, C5 may 
also associate with C4b2a but with a 1000-fold lower affinity than C3 (Rawal and Pangburn, 
2003). Cleavage of C3 into C3b and C3a is executed by the serine protease domain of C4b-bound 
C2a (Krishnan et al., 2007). The specificity of the convertase dramatically alters to C5 upon the 
binding of C3b to the alpha chain of C4b through an ester bond (Takata et al., 1987). The C3a 
fragment is released into the circulation and C3b that does not associate with C4b2a may bind 
directly to the surface of the pathogen via the same exposed thioester, opsonising those cells 
for phagocytosis (Fearon, 1980; Reid and Porter, 1981). C3a is an anaphylatoxin able to 
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chemotactically attract leukocytes to areas of complement activation (Ward et al., 1965). C5 can 
then be cleaved by the C5 convertase (C4b2a3b) generating C5a and C5b. C5a, another 
anaphylatoxin, is released into the circulation (Snyderman et al., 1970). C5b associates with C6, 
C7, C8 and C9 forming the membrane attack complex (MAC) (Serna et al., 2016). 
 
1.3.1.2 Alternative Pathway 
 The alternative pathway of complement activation was first proposed in the 1950s by 
Louis Pillemer et al., following the discovery of properdin (from the Latin perdere meaning ‘to 
destroy’), now known to be positive regulator of the alternative pathway (Nesargikar et al., 
2012; Pillimer et al., 1954). 
 The alternative pathway becomes activated by the spontaneous hydrolysis of the 
internal thioester bond of C3 into C3(H2O), a C3b-like molecule, at a rate of roughly 0.005% per 
minute (Pangburn et al., 1981). In addition, hydrolysis of C3 into C3 (H2O) also reveals the factor 
B (FB) binding region, allowing the formation of the pro-convertase complex C3(H2O)B in the 
presence of Mg++ (Forneris et al., 2010). The association of FB with hydrolysed C3 (or C3b) 
exposes the internal scissile bond in FB for cleavage by the serine protease factor D (FD) into Bb 
and Ba (Milder et al., 2007). In solution, FD is self-inhibited by a structural loop masking the 
active site that is only revealed upon interaction with C3 (H2O) -bound (or C3b-bound) FB (Jing 
et al., 1998). Ba is released into the circulation whereas Bb remains bound to C3b generating the 
C3 convertase of the alternative pathway, C3bBb (Rooijakkers et al., 2009). Properdin binding to 
both C3b and Bb stabilises this convertase by slowing disassociation and inhibiting cleavage by 
factor I (FI) in the presence of FH promoting complement activation (Alcorlo et al., 2013; Fearon 
and Austen, 1975; Hourcade, 2006). 
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 The substrate for C3bBb is C3, cleaving the scissile bond releasing C3a into the 
circulation leaving C3b to bind and opsonise cell surfaces and complex with C3bBb (Reid and 
Porter, 1981). Membrane-bound C3b can again associate with FB forming more C3 convertase 
complexes, cleaving even more C3 driving complement activation in a process known as the 
amplification loop of the alternative pathway (Lachmann, 2009; Müller-Eberhard and Götze, 
1972). The amplification loop of the alternative pathway also amplifies the classical and lectin 
pathways once they themselves are activated (Harboe et al., 2004). Alternative pathway 
inhibition assays show that roughly 80 to 90% of complement activation by the classical pathway 
can be attributed to alternative pathway amplification. The association of additional membrane-
bound C3b molecules with the C3bBb complex forms the C5 convertase of the alternative 
pathway, C3bBb3b (Berends et al., 2015; Daha et al., 1976; Kinoshita et al., 1988). C5 is then 
cleaved by the C5 convertase generating C5a, which is released into the circulation, and C5b, 
which associates with C6, C7, C8 and C9 forming the MAC (Serna et al., 2016). 
 
1.3.2 Functions of Complement 
 
1.3.2.1 Complement Dependent Cytotoxicity 
 Pathogens are directly lysed by complement in a process known as complement 
mediated cytotoxicity (CDC) (Nuttall, 1888). Regardless of the pathway of complement 
activation initially triggered, sufficient complement activation results in the formation of pores 
in the lipid bilayer of cellular membranes (Muller-Eberhard, 1988). Known as the membrane 
attack complex (MAC), these pores are composed of the complement components C5b, C6, C7, 
C8 and C9 in a molar ratio of 1:1:1:1:19-22, respectively (Dudkina et al., 2016; Serna et al., 2016). 
CDC is of particular importance in the clearance of Gram-negative bacteria, such as Neisseria 
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meningitidis (Taylor, 1983). Individuals deficient in the components of MAC are vulnerable to 
recurrent meningococcal disease (Ross and Densen, 1984) 
 Insertion of MAC through the lipid bilayer of pathogens disturbs the permeability and 
stability of the membrane disrupting the osmotic gradient between intercellular and 
extracellular ions (Esser, 1994). The rapid flux of extracellular fluid into the cell and extrusion of 
intracellular material leads to cell death (Podack, 1986). MAC attack that does not directly result 
in cell death can initiate downstream pathways involved in proliferation, apoptosis, 
transcription, lipid metabolism and inflammation (Morgan, 2016; Morgan and Campbell, 1985; 
Takano et al., 2013; Triantafilou et al., 2013).  
 The first event in MAC formation is the cleavage of C5 by the C5 convertase of either 
classical/lectin (C4b2a3b) or alternative (C3bBbC3b) pathways into C5a and C5b tethered to the 
surface of the targeted cell (Medicus et al., 1976; Pangburn and Rawal, 2002). C5b forms an 
irreversible complex with C6 and C7 in the fluid-phase followed by C8 and C9 once membrane-
bound (Aleshin et al., 2012). Binding of C7 to the C5b6 complex causes a significant 
conformational change exposing the hydrophobic stalk of C7 thus anchoring C5b67 into but not 
through the lipid bilayer (DiScipio et al., 1988). C8 is formed of three chains: α, β and γ. 
Membrane-bound C5b67 binds to the β chain of C8 causing a conformational change with the α 
and β chains of C8 inserting their hydrophobic regions into the membrane further anchoring the 
complex (Tegla et al., 2011). C9 then binds the α chains of C8 unravelling C9 through the lipid 
membrane and allowing the addition of further C9 molecules. 
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1.3.2.2 Inflammation 
Complement recruits leukocytes to areas of complement activation by the process of 
chemotaxis (Ward et al., 1965). Complement chemoattractants, also known as anaphylatoxins, 
include C5a and C3a (Frank and Fries, 1991). Anaphylatoxins were named as such due to their 
ability to induce cardiac dysfunction and hypersensitivity reactions in guinea pigs (Del Balzo et 
al., 1985). The complement component C1q, acting through C1q receptors expressed by 
neutrophils, mast cells, DCs and eosinophils, is also a chemoattractant (Eggleton et al., 1998; 
Ghebrehiwet et al., 1995; Kuna et al., 1996; Vegh et al., 2006). Generated in large quantities at 
sites of complement activation, anaphylatoxins diffuse into the circulation forming a 
chemotactic gradient for inflammatory and phagocytic cells to follow (Snyderman et al., 1970). 
Not only are C5a and C3a chemoattractants but also vasodilators, increasing the permeability of 
the microvasculature and facilitating effective cellular migration to sights of inflammation 
(Schumacher et al., 1991). 
 C5a is the most potent of the anaphylatoxins with multiple mechanisms of action (Frank 
and Fries, 1991). Two C5a receptors, known as C5aR and C5L2, have been identified (Cain and 
Monk, 2002; Gerard and Gerard, 1991). C5aR is a G-protein coupled receptor with seven 
transmembrane segments (Geva et al., 2000). C5aR is expressed on many cell types, including 
neutrophils, macrophages, monocytes, eosinophils, T cells and many other non-myeloid cells 
(Nataf et al., 1999; Zwirner et al., 1999).  
Although similar in structure to C5aR (58% homology), the C5a receptor C5L2 is not G-
protein coupled (Li et al., 2013). The exact function of C5L2 is a controversial topic. It was first 
thought to be a non-signalling, decoy receptor for C5a dampening inflammation by inhibiting 
C5aR signally (Okinaga et al., 2003). However, pro-inflammatory consequences of C5LR ligation 
have been described (Gao et al., 2005; Rittirsch et al., 2008). C5L2 also binds the inactive 
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anaphylatoxin fragment C3adesArg and C5adesArg with unknown functional consequences (Cain and 
Monk, 2002; Cui et al., 2009b).  
C3a is roughly 50 to 100 times less potent that C5a (Ehrengruber et al., 1994; Fernandez 
et al., 1978). Only one receptor for C3a, known as C3aR, has been identified (Ames et al., 1996). 
Like C5aR, C3aR is a G-protein coupled receptor with seven transmembrane segments expressed 
on neutrophils, granulocytes and monocytes (but not T cells) (Martin et al., 1997).  
Signalling through C5aR and C3aR changes the morphology of leukocytes (Servant et al., 
2000). Cells quickly adopt a polarised morphology driven by actin polymerisation and the 
concentration of receptor involved in migration towards the leading edge of the cell driving 
migration upstream of the chemotactic gradient (Sadik et al., 2011). 
 
1.3.2.3 Opsonisation 
Deposition of complement proteins on the surface of pathogens targets them for and 
supports their phagocytosis (Aderem and Underhill, 1999; Frank and Fries, 1991; Wright and 
Silverstein, 1982). This process of labelling pathogens for phagocytosis is known as opsonisation. 
Opsonisation is particularly important for the clearance of pathogens resistant to CDC (Ram et 
al., 2010). Complement opsonins include C1q, C4b, MBL and the breakdown products of C3 
cleavage (Bobak et al., 1987; Dunkelberger and Song, 2010; Kuhlman et al., 1989). Complement 
receptors (CRs) expressed by phagocytic cells, such as DCs, macrophages and neutrophils, bind 
complement opsonins initiating and enhancing phagocytosis (Fearon, 1980). At least five CRs 
are involved in effective phagocytosis: CR1, CR2, CR3, CR4 and CRIg (Ross and Medof, 1985). 
 CR1 and CR2 are structurally similar, consisting of an intracellular domain, 
transmembrane region and a long extracellular domain formed of 30 and 15 short consensus 
repeats (SCR), respectively (Ahearn and Fearon, 1989). Both receptors are members of the 
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family of regulators of complement activation which includes MCP, decay-accelerating factor 
(DAF), FH and C4 binding protein (C4BP) (Krych‐Goldberg and Atkinson, 2001). CR1 exhibits the 
widest range of specificities of the receptors binding primarily to C3b and C4b but also MBL, C1q, 
iC3b and C3dg (Fearon, 1980; Ghiran et al., 2000; Klickstein et al., 1997; Krych‐Goldberg and 
Atkinson, 2001). CR1 serves as a co-factor protein for FI and is necessary for the production of 
C3dg, an important molecule in reducing the antigen threshold needed for B cell activation 
(Dempsey et al., 1996; Medof et al., 1982; Nishida et al., 2006).  
CR2 binds only iC3b, C3d and C3dg and, like CR1, serves as a co-factor protein for FI 
(Molina et al., 1994). Concurrent binding of the BCR and CR2 to antigens coated in C3dg 
significantly decreased the activation threshold in B cells (Lyubchenko et al., 2005; Nussenzweig 
et al., 1971). In B cells, CR2 associates with the membrane adapter protein CD19 which acts by 
recruiting SCR kinases (Vav, Lyn and PI 3-kinase) when co-ligated with BCR enhancing B cell 
activation (Fujimoto et al., 2000).  
CR3 and CR4 are β2-integrins composed of CD18 and either CD11b or CD11c, 
respectively. CR3 and CR4 are specific receptors for iC3b (Ross and Větvička, 1993). Whilst both 
receptors are involved in phagocytosis of complement-tagged pathogens, CR3 functionally 
dominates (Sándor et al., 2013). CRIg is a member of the immunoglobulin superfamily which 
also includes CD19, CD4, CD8, antibodies and MHC classes I and II; specific for C3b and iC3b 
(Helmy et al., 2006). 
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1.3.3 Complement Regulation 
Host regulators of the complement system come in two forms; those expressed on the 
cellular surfaces and those that are secreted into the serum (Zipfel and Skerka, 2009).  
 
1.3.3.1 Soluble Complement Regulators 
 C4BP regulates the classical and lectin pathways of complement activation at the level 
of C3 convertase (Blom et al., 2001). C4BP is a large protein (570kDa) composed of eight 
subunits: seven identical α-chains with eight SCR domains and one β-chain with three SCR 
domains (Dahlbäck, 1983; Dahlbäck et al., 1983). The first three SCR domains of the α-chains 
bind C4b inhibiting the association with C2 and C3 convertase formation. C4BP has also been 
shown to accelerate the decay of the C3 convertase and act as a co-factor protein for FI (Gigli et 
al., 1979). It has also been suggested that C4BP binds C3b, functioning as a co-factor for FI (Blom 
et al., 2003). 
 FI is a serine protease regulating all three pathways by inactivating both C3b and C4b 
when they are bound to a co-factor protein (Masaki et al., 1992; Ross et al., 1982). Cofactor 
proteins for FI include FH, MCP, CR1 and C4BP (Lambris et al., 1996; Molina et al., 1994; Nishida 
et al., 2006). C3b cleavage by FI in the presence of the co-factors CR1, MCP or FH produces two 
fragments: iC3b, which remains membrane bound, and C3f, which is released into the circulation 
(Alcorlo et al., 2011). Cleavage disrupts the FB binding site thus removing the ability to form the 
C3 convertase of the alternative pathway. CR1 is the only co-factor able to facilitate further 
cleavage of iC3b between residues Arg932 and Glu933 by FI into C3c, which is released into the 
circulation, and C3dg, which remains anchored to the membrane (Furtado et al., 2008). C3dg is 
a ligand for CR2 involved in reducing the activation threshold in B cells when bound to BCR 
antigens (Dempsey et al., 1996; Lyubchenko et al., 2005). C4b cleavage by FI in the presence of 
the co-factors CR1, MCP and C4BP produces two fragments (iC4b and C4d) that are unable to 
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associate with C2 and form the C3 convertase of the classical and lectin pathways (Masaki et al., 
1992). 
 Not only does FH possess co-factor activity for FI but decay accelerating activity against 
the C3 convertase of the alternative pathway (Wu et al., 2009). FH is a single-chain 155kDa 
plasma glycoprotein formed of 20 homologous SCRs connected to one another by short spacers 
of between three and eight amino acids in length (Kristensen et al., 1986; Nilsson and Müller-
Eberhard, 1965; Ripoche et al., 1988; Whaley and Ruddy, 1976). The SCRs of FH are composed 
of approximately 61 amino acids which are each independently folded into globular structures 
consisting of six stranded antiparallel β-sheets by a series of loops and turns (Barlow et al., 1992; 
Okemefuna et al., 2009; Ripoche et al., 1988). Domains 1 and 2 are primarily responsible for the 
decay accelerator activity of FH which binds to the Bb binding region of C3b thus displacing Bb 
from the complex by steric hindrance and electrostatic repulsion. Domains 7, 19 and 20 anchors 
FH to glycosaminoglycans (GAGs) expressed on cell surfaces as well as membrane-bound C3b. 
Factor H-like protein (FHL-1) is a truncated form of FH composed of the first seven domains of 
FH that retains both co-factor activity for FI and decay accelerating activity for C3bBb (Zipfel and 
Skerka, 1999). The FH–related protein 1 (CFHR-1) is a truncated homologue of FH composed of 
only five SCR domains (de Jorge et al., 2013). The first two domains of CFHR-1 show 42% and 
34% sequence homology with domains 6 and 7 of FH and the remaining three domains of CFHR-
1 show 100%, 100% and 97% sequence homology with domains 18-20 of FH. Furthermore, 
CFHR-1 lacks domains 1-4 of FH responsible for the regulatory activity of C3 convertase but 
retains C3b and GAG binding through domains 4 and 5 (Heinen et al., 2009). 
 The serine proteases C1r and C1s, and MASP-1 and MASP-2 associate with the 
recognition molecules of the classical (C1q) and lectin (MBL) pathways, respectively (Lepow et 
al., 1963; Matsushita and Fujita, 1992; Thiel et al., 1997). Once activated, these serine proteases 
cleave C4 initiating the activation of both pathways (Héja et al., 2012; Müller-Eberhard et al., 
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1967). The activity of these serine proteases is regulated by the protease inhibitor C1-inhibitor 
(C1INH) (Arlaud et al., 1979; Davis et al., 2010; Ratnoff and Lepow, 1957). C1INH is a member of 
the serine protease inhibitor (serpin) superfamily which also includes angiotensinogen and 
antitrypsin (Law et al., 2006). The substrate list for C1INH is not limited to complement proteases 
but includes several involved in the coagulation system, the fibrinolytic system and the plasma 
kallikrein–kinin system (Davis et al., 2008). C1INH becomes activated upon contact and cleavage 
of the peptide bond (Arg444-Thr445) in the reactive centre of C1INH by the C1q or MBL associated 
serine proteases. Cleavage of the peptide bond results in a conformational change of C1INH and 
generation of a covalent bond with the active site of the now inactivated, deformed serine 
protease (Huntington et al., 2000). 
 Plasma proteins clusterin and vitronectin are both negative regulators of complement 
that inhibit the formation of MAC and subsequent CDC of targeted cells (Tschopp et al., 1993). 
Both regulators have two modes of action: blocking the membrane binding site present in C7 in 
C5b-7 and preventing the incorporation of C9 into C5b-8 and C5b-9 (McDonald and Nelsestuen, 
1997; Milis et al., 1993). 
 The activity of the anaphylatoxins C3a and C5a is regulated by the protease enzymes 
carboxypeptidase N and carboxypeptidase B (Bajic et al., 2013; Bokisch and Müller-Eberhard, 
1970). C3a and C5a signal through the G-protein coupled receptors C3aR and C5aR, driving 
inflammation at sites of complement activation (Ames et al., 1996; Cain and Monk, 2002; Gerard 
and Gerard, 1991). C5a also binds to the receptor C5L2 although the exact consequences of this 
are unknown (Li et al., 2013). Carboxypeptidases cleave the C-terminal arginine residues of both 
C3a and C5a necessary for signalling through their respective receptors (Kaneko et al., 1995; 
Wilken et al., 1999). Although both carboxypeptidases show specificity for C3a and C5a, 
carboxypeptidase B shows a preference for C5a whereas carboxypeptidase N shows a 
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preference for C3a (Campbell et al., 2002). C5L2 also binds C3adesArg and C5adesArg (Cain and Monk, 
2002; Cui et al., 2009a; Li et al., 2013). 
 Properdin is the only known positive regulator of the alternative pathway (Alcorlo et al., 
2013; Hourcade, 2006). As previously discussed, properdin stabilises the C3 convertase C3bBb 
by binding to both C3b and Bb in the complex. 
 
1.3.3.2 Membrane-bound Complement Regulators 
CD59 is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein able to 
bind both C8 (in C5b-8) and C9 (in C5b-9), disrupting the formation of MAC thus protecting cells 
from CDC (Meri et al., 1990). Binding of CD59 to C5b-8/9 complexes prevents the unfolding of 
C9 necessary for insertion through lipid membranes and additional polymerisation of C9 (Farkas 
et al., 2002). 
 The GPI-anchored membrane glycoprotein decay-accelerating factor (DAF; CD55) 
regulates the C3 convertases of the classical, lectin and alternative pathways (Nicholson-Weller 
et al., 1982). The extracellular region of DAF is composed of four complement control protein 
domains which bind to both C4b and C3b displacing C2a and Bb, respectively (Brodbeck et al., 
2000). Classical and lectin pathway regulatory activity is contained with domains 2 and 3 
whereas the alternative pathway regulatory activity is contained within domains 2, 3 and 4 
(Brodbeck et al., 1996).  
 The FI co-factor activities of the membrane-bound complement regulators CR1 and MCP 
was previously described in Section 1.3.3.1. CR1 also expresses decay accelerating activity for 
the C3 convertases of the alternative, classical and lectin pathways (Zipfel and Skerka, 2009). 
CR1 shows specificity for both C3b and C4b in each convertase displacing Bb and C2a, 
respectively. 
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1.3.4 Complement and Neisseria meningitidis 
Complement-mediated lysis, facilitated by the MAC, is considered by some to be the 
most important mechanism in the protection against invasive meningococcal disease 
(Goldschneider et al., 1969a; Granoff, 2009). Opsonisation by products of complement 
activation and subsequent phagocytosis of Neisseria meningitis in protection is less well defined 
but thought to play a significant role in some individuals (Granoff, 2009). High incidence rates of 
meningococcal disease in those deficient in terminal pathway components (C5, C6, C7, C8 and 
C9) suggests the importance of bacteriolysis over opsonophagocytosis (Figueroa and Densen, 
1991). Neisseria meningitidis has developed several mechanisms to evade the immune response 
ensuring effective colonisation of the host. The understanding of how Neisseria meningitidis 
manages to establish infection is of particular importance in the generation of potential targets 
for vaccination and prevention of disease. A summary of immune evasion mechanisms of 
Neisseria meningitidis is shown in Figure 1. 7.  
The FHbp is a 27kDa outer membrane lipoprotein expressed by all tested Neisseria 
meningitidis isolates that expresses an affinity for human FH and FHR-3 proteins (Caesar et al., 
2014; Cendron et al., 2011; Madico et al., 2006). Sequence analysis of FHbp variants shows three 
(or two) distinct sub-families sharing at least 63% sequence similarity (Brehony et al., 2009; 
Murphy et al., 2009). FHbp is formed of two domains connected by a short loop: a curved eight-
stranded antiparallel β-sheet at the N-terminal (containing region A and part of region B) and a 
eight-stranded antiparallel β-barrel at the C-terminal (containing the remainder of region B and 
region C) (Cantini et al., 2005; Cendron et al., 2011; Schneider et al., 2009; Serruto et al., 2012). 
Regions A, B and C of FHbp interact with FH SCRs 6 and 7 maintaining co-factor and decay 
accelerator properties of bound FH thus increasing the survival of Neisseria meningitidis in 
serum (Granoff et al., 2009; Madico et al., 2006; Schneider et al., 2009). 
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Figure 1. 7 Complement Evasion Mechanisms of Neisseria meningitis 
Factor H binding protein (FHbp) recruits fluid-phase complement regulator FH to the surface of 
the bacteria inhibiting complement activation by cleaving of C3b, in the presence of Factor I, and 
accelerating the decay of the alternative pathway C3 convertase (C3bBb). Surface proteins 
PorB2 and NspA also bind FH. The porin PorA reduces complement-mediated lysis by binding 
C4BP, a co-factor for FI in the cleavage and inactivation of C4b. The polysaccharide capsule of 
Neisseria limits classical pathway activation by sterically hindering C1q engagement to the 
surface of antibody labelled bacteria. The auto-transporter NalP specifically cleaves human C3 
into inactive C3a-like and C3b-like fragments, reducing anaphylatoxin release and further 
complement activation.  
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Other FH binding proteins identified on Neisseria meningitidis include porin B2 (PorB2), 
PorB3 and Neisserial surface protein A (NspA) (Giuntini et al., 2015; Lewis et al., 2010; Lewis et 
al., 2013). The auto-transporter protease NalP specifically cleaves human C3 into an inactive 
C3b-like fragment and a C3a-like fragment (Del Tordello et al., 2014). Although the C3a-like 
fragment was not functionally assayed, structural analysis revealed the fragment lacked the C-
terminal arginine thought to be essential for activity (Bokisch and Müller-Eberhard, 1970). The 
porin PorA expressed on the surface of the bacterium binds the complement inhibitor C4BP. 
C4BP regulates the classical and lectin pathways of complement activation at the level of C3 
convertase (Jarva et al., 2005).  
Each pathway of complement activation has been implicated in the protection against 
meningococcal disease. The relative importance of each of the three pathways of complement 
activation has been assessed using serum deficient in individual components or pathway-specific 
inhibitors. 
 
1.3.4.1 Neisseria meningitidis and The Classical Pathway 
The classical pathway of complement is activated by C1q binding primarily to antigen 
bound immunoglobulin (Cooper, 1985). The presence of bactericidal antibody specific for 
Neisseria meningitidis is a well-defined correlate of protection as previously discussed. Although 
not nearly as pronounced as terminal pathway deficiency, C2 deficiencies are associated with 
an increased risk of meningococcal disease (Ross and Densen, 1984). However, vaccination 
against Neisseria meningitidis does produce strong SBA titres in individuals deficient in C2. 
Direct C1q binding and classical pathway activation on Gram-negative bacteria has been 
described (Mintz et al., 1995; Tenner et al., 1984); however, the benefit of the classical pathway 
in the absence of bactericidal antibody is minimal (Agarwal et al., 2014; Drogari-Apiranthitou et 
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al., 2002). In a recent study, some classical pathway activation was seen on Neisseria 
meningitidis mutants lacking capsules highlighting the polysaccharide capsule as an important 
virulence factor for invasive disease (Agarwal et al., 2014). Encapsulation of the bacteria 
abolished all C1 activation, which was restored by anti-Neisseria meningitidis antibody. 
 
1.3.4.2 Neisseria meningitidis and The Lectin Pathway 
The lectin pathway is initiated by MBL (Ikeda et al., 1987; Kawasaki et al., 1978; Wild et 
al., 1983). MBL binds a number of ligands, including those expressed on the surface of Neisseria 
meningitis (Estabrook et al., 2004; Sprong et al., 2004). Deficiency in MBL is associated with 
increased meningococcal disease in infants (Hibberd et al., 1999; Jack et al., 1998; Jack et al., 
2001; van Helden and Hoal-van Helden, 1999). It was first thought that the ligand for MBL on 
Neisseria meningitis was lipooligosaccharides and that level of sialylation of lipooligosaccharides 
dictates MBL binding (Estabrook et al., 1997; Jack et al., 1998; Jack et al., 2001; Mackinnon et 
al., 1993; Van Emmerik et al., 1994). It was later shown that MBL binds to both meningococcal 
opacity (Opa) and PorB proteins and complement activation via the lectin pathway is now 
considered somewhat independent of lipooligosaccharide (Estabrook et al., 2004; Sprong et al., 
2004). PorB protein also binds FH (Giuntini et al., 2015; Lewis et al., 2013). 
The bactericidal activity of the lectin pathway towards Neisseria meningitis is unclear. 
In one study, no difference in the bactericidal activity was seen between MBL deficient and 
sufficient serum (Hellerud et al., 2010). In contrast, other studies have shown significantly 
reduced complement activation when the lectin pathway was inhibited or absent (Jack et al., 
2001; Sprong et al., 2003). However, blockade of the alternative pathway abolished almost all 
complement deposition on the bacteria despite an intact lectin pathway showing the 
dependence of lectin pathway activation on amplification by the alternative pathway (Sprong et 
al., 2003). These data suggest that the lectin pathway can be activated by Neisseria meningitis 
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but at such low levels as to not contribute significantly to either direct killing by MAC formation 
or clearance by opsonophagocytosis (Drogari-Apiranthitou et al., 1997). Nevertheless, the 
importance of the lectin pathway in disease prevention in more vulnerable individuals may be 
argued (Hibberd et al., 1999; van Helden and Hoal-van Helden, 1999). 
 
1.3.4.3 Neisseria meningitidis and The Alternative Pathway 
Alternative pathway component deficiencies, genome-wide association studies and 
interactions of Neisseria meningitidis with components of the alternative pathway all indicate 
the importance of the alternative pathway in protection against meningococcal disease 
(Consortium, 2010; Figueroa and Densen, 1991; Madico et al., 2006). 
 Single nucleotide polymorphisms present in genes coding for FH and FH-related protein 
3 (FHR-3) were associated with increased susceptibility to meningococcal disease in a recent 
genome-wide association study (Consortium, 2010). The serum protein FHR-3 is a truncated 
homologue of FH lacking SCRs 1 to 4 and thus has no co-factor and decay accelerator activity 
(Skerka et al., 2013). Additional examination on the specificity of FHbp showed somewhat 
indiscriminate binding between FH and FHR-3 with SPR analyses showing that the equilibrium 
dissociation constants (KD) of FHbp to human FH and FHR-3 are similar; ranging between 2.0e-9 
and 7.2e-9 M (Caesar et al., 2014; Johnson et al., 2012; Schneider et al., 2009). Both FH and FHR-
3 compete for FHbp binding and thus, relative serum levels of each either increase susceptibility 
to or protect against disease. Caesar et al., (2014) showed that the survival of Neisseria 
meningitidis in human serum is significantly reduced when the bacteria are pre-incubated with 
full length FHR-3 due to a reduction in FH binding to FHbp. Increased rates of disease are seen 
in individuals deficient in FD or properdin further supporting the importance of the alternative 
pathway in the clearance of Neisseria meningitidis (Figueroa and Densen, 1991; Linton and 
Morgan, 1999; Morgan and Walport, 1991). 
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Whilst the alternative pathway in conjunction with the classical pathway of complement 
activation is considered crucial in the protection against meningococcal, the direct contribution 
of the alternative pathway to bactericidal activity is less well characterised (Hellerud et al., 2010; 
Ram et al., 2011). In the absence of bactericidal antibody or in the presence of lectin and classical 
pathway inhibitors, active components of the alternative pathway can be found on all 
serogroups following incubation with serum (Bjerre et al., 2002; Ram et al., 2011; Sprong et al., 
2003). The structure of the polysaccharide capsule is thought to regulate alternative pathway 
activity. For serogroups C and B, strains expressing polysaccharide capsules containing sialic acid 
inhibit activation of the alternative pathway and strains resistant to bactericidal killing often 
have very high capsule expression (Hellerud et al., 2010; Jarvis and Vedros, 1987; Uria et al., 
2008). This resistance is thought to be driven by the masking of lacto-N-neotetraose present in 
the LPS of Neisseria meningitidis by sialic acid, reducing C3b binding (Estabrook et al., 1997). 
Conversely, capsule expression of serogroups W and Y has been shown to enhance alternative 
pathway activation by increased interaction with Gal and Glc residues and C3 (Ram et al., 2011). 
This may explain why properdin and FD deficient patients are more susceptible to rarer 
serogroups such as W and Y (Figueroa and Densen, 1991; Morgan and Walport, 1991). In this 
same study, C2 deficient serum did not kill any of the strains tested stressing the importance of 
the classical pathway in bacterial clearance. In conclusion, direct complement activation on 
Neisseria meningitidis by the alternative pathway is highly variable and limited. 
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1.4 Complement Source in Serum Bactericidal Assays 
 Following the successful development of protective meningococcal vaccines against 
serogroups A and C in the 1970s, the World Health Organisation (WHO) published several 
recommendations to public health organisations in regards to standardising the production, 
storage and testing of these vaccines (WHO, 1976). In the absence of an appropriate animal 
model to assess the potential of new meningococcal vaccines in humans, it was proposed that 
vaccine efficacy must be tested by measurement of bactericidal antibody titres before and 2-4 
weeks post vaccination. Bactericidal antibody titres are measured in vaccinee serum by SBA as 
described in Section 1.1.5.1. The bactericidal titre of vaccinee serum is calculated as the dilution 
of serum that results in 50% or greater killing of the target bacteria after a one-hour incubation 
with a source of complement. For a particular vaccine to be considered effective, more than 90% 
of individuals must have a greater than 4-fold rise in bactericidal titre and bactericidal titre of at 
least 4. These recommendations were based on the findings by Gotschlich, Goldschneider and 
Artenstein who demonstrated the correlation between bactericidal antibody and protection 
against invasive meningococcal disease (Goldschneider et al., 1969a; Goldschneider et al., 
1969b; Gotschlich et al., 1969a). Several amendments to these recommendations by WHO have 
been put forward including considerations for additional correlates of protection (WHO, 2004, 
2006). These include the measurement of anti-meningococcal antibody concentration and 
avidity post vaccination (Borrow et al., 2001a; Gheesling et al., 1994; Granoff et al., 1998; Jodar 
et al., 2000). However, the SBA still remains the gold standard correlate in the assessment of 
new meningococcal vaccines for licensure. 
 Despite these recommendations from the WHO on the standard protocol for the SBA, 
many laboratories continued to use different methods when assessing meningococcal vaccines 
(Frasch and Robbins, 1978; Mandrell et al., 1995; Maslanka et al., 1997; Ross et al., 1985; 
Söderström et al., 1987; Zollinger et al., 1988; Zollinger and Mandrell, 1983). Variations in assays 
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(including complement source and concentration, buffers, incubation times and growth of the 
target strain of bacteria) made the inter-laboratory assessment of new vaccines impossible. In 
response, a consortium of researchers in the field evaluated each variation of the SBA to create 
a standardised and reproducible assay (Maslanka et al., 1997). The SBA requires a source of 
complement lacking antibody specific to the target bacteria to measure the true bactericidal 
titre of an individual. Both human and BRS were assessed for their use in the SBA. Although 
human serum would be the ideal source of complement for these assays, the high prevalence 
of naturally acquired or vaccine-induced bactericidal antibody present would make finding a 
suitable donor very difficult indeed. In contrast, BRS was found to be a suitable and convenient 
reagent showing little batch-to-batch variation, minimal background bactericidal activity to 
certain strains of serogroup A and C in the absence of antibody and a reasonable correlation 
between SBA titres and anti-meningococcal antibody concentration.  
 As noted in previous and subsequent studies, SBA titres achieved with BRS are 
significantly higher than with human serum (Borrow et al., 2001a; Jodar et al., 2000; Maslanka 
et al., 1997; Zollinger and Mandrell, 1983). An even greater concern is the poor correlation 
between SBA titres with human serum and BRS, especially for serogroups A, W and Y (Findlow 
et al., 2009; Gill et al., 2011a). Interestingly, SBA titres between both sources of serum for 
serogroup C isolates tend to correlate well. The average correlation (R-squared values ± 
standard deviation) between SBA titres from two individual studies for serogroups A, C W and Y 
was 0.34 ± 0.14, 0.73 ± 0.04, 0.56 ± 0.01 and 0.49 ± 0.78, respectively (Gill et al., 2011a). These 
data have questioned the validity of using BRS in SBAs as a correlate of protection in trials 
assessing the efficacy of meningococcal vaccines for licensure (WHO, 2006). As will be discussed 
below and in subsequent chapters, several hypotheses have been proposed for the differences 
seen between human serum and BRS in SBAs. 
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1.4.1 Differences in the Interaction of Human and Rabbit Complement with 
Neisseria meningitidis 
 Neisseria meningitidis employs a number of techniques to aid survival in the circulation 
by regulating complement activation (Agarwal et al., 2014; Caesar et al., 2014; Del Tordello et 
al., 2014; Giuntini et al., 2015; Jarva et al., 2005; Lewis et al., 2010; Lewis et al., 2013; Madico et 
al., 2006; Uria et al., 2008). These mechanisms include sequestering host regulators of 
complement (such as C4BP and FH), cleavage and inactivation of C3 and evasion of recognition 
by capsule expression containing high levels of sialic acid. Expression of many of these 
complement regulators is upregulated by increases in host temperature; a common response to 
infection (Loh et al., 2013). Neisseria meningitidis is a human only pathogen and no other animal 
reservoirs have been identified. It may be hypothesised that complement regulation by Neisseria 
meningitidis is restricted to human complement only which may account for the higher SBA 
titres seen with BRS. In fact, this species-specific complement regulation has been described for 
Neisserial proteins FHbp and NalP (Del Tordello et al., 2014; Granoff et al., 2009). NalP cleaves 
human C3 into non-functional C3a-like and C3b-like fragments increasing survival in serum but 
did not cleave either mouse or rabbit C3 (Del Tordello et al., 2014). FHbp binds the SCRs 6 and 7 
of human FH, maintaining co-factor factor activity for FI and decay accelerator activity towards 
C3bBb, increasing the survival in serum, but does not bind rabbit or rat FH (Granoff et al., 2009). 
Whether the other mechanisms of complement evasion are restricted to human complement 
has not been investigated. However, based on previous data it is most likely that these 
mechanisms do not regulate rabbit complement. 
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1.4.2 Activation of Human and Rabbit Complement by Human 
Immunoglobulins  
 Whilst differences between the interaction of human and rabbit complement and 
complement regulators with Neisseria meningitidis may explain why SBA titres with BRS are 
much higher than with human serum, these species-specific differences are presumably 
constant and do not provide an adequate explanation for the poor correlation between hSBA 
and rSBA titres seen for some serogroups. In these assays, bacterial strains and complement 
sources are constant. The only variable in these assays are the vaccinee sera which may vary in 
the magnitude and type of antibody response to vaccine antigens. As such, it may be 
hypothesised that differences in antibody response to vaccine antigens and the ability of anti-
meningococcal antibodies to activate human and rabbit complement may account for the poor 
correlation between SBAs with human serum and BRS. 
Differences in the ability of human immunoglobulins to activate human and rabbit 
complement and their impact on SBA titres is poorly understood. Several studies have shown 
that 500-1000 times less human anti-meningococcal IgM antibody is required to kill Neisseria 
meningitidis in the presence of BRS than with human serum in SBA whilst only 10 times less 
human anti-meningococcal IgG antibody is required (Griffiss and Goroff, 1983; Mandrell et al., 
1995; Santos et al., 2001; Zollinger and Mandrell, 1983). Furthermore, it has been shown that 
human IgG1 and IgG3 activates human complement better than rabbit complement whilst 
human IgG2 activates rabbit complement better than human (Dangl et al., 1988). Human IgG4 
does not activate either human or rabbit complement. The mechanisms behind these 
differences and their impact on SBA titres with either human serum or BRS is unknown. 
However, these data suggest that a primarily IgM and IgG2 response to meningococcal vaccines 
will produce misleadingly high SBA titres with BRS whilst a predominantly IgG1 and IgG3 
antibody response will produce a misleadingly low SBA titre with BRS. 
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1.5 Study Aims 
The purpose of this project is to further evaluate the differences between rabbit and 
human complement with regards to interactions with human immunoglobulins and Neisseria 
meningitidis; as one component of this, the antibody subclass response to meningococcal 
polysaccharide vaccination will be explored, in particular how this impacts on SBA titres with 
human serum and BRS. The specific aims of this project are as follows: 
i. To establish whether there are differences in interactions between human IgG 
subclasses and IgM with the vaccine and rabbit and human C1q. 
ii. Investigate which subclasses of antibodies are most strongly induced by conjugated and 
plain polysaccharide meningococcal vaccine and whether the nature of this response 
varies with age. 
iii. Compare whether human IgG subclasses and IgM differentially activate rabbit and 
human complement. 
iv. Assess the contribution of the different IgG subclasses and the various complement 
activation pathways to bactericidal killing with rabbit or human complement. 
Data from this project will help inform a rational approach to selecting a complement source for 
clinical trial serology for regulatory approval of new vaccines and ultimately assist improvements 
in the development and testing of meningococcal vaccines in the future. 
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Chapter Two – Materials and Methods 
 
2.1 Preparation of Plasma and Serum  
Human blood samples were obtained via withdrawal from the median cubital vein by 
syringe draw with a 21-gauge butterfly needle. Fresh rabbit blood was obtained via withdrawal 
from either the marginal ear vein by syringe draw with a 21-gauge butterfly needle or by cardiac 
puncture, the latter under terminal anaesthesia. Frozen rabbit serum was acquired from VH Bio 
Limited, Gateshead, UK. 
For serum, whole blood samples were left to clot for 30 minutes at ambient 
temperature. Clots were contracted on ice for 30 minutes. Samples were then centrifuged at 
3500RPM (2671g) for 30 minutes at 4°C. Serum was aspirated from the clot and re-centrifuged 
at 3500RPM for 30 minutes at 4°C. Serum was aspirated, syringe filtered through a 0.22µm, 
33mm, non-sterile Millex-GP filter (Millipore Limited, Hertfordshire, UK) and stored at -80°C. If 
required, complement was heat-inactivated by incubation of serum at 56°C for 30 minutes in a 
water bath with gentle manipulation every 5-10 minutes. 
Plasma was prepared as with serum but with the addition of 1mL 0.5M 
ethylenediaminetetraacetic acid, pH7.4 (EDTA; Sigma-Aldrich Company Ltd, Dorset, UK) per 
50mL whole blood at time of collection to prevent clotting. Plasma samples were stored in 
aliquots at -20°C. 
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2.2 Fast Protein Liquid Chromatography (FPLC) 
All FPLC work was performed at 4°C using an ÄKTApurifier 10 chromatography machine 
(GE Healthcare Life Sciences, Buckinghamshire, UK) with UNICORN Control Software (GE 
Healthcare Life Sciences). All buffers were vacuum filtered through a 0.2µm cellulose acetate 
membrane (Millipore) before use. 
 
2.2.1 Amine-Coupling to NHS-activated Sepharose™ Columns 
Ligands were amine-coupled to 1mL and 5mL HiTrap N-hydroxysuccinimide- (NHS) 
activated Sepharose™ High Performance (HP) columns as per manufacturer’s instructions (GE 
Healthcare Life Sciences). Briefly, six column volumes (CVs) of ice-cold 1mM HCl was injected 
over the column to wash out the isopropanol used to preserve active esters. Ligands were 
concentrated to 5-10mg/mL using an Amicon (R) Ultra 4mL Centrifugal Filter Unit with Ultracel 
100kDa membrane (Millipore Limited) and dialysed overnight at 4°C in 0.2M NaHCO3 (Sigma), 
0.5M NaCl, pH 8.3 (coupling buffer; CB). One CV of concentrated, equilibrated ligand was 
injected into the column and incubated at ambient temperature for 30 minutes.  
After coupling, the column was washed with CB (3 CV) and fractions collected to 
measure unbound protein and enable coupling efficiency to be calculated. Residual active esters 
were then deactivated by washing with six CV of 0.5M ethanolamine, 0.5M NaCl, pH 8.3 (buffer 
A) followed by six CV of 0.1M sodium acetate, 0.5M NaCl, pH 4 (buffer B). This wash cycle was 
repeated three times. 
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2.2.2 Human IgM and Human and Rabbit IgG Antibody Isolation 
Human IgM was isolated from plasma using a CaptureSelect™ IgM Affinity Matrix (Life 
Technologies, Paisley, UK). CaptureSelect™ IgM Affinity Matrix contains the light chain fragment 
of a monoclonal antibody specific for the Fc region of IgM which is amine coupled to NHS-
activated Sepharose 4 Fast Flow beads (GE Healthcare). The matrix was packed into a Proteus 
5mL FliQ™ Column (Generon Ltd., Berkshire, UK). The column was pre-equilibrated in PBS and 
5CV human plasma injected. Unbound proteins were washed from the column with PBS until 
effluent absorbance (280nm) was below 2mAU and bound IgM antibody was eluted with 3CV 
0.1M glycine-HCl pH2.5 whilst collecting 1mL fractions. Eluted IgM was immediately neutralised 
with a solution of 1M Tris pH8.0 (1mL per 5mL eluted protein), poured in cellulose dialysis tubing 
and dialysed against at least 50 volumes of PBS overnight at 4°C. 
Human and rabbit IgG was isolated by injection of plasma over a 1mL pre-packed Protein 
G column (GE Healthcare Life Sciences). The column was pre-equilibrated in PBS and 5CV human 
plasma injected. Unbound proteins were washed and bound IgG was eluted and prepared as 
described above. 
 
2.2.3 Human Anti-MenACWY Antibody Isolation 
Meningococcal serogroup A, C, W and Y-specific anti-polysaccharide antibody (anti-
MenACWY) was isolated by injecting plasma sequentially over two 5mL HiTrap NHS-Activated 
HP columns. The first column had 40.6mg tetanus toxoid (TT; GlaxoSmithKline (GSK) Biologicals 
SA, Wavre, Belgium) amine-coupled and the second had 25.2mg MenACWY-TT (GSK Biologicals 
SA) coupled. Plasma was first injected over the TT column to deplete anti-TT antibody before 
injection over the MenACWY-TT column to isolate polysaccharide-specific antibody. Unbound 
proteins were washed from each column with PBS (280nm<2mAU) and bound anti-TT (TT 
column) and anti-MenACWY (MenACWY-TT column) antibodies were separately eluted with 
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3CV 0.1M glycine-HCl pH2.5 whilst collecting 1mL fractions. Eluted antibodies were immediately 
neutralised with a solution of 1M Tris pH8.0 (1mL per 5mL eluted protein) and dialysed against 
at least 50 volumes of PBS overnight at 4°C. 
 
2.2.4 Human IgG1, IgG2, IgG3 and IgG4 Antibody Separation 
Human plasma or purified antibody was first injected over an anti-human IgG2 and an 
anti-human IgG4 column connected in series. The anti-human IgG2 column was generated by 
amine coupling 5mg of a monoclonal anti-human IgG2 antibody (Stratech Scientific Limited, 
Suffolk, UK) to a 1mL HiTrap NHS-Activated HP column. The anti-human IgG4 column was 
generated by packing 5mL of CaptureSelect™ IgG4 Affinity Matrix (Life Technologies) into an 
empty XK chromatography column (GE Healthcare Life Sciences). CaptureSelect™ IgG4 Affinity 
Matrix contains the light chain fragment of a monoclonal antibody specific for the Fc region of 
IgG4 which is amine coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare). 
After loading, each of the columns were washed with PBS (280nm<2mAU) and separately eluted 
with 3CV 0.1M glycine-HCl pH2.5 whilst collecting 1mL fractions. Eluted antibodies were 
immediately neutralised with a solution of 1M Tris pH8.0 (1mL per 5mL eluted protein), dialysed 
against at least 50 volumes of PBS overnight at 4°C and concentrated to 1mg/mL. To ensure 
complete depletion, the plasma was injected over each column several times.  
Human IgG1 and IgG3 antibodies were isolated based on their differential binding 
affinities for Protein G and Protein A (Akerström and Björck, 1986; Kronvall and Williams, 1969). 
Protein A binds the Fc region of IgG1, IgG2 and IgG4 but not IgG3 whereas Protein G binds all 
human IgG subclasses. One CV of the IgG2 and IgG4 depleted human plasma was injected over 
a 1mL Protein A column (IgG1), and a 1mL Protein G column (IgG3); the columns were connected 
in series. Both columns were washed in series with PBS and eluted individually as above. Eluted 
antibodies were prepared as described above. 
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2.2.5 Human C1q Isolation 
Human C1q was isolated using the protocol first described by Tenner et al., with minimal 
modification (Tenner et al., 1981). Approximately 80mL, human serum containing 0.01M EDTA 
was injected through BioRex 70 resin (100-200 mesh size; Bio-Rad Laboratories Ltd., 
Hertfordshire, UK) packed into an empty XK chromatography column (GE Healthcare Life 
Sciences;) equilibrated with phosphate buffer pH 7.4 containing 83mM NaCl, 0.01M EDTA; after 
loading, the column was washed in the same buffer to baseline UV. BioRex70 cation exchange 
resin contains carboxylic acid exchange groups which facilitate the electrostatic interaction with 
human C1q. The CV was roughly 40mL. Bound proteins were eluted with phosphate buffer pH 
7.4 containing 300mM NaCl, 0.01M EDTA. The protein-containing fractions were pooled and an 
equal volume of saturated ammonium sulphate solution was added drop-wise to the eluted 
proteins at 4oC. This solution was gently mixed for 30 minutes at 4°C and allowed to fully 
precipitate overnight at 4oC. The resultant suspension was spun at 8000RPM (6105g) for 20 
minutes at 4°C. The supernatant was poured away and pellet dissolved in 500µL 0.5M NaCl, 
0.05M Tris pH7.4, 0.01M EDTA. The dissolved pellet was 0.2uM filtered then 200µL was applied 
to a 24mL Superose 6 gel filtration column (GE Healthcare) to remove aggregates. The main 
protein peak containing monomeric C1q was pooled and applied to a 1mL Protein L column (GE 
Healthcare) pre-equilibrated with 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% v/v 
surfactant P20, to remove contaminating immunoglobulins. The breakthrough protein was 
pooled and stored at -80°C. 
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2.2.6 Rabbit C1q Isolation 
Rabbit C1q was isolated as described by Pohl et al. (1980), with some modification. 
Rabbit anti-human IgG serum was generated as described in Section 2.3. The immune serum 
(80mL), containing 0.01M EDTA, was injected over a 5mL human IgG column, pre-equilibrated 
with PBS 0.01M EDTA. The human IgG column was generated by amine coupling 44.8mg purified 
human IgG antibody to a 5mL HiTrap NHS-Activated HP column. In this way, an immune complex 
(anti-human rabbit IgG bound to human IgG) was generated on the column creating an 
appropriate surface for rabbit C1q to bind.  
After injection, weakly bound proteins were removed from the column without 
disturbing the immune complex by washing to baseline with 1M NaCl, 10mM phosphate pH7.4. 
Non-immune rabbit serum (3x100mL) was then injected over the immune column, pre-
equilibrated with PBS 0.01M EDTA. After loading, the immune complex column was washed with 
PBS 0.01M EDTA (280nm<2mAU) and bound C1q was eluted with 3CV 1M NaCl, 10mM 
phosphate pH7.4. The eluted C1q was concentrated to 5mg/mL using an Amicon Ultra 4mL 
Centrifugal Filter Unit with Ultracel 100kDa membrane (Millipore) and 200µL was applied to a 
24mL Superose 6 gel filtration column to remove aggregates. The main protein peak containing 
monomeric C1q was pooled and applied to a 1mL Protein L column (GE Healthcare) pre-
equilibrated with 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% v/v surfactant P20, to 
remove contaminating immunoglobulins. The breakthrough protein was pooled and stored at -
80°C. 
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2.2.7 Human FH Isolation  
Human FH was isolated from plasma by a two-step affinity chromatography method 
followed by size exclusion chromatography. Human plasma (4x15mL) was injected over a 5mL 
HiTrap NHS-Activated HP column to which 10mg anti-human FH antibody (MBI-7) was coupled 
(Hakobyan et al., 2008). The column was washed with PBS and bound protein eluted with 3CV 
0.1M glycine-HCl pH2.5. Eluted protein was dialysed into 50 times volume of 150mM NaCl, 
20mM Tris, pH7.4 and applied to a 1mL HiTrap™ Heparin HP column (GE Healthcare Life 
Sciences) pre-equilibrated with 150mM NaCl, 20mM Tris, pH7.4. The column was washed to 
baseline with 150mM NaCl, 20mM Tris, pH7.4 and eluted with 1M NaCl 20mM Tris pH7.4. The 
heparin column protein eluate was then injected over Superdex-200 matrix (GE Healthcare Life 
Sciences) in a XK16/70 column (GE Healthcare Life Sciences) pre-equilibrated in PBS in order to 
remove aggregates. The FH-containing fractions were pooled, concentrated to 1mg/mL and 
stored in aliquots at -20°C. 
 
2.3 Rabbit Immunisation with Human IgG Antibody 
Non-specific human IgG (isolated from plasma as described in Section 2.2.2) was diluted 
to 600µg/mL in PBS and mixed thoroughly 1/1 (v/v) with Freund’s Complement Adjuvant (Sigma) 
to create a stable emulsion. A New Zealand White rabbit (Oryctolagus cuniculus) was immunised 
by subcutaneous injection with 1mL of the human IgG-containing emulsion over at least four 
sites on the flanks. The rabbit was boosted at 4, 5 and 6 weeks after first injection with 1mL of 
an emulsion containing 600µg/mL human IgG made with Freund’s Incomplete Adjuvant (Sigma). 
One week after the final immunisation, the rabbit was euthanised by cardiac puncture and 
exsanguination under terminal anaesthesia. 
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2.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Polyacrylamide gels were self-cast in a four gel caster for 10x8cm plates (Hoefer Inc. 
Massachusetts, USA) by pouring 25-30mL resolving gel solution between a sandwich of a glass 
and aluminium plate either side of a 0.75mm spacer (Hoefer Inc.) leaving a 2-4cm air gap above 
the gel. To prevent the resolving gel from drying out whilst setting and to remove air bubbles, 
1mL of 70% (v/v) ethanol (Fisher Scientific UK Ltd, Loughborough, UK) was pipetted over the top 
of the resolving gel carefully, so as to not disturb the gel layer. The resolving gel solution was 
made up of 7-12mL 40% (w/v) acrylamide (Fisher Scientific UK Ltd), 8mL 1.5M Tris pH 8.8, 320µL 
10% (w/v) SDS, 320µL 10% (w/v) ammonium persulfate (Sigma) and 32µL 
tetramethylethylenediamine (TEMED; Bio-Rad Laboratories Ltd). Once set, the ethanol was 
poured away and stacking gel solution poured on top of the resolving gel to the top of the cast. 
A 10-15 well 0.75mm comb (Hoefer Inc.) was inserted between the glass and aluminium plates 
into the stacking gel before the gel had set. Stacking gel solution was made up 2mL 40% (w/v) 
acrylamide, 5mL 0.5M Tris pH 6.8, 200µL 10% (w/v) SDS, 200µL 10% (w/v) ammonium persulfate 
and 20µL TEMED. 
Gel casts, held in a mini-vertical gel electrophoresis unit with spring clamps (Hoefer Inc.), 
were flooded with SDS-PAGE running buffer composed of 25mM Tris, 192mM glycine (Fisher 
Scientific UK Ltd) and 0.1% (w/v) SDS. Between 10-20µL/well of sample, diluted in PBS to 0.1-
1mg/mL, was loaded between the glass and aluminium plates of the gel mould (Hoefer Inc.). 
Prior to loading, each sample was diluted 5/1 (v/v) with non-reducing or reducing loading buffer 
and heated between 90-100°C for two minutes using a dry block heater. Loading buffer was 
composed of 375mM Tris, 12% (w/v) SDS, 60% (v/v), glycerol (Fisher Scientific UK Ltd), 0.06% 
(w/v) bromophenol blue (Bio-Rad Laboratories Ltd) with (reducing) or without (non-reducing) 
5% (v/v) β-mercaptoethanol. Between 5µL and 10µL of a pre-stained protein marker set, 7-
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175kDa or 10-190kDa, was run alongside samples to assess size and progression through the gel 
(New England Biolabs Inc, Massachusetts, USA). Once loaded, the gel electrophoresis unit was 
connected to a 300 volt power pack (VWR International, Leicestershire, UK) and run for 20 
minutes at 120V followed by 1-2 hours at 180V. The gel electrophoresis unit was plumbed into 
a cooling water pump and cooled to 5°C to prevent overheating and the gel from drying out.  
 
2.4.1 Coomassie Stain 
Gels were submerged in a solution of 40% (v/v) methanol (Fisher Scientific UK Ltd), 10% 
(v/v) acetic acid (Fisher Scientific UK Ltd) and 0.5% (w/v) R250 Brilliant Blue (Life Technologies 
Ltd) for one hour at ambient. Gels were destained with 40% (v/v) methanol, 10% (v/v) acetic 
acid overnight at ambient temperature with gentle agitation. Once sufficiently de-stained, gels 
were submerged in a solution of 20% (v/v) ethanol, 10% (v/v) glycerol for one hour at ambient 
temperature and imaged with a myECL™ Imager (Thermo Fisher Scientific, Massachusetts, USA). 
Gels were dried for preservation between two sheets of gel drying film (Promega, Southampton, 
UK) held within a 20cm x 17.5cm gel drying stage (Promega). 
 
2.4.1.1 Calculation of Molecular Weight of Purified Proteins 
A plot of relative migration distance (Rf) and log molecular weight of each protein of the 
molecular weight marker was generated using GraphPad Prism version 6.00 for Windows 
(GraphPad Software, San Diego California USA). Rf was calculated as the distance migrated (cm) 
by the protein through the gel over the distance migrated by the dye front. Distance migrated 
was measured from the top of the resolving gel. The molecular weight for each protein of 
unknown weight was then interpolated from their respective Rf values using the molecular 
weight marker as a standard. 
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2.4.2 Western Blot 
Gels were submerged in Pierce™ 1-Step Transfer Buffer (Thermo Fisher Scientific) for 30 
minutes at ambient. The exact composition of Pierce™ 1-Step Transfer Buffer is not published 
but contains approximately 336mM tris, about 260mM glycine, about 140mM tricine, and if 
EDTA is used, approximately 2.4mM EDTA (Patent Number US20140224655 A1). Four sheets per 
gel of chromatography paper (10x8cm; Whatman™ 3MM Chromatography Paper) and one sheet 
per gel of nitrocellulose membrane (Amersham Protran Supported 0.45µm) of the same size 
were also submerged in Pierce™ 1-Step Transfer Buffer for 30 minutes at ambient. Protein was 
then transferred from the gel onto the nitrocellulose membrane using a Thermo Scientific™ 
Pierce™ Power Blotter as instructed. Once transferred, membranes were submerged in a 
solution of PBS, 0.1% (v/v) Tween 20 (Thermo Fisher Scientific), 5% (w/v) milk (Marvel, blot 
blocking buffer) for one hour at ambient temperature or overnight at 4°C on a roller. Blot 
blocking buffer was poured off and membranes were incubated with a primary detection 
antibody diluted 1/400 to 1/1000 (v/v) in blot blocking buffer for one hour at ambient 
temperature on a roller. A list of antibodies used in western blot assays are shown in Table 2.1. 
Membranes were then washed with PBS, 0.1% (v/v) Tween 20 for five minutes, three times. If a 
secondary detection antibody was required, membranes were incubated with the secondary 
antibody as above. Once sufficiently washed, 1-2mL/membrane of Amersham ECL Western 
Blotting Detection Reagents one and two (mixed 1:1 (v/v) immediately before use; GE 
Healthcare Life Sciences) was distributed over the whole membrane. Membranes were then 
imaged using either a myECL™ Imager (Thermo Fisher Scientific) or Amersham Hyperfilm ECL 
(GE Healthcare Life Sciences) with exposure for up to 100 minutes.  
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Table 2. 1 List of Antibodies 
 
Antigen Subclass Clonality
Target 
Species
Host 
Species
Conjugate Assay Distributor Product Code
IgG1 HC IgG Mono Human Rabbit N/A 1, 2 Stratech 3831-1-EPI
IgG2 HC IgG Mono Human Rabbit N/A 1, 2 Stratech 3410-1-EPI
IgG3 HC IgG Mono Human Rabbit N/A 1, 2 Stratech 3338-1-EPI
IgG4 HC IgG Mono Human Rabbit N/A 1, 2 Stratech 3479-1-EPI
IgG Whole IgG Poly Human Donkey HRP 1, 2 Stratech 709-035-149-JIR
IgM Fc5μ Whole IgG Poly Human Donkey HRP 1, 2 Stratech 709-005-073-JIR
IgG2 Fc IgG1 Mono Human Mouse N/A 3 Stratech 6002P-HRL
IgG Whole IgG Poly Mouse Goat HRP 1, 2 Stratech 115-035-062-JIR
C1q Whole IgG Poly Human Sheep HRP 1, 2 Bio-Rad 2221-5004P
C3 Whole IgG Poly Human Goat N/A 1, 2 Thermo Fisher PA1-29715
IgG Whole IgG Poly Goat Rabbit HRP 1, 2 Thermo Fisher 31402
MBL IgG2A Mono Human Mouse N/A 1, 4 R&D Systems MAB23071
IgG Whole IgG Poly Goat Rabbit HRP 1, 2 Stratech 305-035-045-JIR
C1q IgG1k Mono Human Mouse N/A 1, 4, 5 Pathway Diagnostics A201
IgG4 HC IgG1 Mono Human Mouse N/A 1, 2 Li fe Technologies A-10651
IgG1 HC IgG1 Mono Human Mouse N/A 1, 2 Li fe Technologies A-10630
C3/C3c Whole IgG Poly Human Sheep HRP 1, 2 antibodies -onl ine ABIN293935
IgG2 IgG1 Mono Human Mouse N/A 1, 2 Li fe Technologies MA1-83241
IgG3 IgG1 Mono Human Mouse N/A 1, 2 Li fe Technologies MA1-83242
IgM Whole IgG Poly Human Goat HRP 1, 2 Li fe Technologies A18841
IgG Whole IgG Poly Mouse Goat HRP 1, 2 Li fe Technologies 31446
IgG Whole IgG Poly Mouse Donkey HRP 1, 2 Li fe Technologies A16017
RBC Stroma Whole IgG Poly Sheep Rabbit N/A 5 Sigma-Aldrich S1389
IgG/IgM Whole IgG Poly Human Goat FITC 6 Jackson ImmunoResearch 109-095-003
C3c Whole IgG Poly Human Rabbit FITC 6 Abcam ab4212
C3c Whole IgG Poly Rabbit Goat FITC 6 Acris AP31546FC-N
IgG/IgM Whole IgG Poly Human Goat HRP 1, 2 Jackson ImmunoResearch 109-035-127
C5b-9 Unknown Unknown Human Unknown AP 1 Euro Diagnostica COMPL 300
IgG Unknown Poly Human Unknown HRP 1 Thermo Fisher 991000
IgM Unknown Mono Human Unknown HRP 1 eBioscience 88-50620-22
Factor H IgG1 Mono Human Mouse N/A 2, 3 In-house (OX-24) N/A
Factor H IgG1 Mono Human Mouse N/A 2, 3 In-house (MBI-7) N/A
Factor B IgG2b Mono Human Mouse N/A 1, 4 In-house Gifted from Dr Córdoba
N/A IgM Poly N/A Human N/A 1, 6, 7 In-house N/A
N/A IgG1 Poly N/A Human N/A 1, 6, 7 In-house N/A
N/A IgG2 Poly N/A Human N/A 1, 6, 7 In-house N/A
N/A IgG3 Poly N/A Human N/A 1, 6, 7 In-house N/A
N/A IgG4 Poly N/A Human N/A 1, 6, 7 In-house N/A
MenACWY IgM Poly N/A Human N/A 1, 6, 7 In-house N/A
MenACWY IgG2 Poly N/A Human N/A 1, 6, 7 In-house N/A
MenACWY IgG1 Poly N/A Human N/A 1, 6, 7 In-house N/A
MenACWY IgG/IgM Poly N/A Human N/A 1, 6, 7 In-house N/A
N/A IgG Poly N/A Rabbit N/A 3 In-house N/A
N/A Whole IgG Poly N/A Human N/A 8 In-house N/A
A list of antibodies used in each assay. Antibodies are l isted with their specificity (antigen), clonality, their target and host species, 
their conjugate (if any), the assays they have been used in, the distributor and product code.  Table abbreviations: HC = heavy chain; 
MBL = mannose binding lectin; HRP = horseradish peroxidase; fluorescein isothiocyanate = FITC; poly = polyclonal; mono = 
monoclonal; AP = alkaline phosphatase 1 = ELISA; 2 = western blot; 3 = FPLC; 4 = complement pathway inhibition; 5 = haemolytic 
assay; 6 = flow cytometry; 7 = surface plasmon resonance, 8 = rabbit immunisation.
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2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
 Unless otherwise stated, flat-bottomed 96 well-plates (Microplate Immuno MaxiSorp; 
Fisher Scientific) were coated with 90µL/well ligand diluted in 30mM Na2CO3 (Sigma), 70mM 
NaHCO3 (Sigma) pH9.6 overnight at 4°C. Plates were washed between incubations three times 
with 180µL/well PBS, 0.1% (v/v) Tween20 using a plate washer (Thermo Fisher). Plates were 
blocked for at least one hour at ambient temperature with 180µL/well PBS, 0.1% (v/v) Tween20, 
5% (w/v) bovine serum albumin (BSA, Sigma; blocking buffer). All samples were run in duplicate. 
Plates were developed with 90µL/well SIGMAFAST™ o-Phenylenediamine dihydrochloride (OPD; 
Sigma-Aldrich, Inc) for 5 to 20 minutes. The reaction was stopped with 45µL/well 10% H2SO4. 
Plates were read using an Infinite® F50 plate reader (Tecan, Reading, UK) at a wavelength of 
492nm (A492nm). Antibodies used in each ELISA described below are detailed in Table 2.1. 
 
2.5.1 Competitive ELISA 
2.5.1.1 Functional Affinity of Anti-MenACWY Antibodies to MenACWY Antigen 
The functional affinity (molar; M) of human IgG1, IgG2, IgG3, IgG4 and IgM antibody 
present in the plasma of 14 adult individuals to TT-conjugated meningococcal polysaccharides 
from serogroups A, C, W and Y (MenACWY-TT) was measured by competitive ELISA. The plasma 
was taken at least one month post vaccination with a quadrivalent plain meningococcal 
polysaccharide (from serogroups A, C, W-135 and Y) vaccine (Mencevax™). Two ELISA plates 
were coated with 1µg/mL MenACWY-TT and blocked. Plasma samples, diluted in blocking buffer 
to a factor calculated as described in Section 2.5.1.2, were each mixed with a titration of 
MenACWY-TT (1x10
-7
 to 4x10
-13
M) and left to stand for one hour at ambient. A plasma only 
control was also included in the assay for each sample (no MenACWY-TT). A blocking buffer only 
negative control (no plasma) was also included in each assay. Each plasma:MenACWY-TT 
mixture was added to one plate at 90µL/well in triplicate for 15 minutes. Each 
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plasma:MenACWY-TT mixture was then aspirated from the first plate and transferred to the 
second plate at a volume of 90µL/well in duplicate for a further 15 minutes. Both plates were 
washed and bound antibody was detected with the addition of 90µL/well of either mouse anti-
human IgG1 (1µg/mL; Stratech Scientific Limited, Suffolk, UK), mouse anti-human IgG2 (1µg/mL; 
Stratech), mouse anti-human IgG3 (1µg/mL; Stratech), mouse anti-human IgG4 (1µg/mL; 
Stratech) or donkey anti-human IgM-HRP (diluted 1/1000; v/v; Stratech) diluted in blocking 
buffer to both plates for one hour at ambient. Plates were washed and 90µL/well goat anti-
mouse IgG-HRP, diluted 1/1000 (v/v) in blocking buffer, was added to each plate (apart from 
anti-IgM competitive ELISAs) for one hour at ambient. Plates were washed and developed.  
The percentage inhibition of antibody binding to plates at each concentration of 
MenACWY-TT was calculated as:1 −
(𝑃𝑙𝑎𝑠𝑚𝑎:𝑀𝑒𝑛𝐴𝐶𝑊𝑌𝑇𝑇 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴492)−(𝐵𝑙𝑎𝑛𝑘 𝐴492)
(𝑃𝑙𝑎𝑠𝑚𝑎 𝑤𝑖𝑡ℎ 𝑛𝑜 𝑀𝑒𝑛𝐴𝐶𝑊𝑌𝑇𝑇 𝐴492)−(𝐵𝑙𝑎𝑛𝑘 𝐴492)
 ×100. The 
concentration (M) of MenACWY inhibiting 50% antibody binding (functional affinity) was 
interpolated by plotting percentage inhibition of antibody binding versus concentration of 
MenACWY-TT. Significant differences between the functional affinities of anti-MenACWY-TT 
antibody subclasses were calculated by t-test analysis. Absorbance values from first and second 
plates for each plasma:MenACWY-TT mixtures were compared by linear regression (Prism). 
 
2.5.1.2 Sample Dilution for Competitive ELISA 
Plates were coated with 1µg/mL MenACWY-TT and blocked. Plasma samples were 
serially diluted 1/10-10,000 (v/v) in blocking buffer across the plate at a volume of 90µL/well in 
duplicate for 15 minutes at ambient. Plates were washed and 90µL/well of either mouse anti-
human IgG1 (1µg/mL; Stratech), mouse anti-human IgG2 (1µg/mL; Stratech), mouse anti-human 
IgG3 (1µg/mL; Stratech), mouse anti-human IgG4 (1µg/mL; Stratech) or donkey anti-human IgM-
HRP (diluted 1/1000; v/v; Stratech), diluted in blocking buffer, was added to plates and 
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incubated for one hour at ambient. Plates were washed and 90µL/well goat anti-mouse IgG-
HRP, diluted 1/1000 (v/v) in blocking buffer, was added to each plate (excluding wells previously 
incubated with the anti-IgM-HRP antibody) and incubated for one hour at ambient. Plates were 
then washed and developed. The dilution factor of each antibody subclass in each plasma 
sample achieving an absorbance of 1.0 at 492nm was calculated with Prism by plotting 
absorbance against plasma dilution. 
 
2.5.1.3 Functional Affinity of Purified Versus Plasma Anti-MenACWY IgG1 Antibody with 
MenACWY Antigen  
The functional affinities of IgG1 antibody present in plasma and purified IgG1 antibody 
(from the same plasma sample) to TT-conjugated meningococcal polysaccharides were 
compared by competitive ELISA. IgG1 antibody was purified from a pool of human plasma (n=14 
individuals), taken from adult individuals vaccinated with plain MenACWY, as described in 
Section 2.2.4. The plasma was taken at least one month post vaccination with a quadrivalent 
plain meningococcal polysaccharide (from serogroups A, C, W-135 and Y) vaccine (Mencevax™). 
The competitive ELISA was performed with both samples as described in Section 2.5.1.1. 
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2.5.2 Human and Rabbit C1q Binding ELISA 
ELISA wells were coated with 30µg/mL of either non-specific human IgG1, IgG2, IgG3, 
IgG4, IgM, IgG, anti-MenACWY or non-specific rabbit IgG antibody, or left blank. Once blocked, 
90µL/well 4% human serum diluted in blocking buffer, 4% rabbit serum diluted in blocking buffer 
or blocking buffer only was added to each antibody coating and incubated for two hours at 
ambient. Bound human and rabbit C1q was detected with 90µL/well goat anti-human C1q-HRP 
(Bio Rad), diluted 1/400 (v/v) in blocking buffer. After a one-hour incubation at ambient, plates 
were washed and developed.  
 
2.5.3 Human and Rabbit Complement Activation by Immunoglobulins 
ELISA wells were coated with 90µg/well 15µg/mL of either non-specific human IgG1, 
IgG2, IgG3, IgG4, IgM, IgG, anti-MenACWY or non-specific rabbit IgG antibody preparations, or 
left blank. Once blocked, 90µL/well 0.5% human serum diluted in complement fixation diluent 
(CFD), 10% rabbit serum diluted in CFD, or blocking buffer was added for one hour at ambient. 
Deposited human and rabbit C3 was detected with 90µL/well goat anti-human C3-HRP (Thermo 
Fisher), diluted 1/500 (v/v) in blocking buffer. After a one-hour incubation at ambient, plates 
were washed and developed.  
 
2.5.4 Anti-Meningococcal Polysaccharide Complement Deposition Assay 
 ELISA wells were coated with 20µg/mL MenACWY-TT and blocked. A serial dilution of 
anti-MenACWY IgG1, IgG2 and IgM antibodies (40-0.04µg/mL) was added at 90µL/well and 
incubated for one hour at ambient. The anti-MenACWY IgG1, IgG2 and IgM antibodies were 
isolated from pooled plasma of 14 adult individuals previously vaccinated with a quadrivalent 
plain meningococcal polysaccharide (from serogroups A, C, W-135 and Y) vaccine (Mencevax™). 
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To each plate, 90µL/well 0.5% anti-MenACWY antibody-depleted human serum (diluted in CFD 
and prepared as described in Section 2.5.4.1) or 10% rabbit serum (diluted in CFD) was added 
to each antibody titration and incubate at ambient temperature for 30 minutes. Bound human 
and rabbit C3 was detected with 90µL/well goat anti-human C3-HRP (Thermo Fisher), diluted 
1/500 (v/v) in blocking buffer. After a one-hour incubation at ambient, plates were washed and 
developed.  
 
2.5.4.1 Anti-MenACWY-TT Antibody-Depleted Human Serum 
 Endogenous reactivity to MenACWY-TT in the human serum used in the anti-
meningococcal polysaccharide complement deposition assay (Section 2.5.4) was removed by 
depletion of anti-MenACWY-TT antibody. This was achieved with multiple passages of serum 
over a 5mL MenACWY-TT HiTrap NHS-Activated HP column.  
To ensure no loss of complement activity had occurred during the depletion of anti-
MenACWY-TT antibody, the haemolytic activity of the anti-MenACWY antibody-depleted human 
serum was compared to that of normal human serum as described in Section 2.8.1. 
 To ensure endogenous reactivity to MenACWY-TT had been removed from human 
serum, C3 deposition and IgG binding, following incubation with MenACWY-TT was measured 
by ELISA and compared with normal human serum (C3 deposition and IgG binding) and rabbit 
serum (C3 deposition only). ELISA plates were coated with 20µg/mL MenACWY-TT and blocked. 
A serial dilution series of the anti-MenACWY antibody-depleted human serum, normal human 
serum and rabbit serum (20-0.3% diluted in CFD) was added at 90µL/well for 30 minutes at 
ambient. C3 deposition was detection with 90µL/well goat anti-human C3-HRP (Thermo Fisher), 
diluted 1/500 (v/v) in blocking buffer and bound IgG antibody was detected with 90µL/well anti-
human IgG-HRP (Jackson ImmunoResearch), diluted 1/1000 (v/v) in blocking buffer. After a one-
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hour incubation at ambient, plates were washed and developed. IgG binding and C3 deposition 
achieved with each serum was compared by two-way ANOVA. 
 
2.5.5 WeissLab® Complement System Screen ELISA kit 
Blockade of classical and alternative pathways of complement in human serum, 
incubated with various complement pathway inhibitors, was assessed using a WeissLab® 
Complement System Screen ELISA kit (COMPL 300; Euro Diagnostica, Malmö, Sweden) as 
described by Seelen et al., (2005). 
Plates were pre-coated with either human IgM (classical pathway assay) or LPS 
(alternative pathway assay) and pre-blocked with PBS 1% (w/v) BSA. Human serum from three 
individuals was diluted 1/101 (v/v) in classical pathway diluent (CPD) or 1/18 (v/v) in alternative 
pathway diluent (APD) with or without 0.01M EDTA, 15nM anti-C1q (Pathway Diagnostics), 
250nM anti-FB, 250nM anti-MBL (R&D Systems) and 1.6µM human FH and left at ambient 
temperature for 30 minutes. It is understood that diluent CP consists of veronal buffered saline 
(VBS) 5mM MgCl2, 0.05% (v/v) Tween20, and 0.1% (w/v) gelatine, pH 7.5 and diluent AP consists 
of VBS 10mM EGTA, 5mM MgCl2, 0.05% (v/v) Tween20, and 0.1% (w/v) gelatine, pH 7.5. The 
positive control (lyophilised human serum) was reconstituted with distilled water and left for 5 
minutes at ambient temperature before diluting in either CPD or APD as before. The negative 
control (heat-inactivate human serum) was diluted in either CPD or APD as before.  
Positive controls, negative controls, serum samples and CPD/APD (assay blanks) were 
added to the corresponding wells at 100µL/well and incubated for 65 minutes at 37°C. After 
incubation, wells were aspirated and washed with 300µL/well 1x wash buffer three times. After 
the final wash, 100µL/well anti-human C5b-9 alkaline phosphatase-conjugated detection 
antibody was added to each well and incubated at ambient temperature for 30 minutes. Wells 
were then aspirated and washed three times as before. The substrate solution was added to the 
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plate at 100µL/well and incubated for 30 minutes as ambient. To stop the reaction, 100µL/well 
5mM EDTA was added. Plates were then read at a wavelength of 405nm (A405). The absorbance 
achieved with human serum in the presence of each inhibitor was compared to the absorbance 
achieved with human serum alone by t-test statistical analysis. The percentage inhibition of 
classical and alternative pathway activation achieved with each inhibitor was calculated as: 
absorbance achieved with serum sample plus the inhibitor over the absorbance achieved with 
serum alone. 
 
2.5.6 Lectin Pathway Inhibition ELISA 
 The concentration of an anti-MBL antibody (R&D Systems) required to efficiently block 
complement activation via the lectin pathway in human serum was measured by ELISA. Firstly, 
ELISA plates were coated 200µg/mL mannan (from Saccharomyces cerevisiae; Sigma-Aldrich) 
and blocked. A serial dilution of human serum (10-0.01% diluted in CFD) was added at 90µL/well 
for 30 minutes at ambient. C3 deposition was detected with 90µL/well goat anti-human C3-HRP 
(Thermo Fisher), diluted 1/500 (v/v) in blocking buffer. After a one-hour incubation at ambient, 
plates were washed and developed. The concentration of human serum resulting in 80% 
maximum absorbance was interpolated by fitting a non-linear regression curve to the data. 
 A titration series of the anti-MBL antibody was incubated with the selected 
concentration of human serum resulting in 80% maximum absorbance for 30 minutes. 
Serum:anti-MBL mixtures were then added to a plate coated with mannan and subsequent C3 
deposition was detected as previously described. 
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2.6 Anti-MenACWY Antibody Subclass ELISA 
A series of ELISAs were developed to measure The concentration (µg/mL) or proportion 
(% of total antibody) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific 
IgG1, IgG2 and IgM antibody was measured in the serum of individuals at least one month or 
four months post-vaccination with either a plain (Mencevax™) or a TT-conjugated (Nimenrix™) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. Sample 
were taken as part of two clinical trials (identifiers: NCT00427908 and NCT00718666) as 
described by Vesikaria et al., (2012) and Klein et al., (2013) as described in Section 2.6.3. 
 
2.6.1 Anti-MenACWY Antibody Standard Isolation 
The anti-MenACWY antibody standard was isolated from the plasma of 14 adult 
individuals (40mL per person) as described in Section 2.2.3. The plasma was taken at least one 
month post vaccination with a quadrivalent plain meningococcal polysaccharide (from 
serogroups A, C, W-135 and Y) vaccine (Mencevax™). Roughly 15.3mg anti-MenACWY antibody 
was isolated in total. 
 
2.6.1.1 Anti-MenACWY Antibody Standard Reactivity ELISA 
To ensure the anti-MenACWY antibody standard was specific to MenACWY only and 
devoid of anti-TT antibody, binding to both MenACWY-TT and TT was checked by ELISA. Plates 
were coated with either 5µg/mL TT or 5µg/mL MenACWY-TT and blocked. A titration of the anti-
MenACWY antibody standard (2.5-0.01µg/mL) was added to each coating at 90µL/well for one 
hour at ambient. Two wells for each coating were incubated with 90µL/well blocking buffer as 
the assay blanks. After washing three times, TT and MenACWY-TT bound IgG/IgM antibody was 
detected with 90µL/well goat anti-human IgG/IgM-HRP (Jackson ImmunoResearch Inc. PA, USA), 
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diluted 1/1000 (v/v) in blocking buffer. After a one-hour incubation at ambient, plates were 
washed and developed. 
 
2.6.1.2 Anti-MenACWY Antibody Standard IgM Concentration ELISA 
The concentration of IgM present in the anti-MenACWY standard was assessed using a 
Ready-SET-Go! ® Human IgM ELISA kit (eBioscience, Ltd, Cheshire, UK). A Corning Costar 9018 
ELISA plate was coated overnight at 4°C with 100µL/well with anti-human IgM capture antibody 
diluted 1/250 (v/v) with PBS. Wells were aspirated and washed twice with 400µL/well PBS 0.05% 
(v/v) Tween20. Plates were then blocked for two hours at ambient temperature with 1/10 (v/v) 
dilution of assay buffer A concentrate (20x PBS with 1% Tween 20 and 10% BSA). Plates were 
aspirated and washed twice as before.  
The recombinant IgM antibody standard provided (lyophilized) was reconstituted with 
distilled water to a concentration of 2µg/mL and allowed to stand at ambient temperature for 
20 minutes. The antibody standard was then serially diluted 1 in 2 across the plate in duplicate, 
five times with 1/20 (v/v) assay buffer A concentrate to a final volume of 100µL/well (1000 to 
15.63ng/mL). The anti-MenACWY antibody standard was diluted 1/800 (v/v), 1/1600 (v/v) and 
1/3200 (v/v) in 1/20 (v/v) assay buffer A concentrate and added to the plate at 100µL/well. An 
in-house purified IgM antibody (isolated as described in Section 2.2.2) diluted to 700ng/mL and 
200ng/mL was added to each plate at 100µL/well as the assay control. Samples were incubated 
for two hours at ambient. Wells were then aspirated and washed as before four times. An anti-
human IgM-HRP conjugated antibody, diluted 1/250 (v/v) with 1/20 (v/v) assay buffer A 
concentrate, was added to each well at 100µL/well for one hour at ambient. Plates were 
aspirated and washed four times as before.  
 
 
83 
 
 
Tetramethylbenzidine (TMB) substrate solution was added to each well at 100µL/well 
for 15 minutes followed by 100µL/well 2N H2SO4. Plates were read immediately at a wavelength 
of 450nm with absorbance values at 570nm subtracted. Graph Pad Prism software was used to 
interpolate the concentration of IgM present in the anti-MenACWY antibody standard using the 
recombinant IgM antibody dilution series as the standard curve. 
 
2.6.1.3 Anti-MenACWY Antibody Standard IgG Subclass Concentration ELISA 
The concentration of IgG1, IgG2, IgG3 and IgG4 present in the anti-MenACWY antibody 
standard was assessed using a IgG Subclass ELISA Kit (Thermo Fisher Scientific). To a pre-coated 
plate 50µL/well monoclonal anti-human IgG1/IgG2/IgG3 or IgG4 antibody was added to each 
well apart from blank wells, to which 50µL/well assay diluent buffer and 50µL/well anti-
MenACWY antibody standard (diluted 1/40 (v/v)) was added. Plates were pre-coated in an IgG 
antibody specific for the anti-human IgG1/IgG2/IgG3 or IgG4 capture antibodies. Apart from 
blank wells, 50µL/well anti-MenACWY antibody diluted 1/40, 1/80, 1/160, 1/320 and 1/640 (v/v) 
was added to each IgG subclass capture antibody. The lyophilized human IgG subclass assay 
standard was reconstituted with the assay diluent buffer to a concentration of 13.72µg/mL IgG1, 
5.32µg/mL IgG2, 1.34µg/mL IgG3 and 0.76µg/mL IgG4 and allowed to stand at ambient 
temperature for 10 minutes. The antibody standard was then serially diluted 1 in 2, five times 
(neat to 1/32(v/v)) with diluent buffer and 50µL/well of each dilution was added to each IgG 
subclass capture antibody. Finally, the human serum control (lyophilized) was reconstituted with 
1mL diluent buffer to a concentration of 1.97-2.59µg/mL IgG1, 0.78-1.40µg/mL IgG2, 0.19-
0.30µg/mL IgG3 and 0.16-0.23µg/mL IgG4 and left to stand at ambient temperature for 10 
minutes. The human serum control was added to each IgG subclass capture antibody at 
50µL/well. The plate was then incubated for 30 minutes at ambient. Wells were aspirated and 
washed by adding 400µL/well and soaking for 30 seconds three times.  
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Anti-human IgG-HRP conjugated detection antibody was diluted 1/50 (v/v) in diluent 
buffer and added to each well at 100µL/well for 30 minutes at ambient. Plates were then washed 
three times as before and 100µL/well TMB solution was added for 10 minutes at ambient. After 
10 minutes of developing, 100µL/well stop solution was added and plates read immediately at 
a wavelength of 450nm with absorbance values at 650nm subtracted. Graph Pad Prism software 
was used to interpolate the concentration of IgG1, IgG2, IgG3 and IgG4 present in the anti-
MenACWY antibody standard using the four human IgG subclass antibody dilution series as the 
standard curves. 
 
2.6.2 Anti-MenACWY Antibody Subclass ELISA Protocol 
ELISA plates were coated with 4µg/mL meningococcal polysaccharides from serogroups 
A, C, W or Y plus 4µg/mL methylated human serum albumin (mHSA; National Institute for 
Biological Standards and Control, Hertfordshire, UK) and blocked. mHSA is used to attach 
meningococcal polysaccharides to ELISA plates (Arakere and Frasch, 1991). Plates were washed 
using a SkanWasher 300 Microplate Washer (Molecular Devices (UK) Limited, Berkshire, UK). 
Heat-inactive serum samples (cohorts detailed in Section 2.6.3), diluted 1/5 (v/v) to 1/160 (v/v) 
in blocking buffer, were added to the plate at 90µL/well for one hour at 37°C in duplicate. The 
purified anti-MenACWY antibody standard was serially diluted 1 in 2 with blocking buffer from 
10µg/mL to 0.02µg/mL and added to each plate at 90µL/well for one hour at 37°C. Two controls, 
each created by pooling the plasma of 10 vaccinated individuals, were included in each assay. 
Plates were washed three times and bound IgG1, IgG2 and IgM antibody was detected 
with 90µL/well mouse anti-human IgG1 antibody diluted 1/1000 (v/v) in blocking buffer, mouse 
anti-human IgG2 antibody diluted 1/1000 (v/v) in blocking buffer or goat anti-human IgM HRP 
conjugated antibody diluted 1/1000 (v/v) in blocking buffer (all anti-Ig were from Life 
Technologies). After one hour incubation at 37°C, 90µL/well goat anti-mouse IgG-HRP-
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conjugated antibody (Life Technologies) diluted 1/1000 (v/v) in blocking buffer was added to 
each plate (except those to which goat anti-human IgM HRP conjugated antibody was added) 
and incubated for one hour at 37°C.  
Plates were washed, developed and read using a VersaMax ELISA Microplate Reader 
(Molecular Devices) at a wavelength of 492nm (A492nm). Graph Pad Prism software was used 
to interpolate the concentration of anti-MenA/C/W/Y IgG1, IgG2 and IgM present in each 
sample. 
 
2.6.2.1 Intra-Assay and Inter-Assay Coefficient of Variation  
The intra-assay coefficients of variation of each anti-MenACWY IgG1, IgG2 and IgM assay 
was calculated by running two samples (each created by pooling the plasma of 10 vaccinated 
individuals) through each assay, as described in Section 2.6.2, seven times. Each of the seven 
repeats were run in the same assay and antibody concentration interpolated from one antibody 
standard. The coefficient of variation was calculated as the standard deviation divided by mean 
titre and expressed as the percentage of variation (CV %). 
The inter-assay coefficients of variation of each anti-MenACWY IgG1, IgG2 and IgM assay 
was calculated by running two samples (each created by pooling the plasma of 10 vaccinated 
individuals) through each assay, as described in Section 2.6.2, five times. Each of the five repeats 
were run in separate assays and antibody concentration was interpolated from separate 
antibody standards. The coefficient of variation was calculated as the standard deviation divided 
by mean titre and expressed as the percentage of variation (CV %). 
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2.6.2.2 Assay Lower Limit of Detection 
The lower limits of detection for each anti-MenACWY IgG1, IgG2 and IgM assay was 
interpolated from the average absorbance achieved by a negative sample run in five sequential 
assays plus three standard deviations. 
 
2.6.3 Assay Cohorts and Vaccine Details 
Plasma samples were collected during two clinical trials assessing the immunogenicity 
of a tetanus toxoid conjugated quadrivalent meningococcal vaccine (Nimenrix™; GSK134612; 
GlaxoSmithKline Biologicals SA) in infants and children (Klein et al., 2013; Vesikari et al., 2012). 
The first clinical trial, comparing the response to a single dose Nimenrix™ and a plain 
quadrivalent meningococcal vaccine (Mencevax™, GlaxoSmithKline Biologicals SA) one month 
post vaccination in children 2-10 years of age, is registered at ClinicalTrials.gov (identifier: 
NCT00427908, 2012). Twenty-two samples from subjects vaccinated with Mencevax™ and 
twenty-eight samples from subjects vaccinated with Nimenrix™ were run through each of the 
anti-MenA/C/W/Y antibody subclass ELISAs. The second clinical trial, comparing the response to 
one or two doses of Nimenrix™ four months post final vaccination in babies 9-12 months of age, 
is registered at ClinicalTrials.gov (identifier: NCT00718666, 2013). Twenty-three samples from 
subjects vaccinated with one dose Nimenrix™ and twenty-six samples from subjects vaccinated 
with two doses Nimenrix™ were run through each of the each anti-MenACWY IgG1, IgG2 and 
IgM assay  
Each dose of Nimenrix™ comprises 5µg Neisseria meningitidis group A polysaccharide, 
5µg Neisseria meningitidis group C polysaccharide, 5µg Neisseria meningitidis group W-135 
polysaccharide, 5µg Neisseria meningitidis group Y polysaccharide and 44µg tetanus toxoid 
conjugate. Each dose of Mencevax™ contains 50µg Neisseria meningitidis group A 
polysaccharide, 50µg Neisseria meningitidis group C polysaccharide, 50µg Neisseria meningitidis 
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group W-135 polysaccharide and 50µg Neisseria meningitidis group Y polysaccharide. Both 
vaccines were administered by intramuscular injection. 
SBA titres of serum samples towards Neisseria meningitidis serogroups A (strain 3125), 
C (strain C11), W-135 (strain MP01240070) and Y (strain 1975) were assessed during clinical 
trials NCT00427908 and NCT00718666. SBAs were performed at either GlaxoSmithKline 
Vaccines, Wavre, Belgium by Vesikari et al., (2012) or GlaxoSmithKline Vaccines, Rixensart, 
Belgium by Klein et al., (2013). The source of human complement used in the hSBA was a non-
depleted human serum that was specifically screened to determine absence of antibodies to 
Neisseria meningitidis and absence of intrinsic toxicity. 
 
2.6.4 Anti-MenACWY Antibody Subclass Composition – Pilot Study 
Anti-MenACWY antibody was isolated individually from the plasma of each of eleven 
adult individuals as described in Section 2.2.3. The plasma was taken at least one month post 
vaccination with a quadrivalent plain meningococcal polysaccharide (from serogroups A, C, W-
135 and Y) vaccine (Mencevax™). Anti-MenACWY antibody from each individual was run 
through both the IgG Subclass ELISA Kit and Ready-SET-Go! ® Human IgM ELISA Kit as described 
in Section 2.6.1.2 and Section 2.6.1.3, respectively. The percentage of IgG1, IgG2, IgG3, IgG4 and 
IgM anti-MenACWY antibody present in each sample was calculated as: (antibody subclass 
concentration (µg/mL) over total antibody concentration (µg/mL)) x100.  
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2.7 Surface Plasmon Resonance (SPR) 
The interaction of human IgG1, IgG2, IgG3, IgG4 and IgM with human and rabbit C1q 
was measured by SPR as described by Patel et al., (2015). SPR assays were run on a Biacore™ 
T200 System at a flow rate of 30µL/minute with 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 
0.005% v/v Surfactant P20 (HBS) as the running buffer. All SPR reagents were from GE 
Healthcare. 
Recombinant Protein L (Life Technologies Ltd) was amine coupled to a CM5 Biacore™ 
sensor chip using an Amine Coupling Kit following supplier’s instructions. The chip surface was 
activated with a 400 second injection of 11.5mg/mL N-Hydroxysuccinimide and 75mg/mL 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride mixed 1/1 (v/v) at a flow rate of 
10µL/minute. Protein L was diluted to 0.1mg/mL in 10mM sodium acetate pH4.0 and injected 
for 480 seconds over each flow cell at a flow rate of 10µL/minute. Residual active groups on flow 
cells were deactivated with a 400 second injection of 1M ethanolamine hydrochloride-NaOH 
pH8.5 at a flow rate of 10µL/minute. The flow cell surface was then washed with a 60 second 
injection of 50mM NaOH. Flow cell 2 was used to capture each antibody subclass and flow cell 
1 was used as the reference surface. Non-specific human IgG1, IgG2, IgG3, IgG4 and IgM 
antibodies, prepared from human serum as described in Section 2.2.4., were captured to flow 
cell 2 to levels between 40-300 response units (RU). Rabbit or human C1q, isolated as described 
in Section 2.2.5 and Section 2.5.6, were diluted in HBS to 600-3.125nM and injected over flow 
cells 1 and 2 for 20-40 seconds. Between cycles, chip surfaces were regenerated with a 180 
second injection of 10mM Glycine-HCl pH1.5 at a flow rate of 10µL/minute. The affinity of C1q 
for each antibody subclass was calculated using Biacore™ T200 Evaluation Software (version 
2.0.1025; GE Healthcare) by steady state analysis. A graphical summary of the protocol used to 
assess the affinity of immunoglobulin binding of human and rabbit C1q is shown in Figure 2. 1.  
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Figure 2. 1 Surface Plasmon Resonance (SPR) Assay Layout 
The interaction of purified human IgG1, IgG2, IgG3 and IgG4 to purified human and rabbit C1q 
was assessed by surface plasmon resonance (SPR). Human or rabbit C1q was injected over 
antibody subclasses captured to a protein L coated CM5 Biacore™ sensor chip. 
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2.8 Haemolytic Assays 
2.8.1 Classical Pathway Haemolytic Assay 
Human or rabbit serum was serially diluted (20% starting concentration) across a U-
bottomed plate by 2/3 (v/v) dilutions in CFD to a final volume of 50µL/well in duplicate. 
Antibody-sensitised sheep erythrocytes (EA; 2% suspension in CFD) prepared as described in 
Section 2.8.1.1., were added to each serum concentration (50µL/well) followed by 50µL/well 
CFD. Negative control comprising EA in CFD only (0% haemolysis) and 100% lysis control 
comprising EA in H2O were included in each assay. Plates were sealed and incubated at 37°C for 
30 minutes. After incubation, plates were spun at 1500RPM for 5 minutes at ambient 
temperature and 100µL/well supernatant was carefully aspirated and transferred to a flat 
bottomed plate without disturbing the pellet. Supernatant absorbance was read using a 
VersaMax ELISA Microplate Reader (Molecular Devices) at a wavelength of 405nm (A405). 
Percentage lysis at each serum concentration was calculated as: 
(𝑆𝑒𝑟𝑢𝑚 𝐴405)−(𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴405)
(𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴405)−(𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴405)
 ×100 . GraphPad Prism software was used to 
calculate the serum concentration resulting in 50% haemolysis by plotting log concentration of 
serum against percentage haemolysis and fitting with a non-linear regression equation. 
 
2.8.1.1 Antibody sensitisation of Sheep Erythrocytes 
Erythrocytes were pelleted by centrifugation from between 1-2mL of sheep blood in 
Alsever’s solution (TCS Biosciences Ltd, Buckingham, UK) and the cell pellet was washed in 20mL 
CFD three times at ambient temperature by centrifugation at 2000RPM for 5 minutes. After the 
final wash, 400µL of the erythrocyte pellet was aspirated and re-suspended in 20mL CFD (2% 
suspension) pre-heated to 37°C. Rabbit anti-sheep erythrocyte antiserum (Sigma-Aldrich, 
1/4000 (v/v in CFD)) was added to the erythrocyte suspension and incubated for 30 minutes at 
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37°C with occasional mixing. Excess antibody was removed by washing three times as before 
and the antibody-sensitised erythrocytes (EA) were re-suspended in 20mL CFD (2% EA 
suspension). 
 
2.8.1.2 Classical Pathway Inhibition 
The concentration of a blocking anti-C1q monoclonal antibody (Pathway Diagnostics) 
required to block classical pathway activation was assessed by classical pathway haemolytic 
assay. Human serum (3.5%) was incubated with different amounts of anti-C1q (40-0nM) for 30 
minutes at ambient. Aliquots of each mixture were added to a U-bottomed plate in duplicate 
(50µL/well). EA (50µL; 2% suspension) were added to each well followed by 50µL/well CFD. The 
assay was continued as described in Section 2.8.1. 
 
2.8.2 Alternative Pathway Haemolytic Assay  
Erythrocytes were pelleted by centrifugation from between 1-2mL of rabbit blood in 
Alsever’s solution (TCS Biosciences Ltd) and the pellet washed in 20mL CFD 0.01M EGTA three 
times at ambient. After the final wash, 400µL of the pellet was aspirated and re-suspended in 
20mL CFD containing 0.01M EGTA, creating a 2% suspension of rabbit erythrocytes (RbE). 
Human serum was titrated (20% starting concentration) across a U-bottomed plate by 
2/3 (v/v) dilutions in CFD 0.01M EGTA to a final volume of 50µL/well in duplicate. RbE (2% 
suspension) were added to each serum concentration of serum (50µL/well) followed by 
50µL/well CFD 0.01M EGTA. Plates were sealed and incubated at 37°C for 30 minutes. After 
incubation, plates were spun at 1500RPM for 5 minutes at ambient temperature and 100µL/well 
was carefully aspirated and transferred to a flat-bottomed plate without disturbing the pellet. 
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Supernatant absorbance was read at a wavelength of 405nm (A405). Percentage lysis at each 
serum concentration was calculated as described in Section 2.8.1. 
 
2.8.2.1 Alternative Pathway Inhibition 
The titre of a blocking anti-FB monoclonal antibody required to block alternative 
pathway activation was assessed by alternative pathway haemolytic assay. The anti-FB antibody 
was kindly provided by Dr. Santiago Rodríguez de Córdoba (Centro de Investigaciones Biológicas, 
Consejo Superior de Investigaciones Científicas, Madrid) which was generated by immunising 
FB-deficient mice with purified human FB. Human serum (3.5%; 0.01M EGTA) was incubated 
with different amounts of anti-FB (40-0nM) for 30 minutes at ambient. Each mixture was added 
to a U-bottomed plate in duplicate (50µL/well). RbE (2% suspension in CFD 0.01M EGTA) were 
added to each serum concentration (50µL/well) followed by 50µL/well CFD 0.01M EGTA. The 
assay was continued as described in Section 2.8.2. 
 
2.9 Serum Bactericidal Assay 
 Undiluted, heat-inactivated immune plasma samples or purified anti-MenACWY IgG1, 
IgG2 or IgM antibodies were doubling diluted (neat to 1 in 512 (v/v) in HBSS containing 0.5% 
BSA) across a U-bottomed plate to a final volume of 20µL/well. Live Neisseria meningitidis 
bacteria (serogroup W-135; strain 102/98; prepared as described in Section 2.9.1; 10µL at 6x104 
cells/mL in HBSS 0.5% BSA) were added to each well, followed by IgG-depleted human serum or 
BRS (Cedarlane) at 10µL/well. IgG depleted human serum was prepared as described by Brookes 
et al., (2013). Plates were incubated for one hour at 37°C with shaking at 65RPM using an iEMSTM 
shaking incubator. Controls included bacteria plus serum only, bacteria plus heat inactivated 
serum only, and bacteria plus test immune sample plus heat-inactivated serum. Bacteria (10µL 
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aliquots) taken before the incubation and after the one hour incubation under the stated 
conditions were plated out onto a blood agar plate (bioMerieux, MO, USA) using the tilt method 
(T0; 0% killing). The tilt method involves transferring 10µL of sample to the top of a blood agar 
plate, angled at roughly 45°, and allowing the sample to trickle down to the bottom of the plate. 
Plates were left upright for ten minutes before inverting and incubating overnight at 37°C. The 
number of colonies (colony forming units, CFU) was then counted for each sample. 
 
2.9.1 Preparation of Neisseria meningitidis for Serum Bactericidal Assay 
Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria from frozen stocks 
were streaked on a blood agar plate and incubated overnight at 37°C. Frantz medium (11mM L-
glutamic acid, 103mM NaCl, 17mM Na2HPO4.7H2O, 23mM NH4Cl, 1.2mM KCl, 0.1mM L-cysteine 
hydrochloride monohydrate, 2g/L dialysed yeast extract, 5mM MgSO4.7H2O, 28mM glucose, 
pH7.4) was then inoculated with individual clones to 2x108 cells/mL (absorbance of 0.1 at 
600nm) and grown for three hours at 37°C. Bacteria were diluted to 4x104 cells/mL in HBSS 0.5% 
BSA before use in assays. 
 
2.9.2 Complement Inhibition in SBAs 
The contribution of each pathway of complement activation to killing in SBAs was 
assessed using pathway-specific inhibitors. For classical pathway inhibition, an anti-human C1q 
antibody (A201; Pathway Diagnostics) was added to IgG-depleted human serum to a 
concentration of 15nM. For lectin pathway inhibition, an anti-MBL monoclonal antibody 
(MAB23071; R&D Systems) was added to IgG-depleted human serum and BRS to a concentration 
of 250nM. For alternative pathway inhibition, an anti-FB antibody (kindly provided by Dr. 
Santiago Rodríguez de Córdoba and prepared as described in Section 2.8.2.1) or human FH 
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(prepared in house as described in Section 2.2.7) was added to IgG-depleted human serum and 
BRS to a concentration of 250nM and 1.94µM, respectively. All inhibitor doses were selected to 
give complete inhibition of the respective pathway in the assays described above. The number 
of CFUs was counted after repeating the SBA assay with or without each complement pathway 
inhibitor as described in Section 2.9. 
 
2.10 Flow Cytometry  
Flow cytometric assays were performed using a CyAn flow cytometer (Beckman Coulter 
(UK) Ltd, High Wycombe, UK) with an automated 96-well plate sampler (Cytek Biosciences Inc, 
CA, USA. 
 
2.10.1 Preparation of Neisseria meningitidis Bacteria for Flow Cytometric 
Assays 
Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria were grown for four 
hours at 37°C in 5% (v/v) CO2 in 10mL Frantz medium. Bacteria were then washed by 
centrifugation at 3060g for 5 minutes at 4°C and re-suspension in 10mL PBS, three times. After 
the final spin, bacteria were killed by re-suspension in PBS containing 0.2% (w/v) sodium azide 
and 17µg/mL phenylmethylsulfonyl fluoride and incubation for 48 hours at 37°C with 5% CO2. 
The killed bacteria were plated overnight on Columbia agar with 5% horse blood (bioMérieux, 
MO, USA) to confirm killing. Bacteria were washed as before in PBS and diluted to 2x109 
bacteria/mL. 
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2.10.1.1 Preparation of Neisseria meningitidis Bacteria for Opsonophagocytic Assays 
 Neisseria meningitidis serogroup W-135 (strain 102/98) was grown for four hours at 
37°C in 5% (v/v) CO2 in 10mL Frantz medium. Bacteria were then washed by centrifugation at 
3060g for 5 minutes at 4°C and re-suspension in 10mL PBS three times. After the final spin, 
bacteria were re-suspended in PBS and stained with 10µg/mL 2’,7’-bis-(2- carboxyethyl)-5-(and-
6) carboxyfluorescein acetoxymethyl ester (BCECF-AM) (Life Technologies). The bacteria were 
then killed as described in Section 2.10.1. 
 
2.10.2 Immunoglobulin Deposition Assay 
Undiluted, heat-inactivated immune serum samples or purified anti-MenACWY IgG1, 
IgG2 and IgM antibodies were added to a U-bottomed plate at 2µL/well. Killed Neisseria 
meningitidis serogroup W-135 (strain 102/98) bacteria, prepared as described in Section 2.10.1, 
were added to each well at 198µL/well 2x109 bacteria/mL and incubated at 25°C for 30 minutes 
with shaking at 900RPM (Thermo Fisher Scientific Inc). Plates were then centrifuged at 3060g 
for 5 minutes at 4°C. Supernatants were aspirated and pellets were re-suspended in 200µL/well 
2% BSA PBS. Centrifugation and re-suspension was repeated a further two times to remove 
unbound antibody. After the final wash, the pellet was re-suspended in 200µL/well goat anti-
human IgG/IgM FITC antibody (Jackson Immunochemicals) diluted 1/500 (v/v) in 2% BSA PBS 
and incubated at 4°C for 20 minutes. Stained cells were washed as before, re-suspended in 
200µL/well 2% BSA PBS and analysed by flow cytometry on the day of the assay. The 
fluorescence of 10,000 bacteria/sample (elliptical gating over Neisseria meningitidis population) 
was analysed in the fluorescence channel. A horizontal gate was enforced above the 
fluorescence of bacteria only samples.  
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2.10.3 Complement Deposition Assay 
Undiluted, heat-inactivated immune plasma samples or purified anti-MenACWY IgG1, 
IgG2 and IgM antibodies were added to a U-bottomed plate at 5µL/well. BRS or IgG-depleted 
human serum was added to each well at 5µL/well, apart from bacteria only control and bacteria 
and conjugate antibody-only control. A bacteria plus complement only control was also included 
as the negative control. Killed Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria 
(prepared as described in Section 2.10.1) were added to each well at 90µL/well at 2x109 
bacteria/mL and incubated at 25°C for 45 minutes with shaking at 900RPM. Bacteria were 
washed three times by centrifugation at 3060g for 5 minutes at 4°C, aspiration of supernatant 
and pellet re-suspension in 200µL/well. After the final wash, pellets were re-suspended in 
200µL/well sheep anti-human C3c-FITC (Abcam, Cambridge, UK) or sheep anti-rabbit C3c-FITC 
(Acris, MD, USA) diluted 1/500 (v/v) in 2% BSA PBS at 4°C for 20 minutes. Bacteria were washed 
as before, re-suspended in 200µL/well HBSS and analysed by flow cytometry on the day of the 
assay. The median fluorescence (complement deposition) of 10,000 bacteria/sample (elliptical 
gating over Neisseria meningitidis population) between samples was compared by t-test 
statistical analysis. 
 
2.10.4 Opsonophagocytic Assay 
 Opsonophagocytic assays were performed as described by Humphries et al., (Humphries 
et al., 2015). Undiluted, heat-inactivated immune plasma samples or purified anti-MenACWY 
IgG1, IgG2 and IgM antibodies were added to a U-bottomed plate at 5µL/well. Dulbecco’s PBS 
(DPBS) with 0.5% (w/v) BSA, 5mM glucose, 0.9mM CaCl2.2H2O and 0.5mM MgSO4.H2O (DPBS-
GACM) was added to each well at 15µL/well. BCECF-AM-labelled killed Neisseria meningitidis 
serogroup W-135 (strain 102/98) bacteria (prepared as described in Section 2.10.1.1) were 
added at 20µL/well at 2x109 bacteria/mL and incubated for 30 minutes at 37°C whilst shaking at 
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900RPM with a iEMSTM shaking incubator. BRS diluted 1/10 (v/v) in DPBS-GACM or IgG-depleted 
human serum diluted 1/10 (v/v) in DPBS-GACM was added at 10µL/well and incubated for 15 
minutes at 37°C whilst shaking at 900RPM. Differentiated human promyelocytic leukaemia 
(HL60) cells (prepared as described in Section 2.10.4.1) were added at 40µL/well at 2.5x107 
cells/mL and incubated for 30 minutes at 37°C whilst shaking at 900RPM (multiplicity of infection 
(MOI), 40). A HL60 cells and bacteria only control and a HL60, bacteria and complement only 
control was included in each assay. After incubation, plates were immediately placed on ice and 
80µL/well ice-cold DPBS 0.01M EDTA to stop the reaction. Before analysing by flow cytometry, 
50µL/well of trypan blue was added to each plate to quench the fluorescence of un-
phagocytosed bacteria. The median fluorescence (phagocytosis of BCECF-stained Neisseria 
meningitidis) of 10,000 HL60 cells/sample (elliptical gating over HL60 population) was analysed 
in the fluorescence channel. A horizontal gate was enforced above the fluorescence of HL60 cells 
only samples.  
 
2.10.4.1 Differentiation of Human Promyelocytic Leukemia (HL60) Cells 
HL60 cells (CCL-240™; American Type Culture Collection, Manassas, VA, USA) were 
differentiated into granulocyte-like cells as described by Humphries et al., (Humphries et al., 
2015). HL60 cells, at a density between 1x105 and 1x106 cells/mL were incubated in RPMI 1640 
medium (without phenol red; Thermo Fisher) supplemented with 20% FBS (w/v; LabTech), 1% 
L-glutamine (w/v; Thermo Fisher) and 0.8% (v/v) N,N-dimethylformamide (Sigma) for five days 
at 37°C in 5% CO2. Before each assay, differentiated HL60 cells were diluted in DPBS-GACM to a 
concentration of 2.5x107 cells/mL. 
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2.10.5 Complement Inhibition in Flow Cytometric Assays 
The complement deposition and opsonophagocytic assays were run with human and 
rabbit serum in the presence or absence of the described pathway-specific complement 
inhibitors. IgG-depleted human serum and BRS was pre-incubated with each pathway-specific 
inhibitor as described in Section 2.9.2. Complement deposition on the bacteria and phagocytosis 
of the bacteria, with or without each of the complement pathway inhibitors was measured as 
described in Section 2.10.3 and Section 2.10.4, respectively. 
 
2.11 Data Analysis 
 Apart from the exceptions that will be described below, all figures were generated using 
GraphPad Prism version 6.0.7 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com. Statistical analyses of data (such as t-tests, two-way ANOVAs, one-way 
ANOVAs, linear regressions and non-linear regressions, standard deviations, means, geometric 
means and 95% confidence intervals) was performed using GraphPad Prism version 6.0.7 for 
Windows. All t-tests performed were two-tailed and paired. In ELISAs using a standard of a 
known concentration or in SDS-PAGE gels using a molecular weight marker, unknown 
concentrations and molecular weights were interpolated by fitting a 4PL sigmoidal, non-linear 
regression standard curve using GraphPad Prism version 6.0.7 for Windows. 
 For SPR assays, sensograms and KD values (steady state analysis) were generated using 
Biacore™ T200 Evaluation Software (version 2.0.1025; GE Healthcare). Chromatographs were 
generated using UNICORN Control Software (GE Healthcare Life Sciences). Analysis of flow 
cytometry data was performed using FlowJo® Single Cell Analysis Software (version 10.1; FlowJo, 
LLC, Ashland, Oregon). SDS-PAGE gels stained with Coomassie Brilliant Blue and western blots 
were imaged using with a myECL™ Imager (Thermo Fisher Scientific, Massachusetts, USA).  
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Chapter Three – Humoral Immune Response to 
Vaccination with Meningococcal Polysaccharide 
Conjugate  
 
3.1 Introduction 
The immunogenicity of meningococcal polysaccharide vaccines is routinely assessed by 
SBA using either human serum or BRS as the source of complement. The induction of bactericidal 
antibody is an important factor in SBA titres and protection against invasive meningococcal 
disease (Goldschneider et al., 1969a; Goldschneider et al., 1969b). However, the relationship 
between SBA titres and the concentration of anti-polysaccharide antibody is unclear. 
Studies assessing the relationship between the concentration of anti-polysaccharide IgG 
and rSBA and hSBA titres show significant variation between serogroups (Borrow et al., 2001b; 
Bårnes et al., 2011; Elias et al., 2013; Findlow et al., 2009; Granoff et al., 1998; Guirola et al., 
2006; King et al., 1996; Lee et al., 2014; Lieberman et al., 1996; Maslanka et al., 1998; Mitchell 
et al., 1996; Sikkema et al., 2000). One study, analysing the association between IgG response 
to a plain meningococcal quadrivalent polysaccharide vaccine and rSBA titres, showed a strong 
correlation for anti-MenC IgG titres (R square = 0.67) followed by anti-MenW IgG titres (R square 
= 0.58), anti-MenA IgG titres (R square = 0.38) and a very weak correlation with anti-MenY IgG 
titres (R square = 0.09) (Elias et al., 2013). To our knowledge no study has assessed the 
correlation between the antibody response to a meningococcal quadrivalent polysaccharide 
vaccine and hSBA titres.  
 Higher affinity antibody responses to meningococcal vaccines are associated with higher 
SBA titres (Hetherington and Lepow, 1992; Schlesinger et al., 1992). For this reason, it is thought 
that lower affinity antibodies contribute little to SBA titres. There is a concern that the standard 
ELISA used to measure the concentration of anti-polysaccharide antibody in vaccinee sera does 
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not distinguish between high and low-affinity antibodies and that the inclusion of low affinity 
antibodies, which do not significantly add to SBA titres, to the total concentration of antibody 
response to vaccination may account for the poor correlation seen between SBA titres and the 
concentration of anti-polysaccharide IgG (Elias et al., 2013; Findlow et al., 2009; Granoff et al., 
1998; King et al., 1996; Lieberman et al., 1996). To address this issue, Granoff et al., added the 
chaotropic agent ammonium thiocyanate to vaccinee sera allowing antibodies only of the 
highest affinity to bind to the meningococcal polysaccharide-coated ELISA plates (Ferreira and 
Katzin, 1995; Granoff et al., 1998; MacDonald et al., 1988; Pullen et al., 1986). By selectively 
measuring the concentration of high-affinity anti-polysaccharide IgG only, the correlation 
between SBA titres and concentration of anti-polysaccharide IgG did significantly improve. The 
R values increased from 0.45 in the standard ELISA to 0.85 in the modified ELISA.  
The observation that the concentration of high-affinity anti-polysaccharide IgG 
correlates with SBA titres better than the concentration of total (high and low affinity) IgG may 
explain why the correlation between SBA titres and anti-polysaccharide IgG is significantly 
stronger in cohorts vaccinated with conjugate meningococcal vaccines when compared to plain 
meningococcal vaccines (Findlow et al., 2009; Lieberman et al., 1996; Sikkema et al., 2000). 
Meningococcal polysaccharides are TI-2 antigens which characteristically produce antibodies of 
a lower affinity when compared to TD antigens (Mond et al., 1995; Parker, 1993). Protein TD 
antigens, such as tetanus toxoid (TT), are often conjugated to meningococcal polysaccharides to 
improve vaccine immunogenicity (Richmond et al., 1999b). In this way, more of the antibodies 
induced by conjugate vaccination contributes to the SBA titre compared to vaccination with the 
plain polysaccharides alone thus improving the correlation between the two. In one study, the 
R value improved from 0.45, in those vaccinated with the plain polysaccharide, to 0.77, in those 
vaccinated with the conjugate vaccine (Findlow et al., 2009).  
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Neither the standard nor modified anti-polysaccharide IgG ELISAs distinguish between 
the different IgG subclasses (IgG1, IgG2, IgG3, and IgG4), which vary significantly in their ability 
to activate complement (Brüggemann et al., 1987; Gadjeva et al., 2008; Garred et al., 1989). The 
inclusion of IgG subclasses that do not fix complement to the total concentration of antibody 
response to vaccination may also contribute to the poor correlation seen between SBA titres 
and the concentration of anti-polysaccharide IgG. Although the antibody subclass response to 
meningococcal vaccines has been assessed to some degree, the relationship between the 
concentration of anti-polysaccharide IgG subclasses and h/rSBA titres has not been investigated.  
 The bactericidal activity of vaccinee sera in the presence of human or rabbit 
complement correlate poorly (Findlow et al., 2009; Gill et al., 2011a). As previously discussed, 
there is some evidence that human antibodies differentially activate human and rabbit 
complement (Griffiss and Goroff, 1983; Mandrell et al., 1995; Santos et al., 2001; Zollinger and 
Mandrell, 1983). I hypothesise that difference in the ability of antibody subclasses to activate 
human and rabbit complement differentially skew SBA titres and account for the poor 
correlation between rSBA and hSBA titres. 
 
3.1.1 Study Aims 
 The aim of this study is as follows: 
i. To assess the relationship between the concentration of meningococcal 
polysaccharide-specific antibody subclasses and SBA titres with either human 
or rabbit serum. 
Knowledge of the differences, if any, in which anti-polysaccharide antibody subclasses correlate 
with rSBA and hSBA titres may highlight important mechanisms driving the poor correlation 
between both assays. 
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3.1.1.1 Informed Consent 
All testing performed in this study on clinical trial samples is covered by the consent 
given by the trial subjects. Furthermore, the sponsors have taken all necessary measures to 
ensure that the informed consent from any subject participating in this project has been 
obtained. Additionally, the Sponsors have taken all necessary measures to ensure that the 
sample information does not include any personal information (i.e., the samples have been 
anonymized). 
 
3.2 Anti-MenACWY Antibody Subclass Composition – Pilot Study 
To ascertain the predominant antibody subclass response to meningococcal 
polysaccharide vaccination, the proportion of IgG1, IgG2, IgG3, IgG4 and IgM present in affinity-
purified anti-MenACWY antibody isolated from the plasma of eleven adult volunteers was 
assessed using a Ready-SET-Go!® Human IgM ELISA kit (eBioscience) and IgG Subclass ELISA Kit 
(Thermo Fisher Scientific) (Figure 3. 1). Plasma samples were taken at least one month post-
vaccination with a quadrivalent plain polysaccharide (serogroups A, C, W-135 and Y) 
meningococcal vaccine (Mencevax™; Table 3.1). The presence of other antibody subclasses was 
not assessed. Anti-MenACWY antibody was purified from anti-TT antibody-depleted plasma by 
affinity chromatography by injection through a 5ml MenACWY-TT-conjugated Sepharose 
column as described in Chapter 2: Section 2.2.3.  
On average, the most predominant antibody subclass present in the purified anti-
MenACWY antibody was IgG2 (38.7% of total antibody) followed by IgM (23.3%), IgG1 (19.9%), 
IgG3 (10.2%) and IgG4 (8.2%) (Figure 3. 1). 
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Figure 3. 1 Antibody Composition of Purified Anti-MenACWY Antibodies 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was affinity-
purified from the plasma of eleven adult individuals. Plasma samples were taken at least one 
month post-vaccination with a quadrivalent plain polysaccharide (serogroups A, C, W-135 and 
Y) meningococcal vaccine (Mencevax™). The concentration of IgG1, IgG2, IgG3, IgG4 and IgM 
present in the antibody purified from each individual was assessed by running each sample (in 
duplicate) though a commercial IgM ELISA kit and a commercial IgG subclass ELISA kit. The 
proportion of each antibody subclass in each sample was calculated as the percentage of total 
antibody concentration (e.g. the concentration of IgG1 antibody present in the sample over the 
concentration of IgG1 plus IgG2 plus IgG3 plus IgG4 plus IgM present in the sample). The mean 
proportion of each antibody subclass present in purified meningococcal polysaccharide-specific 
antibody was calculated as 19.9±5.9% IgG1, 38.7±12.3% IgG2, 10.2±6.7% IgG3, 8.2±4.8% IgG4 
and 23.3±5.7% IgM. Each point represents the average proportion of an antibody subclass 
present in the antibody purified from one individual. The errors bars represent the mean 
proportion (middle line) with the standard deviation (top and bottom lines) of an antibody 
subclass. 
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Table 3. 1 Cohort Details 
The concentration (µg/mL) or proportion (% of total antibody) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM antibody 
was measured in the serum of individuals at least one month or four months post-vaccination with either a plain (Mencevax™) or a TT-conjugated (Nimenrix™) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. Sample were taken as part of two clinical trials (identifiers: NCT00427908 and 
NCT00718666) as described by Vesikaria et al., (2012) and Klein et al., (2013) or as part of this project. The details of each cohort are listed below.  
 
Clinical Trial 
(identifier) 
Vaccine 
Number 
of Doses 
Sample Taken 
Number of 
Samples 
Age at vaccination 
(months) Reference 
Mean Range 
NCT00427908 
Mencevax™ 1 One month post 
vaccination 
22 65 16-125 (Vesikari et al., 
2012) 
Nimenrix™ 
1 28 41 15-131 
NCT00718666 
1 
Four months post 
final vaccination 
23 12 
(Klein et al., 2013) 
2 26 
9 (first dose); 12 
(second dose) 
N/A Mencevax™ ≥1 
>one month post 
vaccination 
11 Adult (18-55) N/A 
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3.3 Anti-MenACWY IgG1, IgG2 and IgM Antibody ELISA 
 A series of ELISAs were developed to measure the serum concentration of Neisseria 
meningitidis serogroups A, C, W and Y polysaccharide-specific IgG1, IgG2 and IgM antibodies in 
individuals vaccinated with a TT-conjugated or a plain quadrivalent meningococcal 
polysaccharide vaccine. The details of each cohort run through each of the assays are listed in 
Table 3.1. Firstly, a large quantity of anti-MenACWY antibody was purified and characterised for 
use in each assay as the standard to be used to interpolate the concentration of meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM antibody present in 
serum. To ascertain whether human antibody subclasses contribute differentially in SBAs using 
either human or rabbit serum as the source of complement, the concentration of meningococcal 
polysaccharide specific IgG1, IgG2 and IgM antibody in a sample will be correlated with the 
corresponding hSBA or rSBA titres achieved for that sample with each serogroup. 
 
3.3.1 Isolation of Anti-MenACWY Antibody Standard 
Anti-MenACWY antibody was isolated by affinity chromatography from 500ml pooled 
plasma, taken from fourteen adult individuals previously vaccinated with a quadrivalent 
meningococcal polysaccharide vaccine. These plasma samples were taken at least one month 
post-vaccination with a quadrivalent plain polysaccharide (serogroups A, C, W-135 and Y) 
meningococcal vaccine (Mencevax™). The plasma was first depleted of anti-TT antibody by 
injection through a 5ml TT-conjugated Sepharose column as described in Chapter 2: Section 
2.2.3. Roughly 25.5mg of anti-TT antibody and 15.3mg anti-MenACWY antibody were isolated 
in total. The purity and composition of the purified antibody standard was assessed by SDS-PAGE 
(Figure 3.2). SDS-PAGE analysis showed that the purified anti-MenACWY antibody standard 
consisted of both IgG and IgM antibody subclasses (Figure 3. 2).  
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Figure 3. 2 SDS-PAGE Analysis of Anti-MenACWY Antibody Standard 
A meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody standard was 
affinity-purified from the (pooled) plasma of fourteen adult individuals. Plasma samples were 
taken at least one month post-vaccination with a quadrivalent plain polysaccharide (serogroups 
A, C, W-135 and Y) meningococcal vaccine (Mencevax™). The purity and composition of the 
purified antibody was assessed by SDS-PAGE. a, 200ng of the purified antibody was run through 
a 15% polyacrylamide gel under non-reducing (NR) and reducing conditions (R) and stained with 
coomassie Brilliant Blue dye. Under non-reducing conditions, the purified antibody appeared as 
two distinct bands: one of which did not migrate through the stacking gel and one of which 
migrated above the 190kDa molecular weight marker. Under reducing conditions the purified 
antibody appeared as three bands with apparent molecular weights of 74.4kDa, 46.5kDa and 
23.0kDa. These data suggested the presence of both IgG and IgM antibody subclasses in the 
purified antibody standard. b, By western blot analysis using a donkey anti-human IgM HRP 
conjugate antibody, the larger band (in the non-reducing lane) and the 74.4kDa band (in the 
reduced lane) were positive for IgM confirming the presence of IgM in the purified antibody 
standard. c, By western blot analysis using a donkey anti-human IgG HRP conjugate antibody, 
the smaller band (in the non-reducing lane) and 46.5kDa band (in the reducing lane) were both 
positive for IgG confirming the presence of IgG in the purified antibody standard. 
  
b c a 
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The reactivity of the purified anti-MenACWY antibody standard to TT protein and 
MenACWY polysaccharides was assessed by ELISA (Figure 3. 3). The anti-MenACWY antibody 
bound well to MenACWY polysaccharides whereas minimal binding to TT protein could be 
detected confirming efficient depletion. 
 
3.3.2 Antibody Composition of Anti-MenACWY Antibody Standard 
 The concentration of IgM, IgG1, IgG2, IgG3 and IgG4 present in the anti-MenACWY 
antibody standard was measured using a Ready-SET-Go! ® Human IgM ELISA kit (eBioscience) 
and IgG Subclass ELISA Kit (Thermo Fisher Scientific) (Figure 3. 4 and Figure 3. 5). The anti-
MenACWY antibody standard was run through both assays at several dilutions. The composition 
of the anti-MenACWY antibody standard was calculated as 335.2±26.4µg/ml IgG1, 
534±31.6µg/ml IgG2, 57.5±7.5µg/ml IgG3, 77.7±5.2µg/ml IgG4 and 430.5±39.9µg/ml IgM 
(Figure 3. 6). 
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Figure 3. 3 Anti-MenACWY Antibody Standard Reactivity (ELISA) 
A meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody standard was 
affinity-purified from the (pooled) plasma of fourteen adult individuals. The antibody was 
purified by injection of the plasma over a MenACWY-tetanus toxoid (TT)-conjugated Sepharose 
column. To ensure the specificity of the purified antibody was to the meningococcal 
polysaccharides and not also to the TT conjugate, the plasma was first depleted of antibody 
specific to the TT conjugate by injection over a TT-conjugated Sepharose column prior to 
injection over the MenACWY-TT-conjugated Sepharose column. The reactivity of the purified 
antibody to TT and MenACWY-TT was assessed by ELISA. A titration (2.5-0.01µg/ml) of the 
purified antibody standard was incubated on ELISA plates coated with the TT conjugate or 
MenACWY-TT in duplicate. Subsequent IgG/M antibody binding was detected with a goat anti-
human IgG/IgM HRP conjugate antibody. By two-way ANOVA multiple comparison statistical 
analysis comparing IgG/IgM antibody binding (absorbance 492nm) to both coatings at each 
concentration of the purified antibody standard, significantly more IgG/IgM binding was 
detected to wells coated with MenACWY-TT (open circles) compared to wells coated with TT 
(open triangles). These data confirmed that the specificity of the purified antibody was to the 
meningococcal polysaccharides and not the TT conjugate. Each point represents the average 
absorbance achieved for each coating at each concentration of the purified antibody standard. 
The errors bars represent the standard deviation. The asterisks indicate the statistical 
significance of the difference between the average absorbance achieved for each coating at each 
concentration of the purified antibody standard (*** = P value<0.001; **** = P value<0.0001). 
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Figure 3. 4 Anti-MenACWY Antibody Standard IgM Concentration (ELISA) 
A meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody standard was 
affinity-purified from the (pooled) plasma of fourteen adult individuals. The concentration of 
IgM present in the purified antibody standard was assessed using a Ready-SET-Go!® Human IgM 
ELISA kit (eBioscience). ai, The purified antibody standard was run through  the assay at three 
different dilutions in duplicate and the concentration of IgM at each dilution was interpolated 
using the IgM antibody standard provided with the assay. Each point (solid circles) represents 
the average absorbance achieved at each concentration of the IgM antibody standard provided 
with the assay. The errors bars represent the standard deviation. The dotted line represents the 
standard curve model used to interpolate the concentration of IgM present in the three dilution 
of the purified antibody standard (non-linear regression; sigmoidal, 4PL standard curve). The 
average absorbance and interpolated concentration of each dilution of the purified antibody 
standard is shown as a red vertical line. aii, The average interpolated concentration and 
standard deviation (error bars) of IgM present at each dilution of the purified antibody standard 
is shown. bi, Two concentrations (700ng/ml and 200ng/ml ) of an in-house purified human IgM 
were run through the same Ready-SET-Go!® Human IgM ELISA kit as a control for the assay. The 
absorbance achieved with each control is shown as a red vertical line. bii, The average 
interpolated concentration and standard deviation (error bars) of each control is shown. 
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Figure 3. 5 Anti-MenACWY Antibody Standard IgG Subclass Concentration (ELISA) 
A meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody standard was 
affinity-purified from the (pooled) plasma of fourteen adult individuals. The concentration of 
IgG1 (ai), IgG2 (aii), IgG3 (aiii) and IgG4 (aiv) present in the purified antibody standard was 
assessed using a IgG Subclass ELISA Kit (Thermo Fisher Scientific). The purified antibody standard 
was run through the assay at five different dilutions in duplicate and the concentration of IgG1, 
IgG2, IgG3 and IgG4 at each dilution was interpolated using the IgG1, IgG2, IgG3 or IgG4 antibody 
standards provided with the assay. Each point (solid circles) represents the average absorbance 
achieved at each concentration of the antibody standards provided with the assay. The errors 
bars represent the standard deviation. The dotted line represents the standard curve model 
used to interpolate the concentration of IgG1, IgG2, IgG3 and IgG4 present in the five dilution of 
the purified antibody standard (non-linear regression; sigmoidal, 4PL standard curve). Where 
possible, the average absorbance and interpolated concentration of each dilution of the purified 
antibody standard is shown as a red vertical line. b, The average interpolated concentrations 
and standard deviations (error bars) of IgG1, IgG2, IgG3 and IgG4 present in each dilution of the 
purified antibody standard are shown. The dilutions of the purified antibody standard that 
produced too high or too low a signal to interpolate using the antibody standards provided with 
the assay are also indicated. c, A sample with known concentrations of IgG1, IgG2, IgG3 and IgG4 
(provided with the assay) was included in the assay as the control. The average concentrations 
and standard deviations of IgG1, IgG2, IgG3 and IgG4 in the control sample interpolated in this 
assay are shown (open bars). The known concentrations and standard deviations (the details of 
which were provided by the supplier of the assay) of IgG1, IgG2, IgG3 and IgG4 in the control 
sample are also shown for comparison (filled bars).   
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Figure 3. 6 Antibody Subclass Composition of the Anti-MenACWY Antibody Standard 
A meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody standard was 
affinity-purified from the (pooled) plasma of fourteen adult individuals. Plasma samples were 
taken at least one month post-vaccination with a quadrivalent plain polysaccharide (serogroups 
A, C, W-135 and Y) meningococcal vaccine (Mencevax™). The concentration of IgM, IgG1, IgG2, 
IgG3 and IgG4 present in the purified antibody standard was assessed using a Ready-SET-Go!® 
Human IgM ELISA kit and a IgG Subclass ELISA Kit (detailed in Figure 3.4 and Figure 3.5, 
respectively). The purified antibody standard was calculated to consist of 335.2µg/ml IgG1, 
534µg/ml IgG2, 57.5µg/ml IgG3, 77.7µg/ml IgG4 and 430.5µg/ml IgM. Each bar represents the 
average interpolated concentration and standard deviation (error bars) of each antibody 
subclass present in the purified antibody standard assessed by each assay at three (IgM) or five 
(IgG) different dilutions.  
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3.3.3 Intra-Assay and Inter-Assay Coefficients of Variation and Lower Limits of 
Detection 
In order to ascertain the precision of each of the anti-MenACWY IgG1, IgG2 and IgM 
ELISAs, the intra-assay and inter-assay coefficients of variation were assessed. The intra-assay 
coefficient of variation describes the percentage of variation the interpolated value a sample is 
assigned within the same experiment/plate in an assay whereas the inter-assay coefficient of 
variation describes the percentage of variation the interpolated value a sample is assigned 
between experiments/plates in an assay.  
The intra-assay coefficients of variation of anti-MenACWY IgG1, IgG2 and IgM assays 
were calculated by running two pooled samples through each assay seven times in duplicate 
(Table 3. 2a). The two pooled samples were created by pooling equal volumes of 10 different 
serum samples (20 samples in total) taken one month post-vaccination with Nimernrix™ as part 
of the clinical trial NCT00427908 (Table 3.1). Each of the seven repeats were run on the same 
assay plate and antibody concentration interpolated from one antibody standard. The 
coefficient of variation was calculated as the standard deviation divided by mean titre and 
expressed as the percentage of variation. The inter-assay coefficients of variation of anti-
MenACWY IgG1, IgG2 and IgM assays were calculated by running two samples (pools of 10 
individual samples) through each assay five times in duplicate (Table 3. 2b). Each of the five 
repeats were run on the separate assay plates and antibody concentration interpolated from 
separate antibody standards. The coefficient of variation was calculated as the standard 
deviation divided by mean titre and expressed as the percentage of variation. Both the inter-
assay and intra-assay coefficients of variation were lower than 15% indicating sufficient 
precision for each of the anti-MenACWY IgG1, IgG2 and IgM ELISAs. 
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Table 3. 2 Intra-Assay and Inter-Assay Coefficient of Variation and Lower Limits of 
Detection 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured by ELISA in the serum of individuals at least 
one month or four months post-vaccination with either a plain (Mencevax™) or a TT-conjugated 
(Nimenrix™) quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine 
as described in Section 2.6. a, The intra-assay coefficients of variation (%) of anti-MenACWY 
IgG1, IgG2 and IgM assays were calculated by running two samples (pools of 10 individual serum 
samples) through each assay seven times time in duplicate. The average intra-assay coefficients 
of variation and standard deviation (SD) for both samples is shown for each assay. b, The inter-
assay coefficients of variation (%) of anti-MenACWY IgG1, IgG2 and IgM assays were calculated 
by running two samples (pools of 10 individual serum samples) through each assay five times 
time in duplicate. The average inter-assay coefficients of variation and SD for both samples is 
shown for each assay. c, The lower limit of detection for each anti-MenACWY IgG1, IgG2 and 
IgM ELISAs was interpolated from the average absorbance achieved by a negative sample run in 
five sequential assays plus three standard deviations. The average lower limit of detection 
(µg/mL) and SD is shown for each assay. 
 
Intra-assay Coefficients of Variation (%) 
Antibody 
Subclass 
Serogroup A Serogroup C Serogroup W Serogroup Y 
Mean SD Mean SD Mean SD Mean SD 
IgG1 3.79 0.37 3.41 0.25 3.45 0.63 3.46 0.65 
IgG2 8.29 0.01 8.54 2.02 6.27 0.95 7.04 1.25 
IgM 4.10 0.45 4.63 3.56 5.96 2.56 8.34 1.91 
         
Inter-assay Coefficients of Variation (%) 
Antibody 
Subclass 
Serogroup A Serogroup C Serogroup W Serogroup Y 
Mean SD Mean SD Mean SD Mean SD 
IgG1 8.17 3.00 8.22 4.56 9.88 4.65 10.14 2.00 
IgG2 9.04 5.61 8.36 7.01 7.76 0.27 11.13 4.38 
IgM 6.15 2.40 8.11 2.58 8.64 1.51 7.33 0.35 
         
Lower Limit of Detection (µg/ml) 
Antibody 
Subclass 
Serogroup A Serogroup C Serogroup W Serogroup Y 
Mean SD Mean SD Mean SD Mean SD 
IgG1 0.16 0.03 0.17 0.03 0.17 0.03 0.15 0.07 
IgG2 0.02 0.01 0.02 0.01 0.02 0.01 0.04 0.05 
IgM 0.02 0.00 0.02 0.01 0.02 0.01 0.02 0.02 
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In order to ascertain the minimum signal of a sample in each of the anti-MenACWY IgG1, 
IgG2 and IgM ELISAs where a reliable value can be interpolated, the lower limits of detection 
were calculated. The lower limits of detection for each anti-MenACWY IgG1, IgG2 and IgM ELISAs 
was interpolated from the average absorbance achieved by a negative sample run in five 
sequential assays plus three standard deviations. (Table 3. 2c).  
 
3.4 Comparison of Antibody Response to either Plain or TT-
Conjugated Quadrivalent Polysaccharide Vaccination 
To ascertain whether human antibody subclasses contribute differentially in SBAs using 
either human or rabbit serum as the source of complement, the concentration (µg/mL) of 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibody was measured in the serum of individuals one month post-vaccination with either a 
plain (Mencevax™; n=22) or a TT-conjugated (Nimenrix™; n=28) quadrivalent meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) vaccine. Serum samples were taken as part of a 
clinical trial (identifier: NCT00427908) comparing the efficacy of both vaccines as described by 
Vesikaria et al., (2012). The average age of those vaccinated with Mencevax™ was 65 months 
(ranging from 16 to 125 months). The average age of those vaccinated with Nimenrix™ was 41 
months (ranging from 15 to 131 months) (Table 3.1). 
A summary table showing the geometric mean serum concentrations with confidence 
intervals (95%) of anti-MenACWY IgG1, IgG2 and IgM antibodies one month post-vaccination 
with either TT- conjugated or plain MenACWY polysaccharide vaccines are shown in Table 3.3. 
Serogroup-specific antibody subclass responses one-month post plain and TT-conjugated 
quadrivalent meningococcal vaccination were compared by t-test analysis (Figure 3. 7). A 
significantly higher concentration of IgG1 (MenA P < 0.001; MenC P < 0.01; MenW P < 0.01; 
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MenY P < 0.05) and IgM (MenA P < 0.001; MenC P < 0.01; MenW P < 0.001; MenY P < 0.001) 
antibody was measured in response to the TT-conjugated quadrivalent meningococcal vaccine 
compared to the plain quadrivalent meningococcal vaccine for all serogroups. A significantly 
higher concentration of serogroup W (P < 0.001) and Y (P < 0.05)-specific IgG2 antibody and a 
significantly lower concentration of serogroup A (P < 0.05)-specific IgG2 antibody was measured 
in response to the TT-conjugated quadrivalent meningococcal vaccine. 
The antibody subclass responses between serogroups, one-month post plain and TT-
conjugated quadrivalent meningococcal vaccine, were compared by t-test analysis (Figure 3. 8). 
The individuals shown in Figure 3.8 are the same as shown in Figure 3.7. In general, a 
significantly higher concentration of IgG1, IgG2 and IgM antibody was measured in response to 
serogroup A compared to serogroups C, W and Y for both plain and TT-conjugated quadrivalent 
meningococcal vaccines (P values detailed in Figure 3.8).  
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Table 3. 3 Antibody Subclass Response to Plain and TT-Conjugated Quadrivalent 
Meningococcal Polysaccharide Vaccines 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one month post-
vaccination with either a plain (Mencevax™; n=22) or a TT-conjugated (Nimenrix™; n=28) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. Serum 
samples were taken as part of a clinical trial (identifier: NCT00427908) comparing the efficacy 
of both vaccines as described by Vesikaria et al., (2012). The average age of those vaccinated 
with Mencevax™ was 65 months (ranging from 16 to 125 months). The average age of those 
vaccinated with Nimenrix™ was 41 months (ranging from 15 to 131 months). Geometric mean 
concentrations (GMC; µg/mL) with 95% confidence intervals (95% CI) are shown for each 
serogroup-specific antibody subclass assessed one month post-vaccination with Mencevax™ (a; 
plain polysaccharide) or Nimenrix™ (b; TT conjugated polysaccharide). 
 
Mencevax™ (Plain Polysaccharide) 
Serogroup  
IgG1 (µg/mL) IgG2 (µg/mL) IgM (µg/mL) 
GMC 95% CI GMC 95% CI GMC 95% CI 
A 9.67 7.68-12.17 2.12 1.06-4.26 53.23 36.03-78.64 
C 5.33 3.86-7.36 0.48 0.34-0.68 7.36 6.11-8.86 
W 1.91 1.48-2.46 0.19 0.16-0.22 5.88 4.94-7.00 
Y 2.68 1.75-4.11 0.32 0.23-0.45 7.46 6.15-9.06 
       
Nimenrix™ (TT-Conjugated Polysaccharide) 
Serogroup  
IgG1 (µg/mL) IgG2 (µg/mL) IgM (µg/mL) 
GMC 95% CI GMC 95% CI GMC 95% CI 
A 39.03 25.05-60.82 1.37 0.91-2.07 102.1 62.59-166.6 
C 15.56 10.9-22.23 0.74 0.54-1.01 10.47 7.69-14.26 
W 4.51 3.28-6.21 0.35 0.27-0.47 14.99 10.82-20.78 
Y 6.59 4.27-10.16 0.72 0.48-1.10 18 13.11-24.74 
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Figure 3. 7 Antibody Subclass Response to Plain versus TT-Conjugated Quadrivalent 
Meningococcal Polysaccharide Vaccines 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A (a), C (b), W-135 (c) 
and Y (d)) specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one 
month post-vaccination with either a plain (Mencevax™; n=22) or a TT-conjugated (Nimenrix™; 
n=28) quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. 
Serum samples were taken as part of a clinical trial (identifier: NCT00427908) comparing the 
efficacy of both vaccines as described by Vesikaria et al., (2012). The average age of those 
vaccinated with Mencevax™ was 65 months (ranging from 16 to 125 months). The average age 
of those vaccinated with Nimenrix™ was 41 months (ranging from 15 to 131 months). Significant 
differences in antibody subclass concentrations between plain and TT-conjugated vaccines for 
each serogroup were calculated by t-test statistical analysis. The asterisks indicate the statistical 
significance of the difference between the serum antibody subclass concentration post 
vaccination with either Mencevax™ or Nimenrix™ for each of the serogroups (* = P<0.05; ** = P 
value <0.01; *** = P value<0.001). Each serum sample was run through each assay in duplicate. 
Each point represents the average concentration (µg/mL) of the serogroup-specific antibody 
subclass present in the serum of one individual. The errors bars represent the geometric mean 
concentration (µg/mL; middle line) of the serogroup-specific antibody subclass with the 95% 
confidence intervals (top and bottom lines). The geometric mean concentrations (µg/mL) and 
95% confidence intervals for each serogroup-specific antibody subclass in each group are 
summarised in Table 3.3.  
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Figure 3. 8 Antibody Subclass Response to Plain and TT-Conjugated Quadrivalent 
Meningococcal Polysaccharide Vaccine by Serogroup 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one month post-
vaccination with either a plain (Mencevax™; n=22) or a TT-conjugated (Nimenrix™; n=28) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The 
individuals shown here are the same as shown in Figure 3.7). Serum samples were taken as part 
of a clinical trial (identifier: NCT00427908) comparing the efficacy of both vaccines as described 
by Vesikaria et al., (2012). Significant differences in the antibody subclass concentrations specific 
for each of the four serogroups after vaccination with either Mencevax™ (a, b and c) or 
Nimenrix™ (d, e and f) were compared by t-test statistical analysis. The asterisks indicate the 
statistical significance of the difference between the antibody subclass concentration specific 
for each of the four serogroups (* = P<0.05; ** = P value <0.01; *** = P value<0.001). Each serum 
sample was run through each assay in duplicate. Each point represents the average 
concentration (µg/mL) of the serogroup-specific antibody subclass present in the serum of one 
individual. The errors bars represent the geometric mean concentration (µg/mL; middle line) of 
the serogroup-specific antibody subclass with the 95% confidence intervals (top and bottom 
lines). The geometric mean concentrations (µg/mL) and 95% confidence intervals for each 
serogroup-specific antibody subclass in each group are summarised in Table 3.3.   
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3.4.1 Relationship between Antibody Subclasses and SBA Titres 
To ascertain whether human antibody subclasses contribute differentially in SBAs using 
either human or rabbit serum as the source of complement, the relationship between the 
concentration of serogroup-specific antibody subclasses and h/rSBA titres was investigated by 
analysing the serum from individuals one month post vaccination with either plain or TT-
conjugated quadrivalent meningococcal polysaccharide vaccines (Figure 3. 9 and Figure 3. 10). 
The individuals shown in Figure 3.9 and Figure 3.10 are the same as shown in Figure 3.7 and 
Figure 3.8. SBA titres of serum samples towards Neisseria meningitidis serogroups A (strain 
3125), C (strain C11), W-135 (strain MP01240070) and Y (strain 1975) were assessed during the 
clinical trial NCT00427908 (ClinicalTrials.gov, 2012). SBAs were performed at GlaxoSmithKline 
Vaccines, Wavre, Belgium by Vesikari et al., (2012). The source of human complement used in 
the hSBA is a non-depleted human serum that was specifically screened to determine absence 
of antibodies to Neisseria meningitidis and absence of intrinsic toxicity. Scatter plots comparing 
the concentration of each serogroup-specific antibody subclass with hSBA and rSBA titres are 
shown in Figure 3. 9 and Figure 3. 10, respectively. The numbers of individuals vary due to the 
availability of hSBA and rSBA titres for each individual.  
hSBA titres correlated most significantly with the concentration of serogroup A (strain 
3125), W-135 (strain MP01240070) and Y (strain 1975)-specific IgG1 antibody in response to the 
TT-conjugated quadrivalent meningococcal polysaccharide vaccine only. Aside from the 
concentration of serogroup A (strain 3125)-specific IgG1 antibody, hSBA titres correlated poorly 
with the concentration of serogroup-specific IgG1, IgG2 and IgM antibody in response to the 
plain quadrivalent meningococcal polysaccharide vaccine. In contrast, rSBA titres correlated 
most significantly with the concentration of serogroups A (strain 3125), C (strain C11), W-135 
(strain MP01240070) and Y (strain 1975)-specific IgM antibody in response to both the plain and 
TT-conjugated quadrivalent meningococcal polysaccharide vaccines.  
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Figure 3. 9 Relationship between Antibody Subclasses and hSBA Titres  
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one month post-
vaccination with either a plain (Mencevax™) or a TT-conjugated (Nimenrix™) quadrivalent 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The individuals 
shown here are the same as shown in Figure 3.7 and Figure 3.8). Serum samples were taken and 
SBA titres (using human serum as the source of complement; hSBA titre) were assessed to each 
serogroup as part of a clinical trial (identifier: NCT00427908) comparing the efficacy of both 
vaccines as described by Vesikaria et al., (2012). Each scatter plot shows the relationship 
between the concentration of a serogroup-specific antibody subclass and hSBA titres one month 
post vaccination with either plain (open circle; solid line) or TT-conjugated (open square; dotted 
line) quadrivalent polysaccharide vaccines. Each point represents the average serum 
concentration (µg/mL) of a serogroup-specific antibody subclass and the hSBA titre to the same 
serogroup of one individual. The number of samples in each group are indicated in each of the 
scatter plots. N numbers vary due to the availability of hSBA titres for each individual. The 
correlation (R value) is indicated for each group in each of the scatter plots which was calculated 
by linear regression. The statistical significance (P value) of each correlation is also shown. 
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Figure 3. 10 Relationship between Antibody Subclasses and rSBA Titres 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one month post-
vaccination with either a plain (Mencevax™) or a TT-conjugated (Nimenrix™) quadrivalent 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The individuals 
shown here are the same as shown in Figure 3.7, Figure 3.8 and Figure 3.9). Serum samples 
were taken and SBA titres (using rabbit serum as the source of complement; rSBA titre) were 
assessed to each serogroup as part of a clinical trial (identifier: NCT00427908) comparing the 
efficacy of both vaccines as described by Vesikaria et al., (2012). Each scatter plot shows the 
relationship between the concentration of a serogroup-specific antibody subclass and rSBA 
titres one month post vaccination with either plain (open circle; solid line) or TT-conjugated 
(open square; dotted line) quadrivalent polysaccharide vaccines. Each point represents the 
average serum concentration (µg/mL) of a serogroup-specific antibody subclass and the rSBA 
titre to the same serogroup of one individual. The number of samples in each group are indicated 
in each of the scatter plots. N numbers vary due to the availability of hSBA titres for each 
individual. The correlation (R value) is indicated for each group in each of the scatter plots which 
was calculated by linear regression. The statistical significance (P value) of each correlation is 
also shown.   
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3.5 Comparison of Antibody Response to either One or Two 
Vaccinations with TT-Conjugated Quadrivalent Polysaccharide 
Vaccine 
To ascertain whether human antibody subclasses contribute differentially in SBAs using 
either human or rabbit serum as the source of complement, the concentration (µg/mL) of 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibody was measured in the serum of individuals four months post-vaccination with either 
one dose (n=23) or two doses of TT-conjugated (n=26) quadrivalent meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) vaccine. Serum samples were taken as part of a 
clinical trial (identifier: NCT00718666) comparing the efficacy of one versus two doses of 
Nimenrix™ as described by Klein et al., (2013). The age of those vaccinated with one dose 
Nimenrix™ was 12 months. The age of those vaccinated with two doses Nimenrix™ was 9 
months (first dose) and 12 months (second dose).  
A summary table of geometric mean concentrations with confidence intervals (95%) of 
anti-MenACWY IgG1, IgG2 and IgM antibodies following either one or two doses Nimenrix™ 
vaccine is shown in Table 3.4. Serogroup-specific antibody subclass responses four months post 
one versus two doses TT-conjugated quadrivalent meningococcal vaccine were compared by t-
test analysis (Figure 3. 11). A significantly lower concentration of serogroup A-specific IgG1 
(P<0.05), IgG2 (P<0.05) and IgM (P<0.05) and serogroup C-specific IgM (P<0.05) antibody was 
measured in response to two doses of the TT-conjugated quadrivalent meningococcal vaccine 
compared to one dose. In contrast, a significantly higher concentration of serogroup Y-specific 
IgG1 (P<0.05) and IgG2 (P<0.05) and serogroup W-specific IgG2 (P<0.05) antibody was measured 
in response to two doses of the TT-conjugated quadrivalent meningococcal vaccine compared 
to one dose.  
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Table 3. 4 Antibody Subclass Response to One and Two Doses TT-Conjugated 
Quadrivalent Meningococcal Polysaccharide Vaccine 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four months 
post-vaccination with either one dose (n=23) or two doses of TT-conjugated (n=26) quadrivalent 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. Serum samples were 
taken as part of a clinical trial (identifier: NCT00718666) comparing the efficacy of one versus 
two doses of Nimenrix™ as described by Klein et al., (2013). The age of those vaccinated with 
one dose Nimenrix™ was 12 months. The age of those vaccinated with two doses Nimenrix™ 
was 9 months (first dose) and 12 months (second dose). Geometric mean concentrations (GMC; 
µg/mL) with 95% confidence intervals (95% CI) are shown for each serogroup-specific antibody 
subclass assessed four months post-vaccination with a single dose of Nimenrix™ (a) or two doses 
of Nimenrix™ (b). 
 
 
 
One Dose Nimenrix™  
Serogroup  
IgG1 (µg/mL) IgG2 (µg/mL) IgM (µg/mL) 
GMC 95% CI GMC 95% CI GMC 95% CI 
A 19.29 12.94-28.74 1.09 0.55-2.18 20.5 14.04-29.94 
C 9.89 7.931-12.32 0.42 0.33-0.53 7.4 5.89-9.31 
W-135 4.391 3.21-6.01 0.312 0.21-0.47 7.11 5.73-8.83 
Y 5.43 3.21-9.20 0.35 0.22-0.53 7.58 6.26-9.18 
       
       
Two Doses Nimenrix™  
Serogroup  
IgG1 (µg/mL) IgG2 (µg/mL) IgM (µg/mL) 
GMC 95% CI GMC 95% CI GMC 95% CI 
A 10.02 7.83-12.83 0.37 0.26-0.53 9.44 6.56-13.60 
C 7.68 5.82-10.14 0.39 0.29-0.53 4.25 3.49-5.17 
W-135 4.84 2.85-8.20 0.74 0.35-1.59 6.2 5.13-7.49 
Y 11.87 6.47-21.76 1.17 0.58-2.37 6.16 5.10-7.45 
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Figure 3. 11 Antibody Subclass Response to One Versus Two Doses TT-Conjugated 
Quadrivalent Meningococcal Polysaccharide Vaccine 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A (a), C (b), W-135 (c) 
and Y (d)) specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four 
months post-vaccination with either one dose (n=23) or two doses of TT-conjugated (n=26) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine. Serum 
samples were taken as part of a clinical trial (identifier: NCT00718666) comparing the efficacy 
of one versus two doses of Nimenrix™ as described by Klein et al., (2013). The age of those 
vaccinated with one dose Nimenrix™ was 12 months. The age of those vaccinated with two 
doses Nimenrix™ was 9 months (first dose) and 12 months (second dose). Significant differences 
in antibody subclass concentrations between one and two doses of the Nimenrix™ vaccine for 
each serogroup were calculated by t-test statistical analysis. The asterisks indicate the statistical 
significance of the difference between the serum antibody subclass concentration post 
vaccination with either one dose or two doses Nimenrix™ for each of the serogroups (* = P<0.05; 
** = P value <0.01; *** = P value<0.001). Each serum sample was run through each assay in 
duplicate. Each point represents the average concentration (µg/mL) of the serogroup-specific 
antibody subclass present in the serum of one individual. The errors bars represent the 
geometric mean concentration (µg/mL; middle line) of the serogroup-specific antibody subclass 
with the 95% confidence intervals (top and bottom lines). The geometric mean concentrations 
(µg/mL) and 95% confidence intervals for each serogroup-specific antibody subclass in each 
group are summarised in Table 3.5.  
 
 
125 
 
 
The antibody subclass responses between serogroups, four months post one and two 
doses TT-conjugated quadrivalent meningococcal vaccine, were compared by t-test analysis 
(Figure 3. 12). The individuals shown in Figure 3.12 are the same as shown in Figure 3.11. 
Following one dose of the vaccine, a significantly higher concentration of IgG1, IgG2 and IgM 
antibody was measured in response to serogroup A compared to serogroups C, W and Y.  
 
3.5.1 Relationship between Antibody Subclasses and SBA Titres 
To ascertain whether human antibody subclasses contribute differentially in SBAs using 
either human or rabbit serum as the source of complement, the relationship between the 
concentration of serogroup-specific antibody subclasses and h/rSBA titres was investigated 
following one and two doses TT-conjugated MenACWY polysaccharide vaccine (Figure 3. 13 and 
Figure 3. 14). The individuals shown in Figure 3.11 and Figure 3.12 are the same as shown in 
Figure 3.13 and Figure 3.14. There was no significant difference between the correlations of 
serogroup-specific antibody subclasses and h/rSBA titres of individuals vaccinated with either 
one or two doses. As such, the data from these two cohorts were combined to improve the 
power of this study. SBA titres of serum samples towards Neisseria meningitidis serogroups A 
(strain 3125), C (strain C11), W-135 (strain MP01240070) and Y (strain 1975) were assessed 
during the clinical trial NCT00718666 (ClinicalTrials.gov, 2013). SBAs were performed at either 
GlaxoSmithKline Vaccines, Rixensart, Belgium by Klein et al., (2013). The source of human 
complement used in the hSBA is a non-depleted human serum that was specifically screened to 
determine absence of antibodies to Neisseria meningitidis and absence of intrinsic toxicity. 
Scatter plots comparing the concentration of each serogroup-specific antibody subclass with 
hSBA and rSBA are shown in Figure 3. 13 and Figure 3. 14, respectively. The numbers of 
individuals vary due to the availability of hSBA and rSBA titres for each individual. Aside from 
the concentration of serogroup A-specific IgG1 and IgG2 antibody, hSBA titres correlated most 
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significantly with the concentration of serogroup-specific IgG1 and IgG2 antibody in response to 
one and two doses of the TT-conjugated quadrivalent meningococcal polysaccharide vaccine. 
Furthermore, hSBA titres correlated poorly with the concentration of serogroup-specific IgM 
antibody. In contrast, rSBA titres correlated most significantly with the concentration of 
serogroup A (strain 3125), W-135 (strain MP01240070) and Y (strain 1975) IgM antibody but 
correlated poorly with the concentration of serogroup-specific IgG1 and IgG2 antibody. 
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Figure 3. 12 Antibody Subclass Response to One and Two Doses TT-Conjugated 
Quadrivalent Meningococcal Polysaccharide Vaccine by Serogroup 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four months 
post-vaccination with either one dose (n=23) or two doses of a TT-conjugated (n=26) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The 
individuals shown here are the same as shown in Figure 3.11). Serum samples were taken as 
part of a clinical trial (identifier: NCT00718666) comparing the efficacy of one versus two doses 
of Nimenrix™ as described by Klein et al., (2013). Significant differences in the antibody subclass 
concentrations specific for each of the four serogroups after vaccination with either one dose 
(a, b and c) or two doses of Nimenrix™ (d, e and f) were compared by t-test statistical analysis. 
The asterisks indicate the statistical significance of the difference between the antibody subclass 
concentration specific for each of the four serogroups (* = P<0.05; ** = P value <0.01; *** = P 
value<0.001). Each serum sample was run through each assay in duplicate. Each point 
represents the average concentration (µg/mL) of the serogroup-specific antibody subclass 
present in the serum of one individual. The errors bars represent the geometric mean 
concentration (µg/mL; middle line) of the serogroup-specific antibody subclass with the 95% 
confidence intervals (top and bottom lines). The geometric mean concentrations (µg/mL) and 
95% confidence intervals for each serogroup-specific antibody subclass in each group are 
summarised in Table 3.5. 
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Figure 3. 13 Relationship between Antibody Subclass Response Post Vaccination with 
TT-Conjugated Quadrivalent Polysaccharide Vaccine and hSBA Titres 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four months 
post-vaccination with either one dose (n=23) or two doses of a TT-conjugated (n=26) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The 
individuals shown here are the same as shown in Figure 3.11 and Figure 3.12). Serum samples 
were taken and SBA titres (using human serum as the source of complement; hSBA titre) were 
assessed to each serogroup as part of a clinical trial (identifier: NCT00718666) comparing the 
efficacy of one versus two doses of Nimenrix™ as described by Klein et al., (2013). Each scatter 
plot shows the relationship between the concentration of a serogroup-specific antibody subclass 
and hSBA titres four months post vaccination with one and two doses of the TT-conjugated 
quadrivalent polysaccharide vaccine (open circle; solid line). Each point represents the average 
serum concentration (µg/mL) of a serogroup-specific antibody subclass and the hSBA titre to the 
same serogroup of one individual. The number of samples in each group are indicated in each 
of the scatter plots. N numbers vary due to the availability of hSBA titres for each individual. The 
correlation (R value) is indicated for each group in each of the scatter plots which was calculated 
by linear regression. The statistical significance (P value) of each correlation is also shown. 
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Figure 3. 14 Relationship between Antibody Subclass Response Post Vaccination with 
TT-Conjugated Quadrivalent Polysaccharide Vaccine and rSBA Titres 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four months 
post-vaccination with either one dose (n=23) or two doses of a TT-conjugated (n=26) 
quadrivalent meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (NB. The 
individuals shown here are the same as shown in Figure 3.11, Figure 3.12 and Figure 3.13). 
Serum samples were taken as part of a clinical trial (identifier: NCT00718666) comparing the 
efficacy of one versus two doses of Nimenrix™ as described by Klein et al., (2013). Serum 
samples were taken and SBA titres (using rabbit serum as the source of complement; rSBA titre) 
were assessed to each serogroup as part of a clinical trial (identifier: NCT00718666) comparing 
the efficacy of one versus two doses of Nimenrix™ as described by Klein et al., (2013). Each 
scatter plot shows the relationship between the concentration of a serogroup-specific antibody 
subclass and hSBA titres four months post vaccination with one and two doses of the TT-
conjugated quadrivalent polysaccharide vaccine (open circle; solid line). Each point represents 
the average serum concentration (µg/mL) of a serogroup-specific antibody subclass and the 
rSBA titre to the same serogroup of one individual. The number of samples in each group are 
indicated in each of the scatter plots. N numbers vary due to the availability of hSBA titres for 
each individual. The correlation (R value) is indicated for each group in each of the scatter plots 
which was calculated by linear regression. The statistical significance (P value) of each 
correlation is also shown. 
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3.6 Discussion 
3.6.1 Antibody Response to Plain versus TT-Conjugated Quadrivalent 
Meningococcal Polysaccharide Vaccines 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 
and Y) specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals one month 
post-vaccination with either a plain (Mencevax™) or a TT-conjugated (Nimenrix™) quadrivalent 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine (Figure 3. 7, Figure 3. 8 
and Table 3.3). Serum samples were taken and SBA titres (using human serum as the source of 
complement; hSBA titre) were assessed to each serogroup as part of a clinical trial (identifier: 
NCT00427908) comparing the efficacy of both vaccines as described by Vesikaria et al., (2012).  
A significantly higher concentration of polysaccharide-specific IgG1 and IgM antibodies 
was induced by TT-conjugated polysaccharides compared to plain polysaccharides for all 
serogroups (Figure 3. 7). Previous studies have shown that protein conjugation of 
meningococcal polysaccharides with TT produces significantly higher SBA titres when compared 
to plain polysaccharides by presumably inducing a stronger humoral immune response (Bermal 
et al., 2011; Dbaibo et al., 2012; Knuf et al., 2010; Lupisan et al., 2013; Memish et al., 2011; 
Pellegrino et al., 2015; Vesikari et al., 2012).  
Protein conjugation of meningococcal polysaccharides (and other polysaccharide-based 
vaccines) aims to boost immunity to vaccination by altering the nature of B cell activation 
(Findlow et al., 2009; Lieberman et al., 1996; Sikkema et al., 2000). Bacterial polysaccharides 
induce T cell-independent B cell activation characterised by generally reduced antibody 
production along with minimal affinity maturation, class switching and memory compared to T 
cell-dependent B cell activation (Mond et al., 1995; Parker, 1993). Protein conjugation will drive 
antibody responses towards those seen with T cell-dependent B cell activation. This study has 
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confirmed that TT-conjugation of meningococcal polysaccharides gives higher SBA titres by 
inducing greater antibody responses. 
The proportion of IgG1, IgG2, IgG3, IgG4 and IgM present in affinity-purified anti-
MenACWY antibody isolated from the plasma of eleven adults was assessed by ELISA (Figure 3. 
1). The predominant antibody subclass was IgG2 followed by IgM > IgG1 > IgG3 and IgG4. The 
individual antibody composition specific for each serogroup was not assessed. This predominant 
IgG2 antibody response measured in adults is dramatically different that measured in children 
where the IgG2 antibody response was very low (Table 3.3 and Table 3.4). This difference in 
response to meningococcal polysaccharides may be explained by the difference in age of the 
individuals vaccinated. Previous studies have shown that for infants, children and adolescents 
the major subclass is IgG1 whereas a predominant IgG2 response is seen in adults (de Voer et 
al., 2011; Findlow et al., 2006; Holme et al., 2015; Joseph et al., 2004; Stoof et al., 2014).  
 
3.6.2 Antibody Response to One versus Two Doses TT-Conjugated 
Quadrivalent Meningococcal Polysaccharide Vaccine 
The concentration (µg/mL) of meningococcal polysaccharide (serogroups A, C, W-135 
and Y) specific IgG1, IgG2 and IgM antibody was measured in the serum of individuals four 
months post-vaccination with either one dose or two doses of TT-conjugated quadrivalent 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) vaccine(Table 3.4, Figure 3. 11 
and Figure 3. 12). Serum samples were taken as part of a clinical trial (identifier: NCT00718666) 
comparing the efficacy of one versus two doses of Nimenrix™ as described by Klein et al., (2013). 
The age of those vaccinated with one dose Nimenrix™ was 12 months. The age of those 
vaccinated with two doses Nimenrix™ was 9 months (first dose) and 12 months (second dose).  
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A significantly lower concentration of anti-MenA IgG1, IgG2, IgM and anti-MenC IgM 
antibody was measured four months post two doses TT-conjugated quadrivalent meningococcal 
vaccine compared to one dose (Figure 3. 11). In contrast, significantly higher titres of anti-MenW 
IgG2, anti-MenY IgG1 and IgG2 were seen after two doses TT-conjugated quadrivalent 
meningococcal vaccine compared to one dose. Hypo-responsiveness following vaccination with 
a TT-conjugated serogroup C polysaccharide vaccine has previously been described (Burrage et 
al., 2002). The exact mechanism behind this suppressed response to a second dose of the 
tetanus toxoid conjugated polysaccharide vaccine is unknown but may be as a result of CIES 
(Burrage et al., 2002). CEIS is thought to occur when antibodies specific to the conjugate protein 
sterically hinder B cell access to the polysaccharide antigen, when the immune response to the 
carrier protein is prioritised over the response to the polysaccharide antigen and/or when 
conjugate protein-specific regulatory T cells dampen the response to the polysaccharide antigen 
(Findlow and Borrow, 2016). Whether CEIS occurs following vaccination with a TT-conjugated 
quadrivalent meningococcal vaccine has not previously been described. The data from this study 
suggest a second dose of tetanus toxoid conjugated polysaccharide vaccine produces a 
suppressed response to serogroups A, C and W (Figure 3. 11). In contrast, a second dose of the 
vaccine appears to provide a boosted response to serogroup Y.  
In contrast to antibody subclasses responses measured one month post vaccination, 
where IgM was the predominant response, the proportion of IgG1 and IgM antibodies four 
months post vaccination were not significantly different. This suggests that the concentration of 
IgM antibody drops more dramatically in the first four months after vaccination compared to 
the concentration of IgG1 antibody. However, it must be noted that the concentration of 
serogroup-specific antibodies measured one month post vaccination were in a cohort of 
individuals aged 2-10 years and the concentration of serogroup-specific antibodies measured 
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four months post vaccination were in a cohort of individuals aged 9-12 months and therefore 
may not be directly compared. 
 
3.6.3 Relationship between Concentration of Antibody Subclasses and SBA 
Titres 
The relationship between the concentration of serogroup-specific antibody subclasses 
and h/rSBA titres was investigated for each cohort (Figure 3. 9, Figure 3. 10, Figure 3. 13 and 
Figure 3. 14). In cohorts vaccinated with the TT-conjugated quadrivalent meningococcal 
polysaccharide vaccine, hSBA titres correlated best with the concentration of serogroup-specific 
IgG1 antibody whereas rSBA titres correlated best with the concentration of serogroup-specific 
IgM antibody. The concentration of serogroup-specific IgG3 (and IgG4) antibody was not 
assessed in this study due to the low concentration of these subclasses in response to 
meningococcal vaccines and restricted volumes of sample available (Figure 3. 1). To fully 
appreciate the differential relationship between rSBA and hSBA titres with antibody responses 
to meningococcal vaccination IgG3 and IgG4 titres must be assessed. Despite its perceived low 
concentration in response to meningococcal polysaccharides, IgG3 most likely plays an 
important role in protection against invasive disease due to its enhanced complement fixing 
capabilities compared to the other human IgG subclasses. 
A previous study, investigating the relationship between anti-MenC IgG and IgM and 
SBA titres in the presence of human and rabbit serum, showed a significant correlation between 
IgG and rSBA and hSBA titres (Santos et al., 2001). In the same study, anti-MenC IgM titres 
correlated well with rSBA titres but not with hSBA titre as shown in this study. Another study, 
showed significantly reduced survival of serogroup B coated with human IgM antibody in the 
presence of rabbit serum compared to human serum (Mandrell et al., 1995). As with these 
previous studies, the data from this study further suggest that serogroup-specific IgM 
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contributes significantly more to bactericidal titres in rSBAs compared to hSBAs and that the 
differential ability of human antibody subclasses to activate human and rabbit complement is 
most likely responsible for the poor correlation between rSBA and hSBA titres. 
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Chapter Four – Differences in Interaction between 
Human IgM and IgG Subclasses with Meningococcal 
Polysaccharides and Rabbit and Human C1q 
 
4.1 Introduction 
4.1.1 Interaction of Antibody Subclasses with Meningococcal Polysaccharides 
 The SBA measures the ability of vaccinee sera to kill Neisseria meningitidis bacteria 
(Goldschneider et al., 1969a; Maslanka et al., 1997). Bacteria are killed by mechanism of CDC 
driven by complement-activating antibody present in the sera of an individual acquired either 
naturally or by vaccination (Goldschneider et al., 1969a; Goldschneider et al., 1969b; Granoff et 
al., 1998).  
It is thought that the affinity of antibody to bacteria significantly impacts upon SBA 
titres. Higher affinity antibodies are associated with higher SBA titres (Hetherington and Lepow, 
1992; Schlesinger et al., 1992). One study, investigating the relationship between the 
concentration of meningococcal polysaccharide-specific IgG1 and IgG2 and antibody affinity to 
polysaccharide, showed that higher concentrations of IgG2 antibody were associated with a 
lower overall affinity of antibody (de Voer et al., 2011). In contrast, the concentration of IgG1 
antibody significantly correlated with a higher overall affinity of antibody to meningococcal 
polysaccharide. These data suggest that the IgG1 antibody induced by vaccination with 
meningococcal polysaccharide are of a higher affinity than IgG2 antibody. However, the 
mechanisms responsible for the association of IgG1 antibody concentration and higher overall 
antibody affinity to meningococcal polysaccharide are not known. The affinity of individual 
antibody subclasses to polysaccharide has not been investigated. 
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4.1.2 Interaction of Human and Rabbit C1q with Antibody Subclasses 
SBAs which measure the efficacy of new meningococcal vaccines utilise BRS as the 
source of complement. The relevance of BRS as the source of complement in SBAs in the 
licensure of new meningococcal vaccines has been questioned. Bactericidal titres in assays 
performed using BRS correlate poorly with the bactericidal titres in SBAs performed with human 
serum (Findlow et al., 2009; Gill et al., 2011a). In the previous chapter, I showed that hSBA titres 
correlated best with the concentration of serogroup-specific IgG1 antibody whereas rSBA titres 
correlated best with the concentration of serogroup-specific IgM antibody (Chapter 3: Section 
3.4.1 and Section 3.5.1). These data suggest that human IgG1 and IgM differentially activate 
human and rabbit complement. 
Activation of the classical pathway of complement by antibody specific for the bacteria 
is the most important factor dictating the bactericidal activity of vaccinee sera in SBAs (Agarwal 
et al., 2014; Drogari-Apiranthitou et al., 2002; Goldschneider et al., 1969a; Granoff, 2009). The 
first component of the classical pathway, C1q, is activated by antigen-bound antibody (Cooper, 
1985). The affinity of C1q to human antibody subclasses varies significantly. C1q exhibits the 
highest affinity to IgG3 antibody followed by IgG1, IgM, IgG2 and IgG4 (Bindon et al., 1988; 
Emanuel et al., 1982; Hughes-Jones, 1977; Moore et al., 2010; Painter et al., 1982; Patel et al., 
2015; Quast et al., 2015). The affinity of rabbit C1q to human antibody subclasses has not been 
assessed. I hypothesise that the differential affinity of human and rabbit C1q to human antibody 
subclasses accounts for the poor correlation between hSBA and rSBA titres. 
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4.1.3 Chapter Aims 
The aims of the work described in this chapter are as follows: 
i. To investigate functional and kinetic differences between the interaction of human 
antibody subclasses with meningococcal polysaccharide vaccine antigens. 
ii. To establish and quantitate any differences between the interaction of rabbit and 
human C1q with human IgM and IgG subclasses. 
 
4.2 Competitive ELISA 
It is thought that the affinity of antibody to bacteria significantly impacts upon SBA titres 
with higher affinity antibodies being associated with higher SBA titres (Hetherington and Lepow, 
1992; Schlesinger et al., 1992). The affinity of individual antibody subclasses to polysaccharide 
has not been investigated but it is hypothesised that certain subclasses are of a higher affinity 
and therefore contribute more to SBA titres. To address this the affinity of IgG1, IgG2, IgG3 and 
IgG4 and IgM antibody subclasses to meningococcal polysaccharide (serogroups A, C, W-135 and 
Y) was assessed by competitive ELISA. 
The competitive ELISA measures the affinity of an antibody to antigen by measuring the 
concentration of fluid-phase antigen (mixed with the antibody) required to block antibody 
binding to solid-phase antigen (adsorbed onto an ELISA plate). The concentration of fluid-phase 
antigen blocking 50% binding to solid-phase antigen is considered the ‘functional affinity’ of the 
antibody to the antigen.  
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4.2.1 Interaction of Antibody Subclasses with Meningococcal Polysaccharides 
In preparation for the meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2, IgG3 and IgG4 and IgM competitive ELISA assays, the dilution factor required 
in each competitive ELISA assay for each plasma sample (n=14) was assessed by ELISA (Figure 
4.1). In this way, the ELISA signal achieved with each plasma sample in each competitive ELISA 
assay was normalised. Plasma samples were taken from adult individuals at least one month 
post-vaccination with a quadrivalent plain polysaccharide (serogroups A, C, W-135 and Y) 
meningococcal vaccine (Mencevax™). Plasma samples were diluted in duplicate across ELISA 
plates coated with a mixture of TT-conjugated meningococcal polysaccharides from serogroups 
A, C, W and Y. Subsequent IgG1, IgG2, IgG3, IgG4 or IgM antibody binding was detected with 
either a rabbit anti-human IgG1, a rabbit anti-human IgG2, a rabbit anti-human IgG3, a rabbit 
anti-human IgG4 or a donkey anti-human IgM antibody (Stratech). Typical binding curves for 
each antibody subclass selected from five representative individuals are shown in Figure 4.1a. 
The dilution factors required for each plasma sample with each antibody subclass to achieve an 
absorbance of 1.0 (492nm) are shown in Figure 4.1b. 
The functional affinity of IgG1 (n=12), IgG2 (n=10), IgG3 (n=6), IgG4 (n=6) and IgM (n=12) 
antibody to TT-conjugated meningococcal polysaccharides in vaccinee plasma of these fourteen 
adult individuals to the meningococcal polysaccharide (serogroups A, C, W-135 and Y) was then 
assessed by competitive ELISA (Figure 4.2a and Figure 4.2c). The number of individuals varies 
between antibody subclasses due to the sample exclusion criteria described in Figure 4.1 and 
Figure 4.3. Vaccinee plasma was diluted to the factor calculated in Figure 4.1 and incubated with 
a range of concentrations of fluid-phase TT-MenACWY. Plasma samples were then incubated on 
plates coated with TT-conjugated meningococcal polysaccharides and binding of IgG1, IgG2, 
IgG3, IgG4 and IgM measured at each concentration of fluid-phase TT-MenACWY. 
Representative curves showing inhibition of binding of IgG1, IgG2, IgG3, IgG4 and IgM to TT-
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MenACWY-coated plates at each concentration of fluid-phase TT-MenACWY are shown in Figure 
4.2b. The concentration of TT-conjugated meningococcal polysaccharides which inhibited 50% 
binding of the specific antibody subclass was calculated as the functional affinity. The geometric 
mean of the functional affinity for antibody subclasses for TT-conjugated meningococcal 
polysaccharides was calculated as 3.0x10-10M (IgG1; n=12), 1.3x10-9M (IgG2; n=10), 4.4x10-10M 
(IgG3; n=6), 3.7x10-9M (IgG4; n=6) and 3.7x10-10M (IgM; n=12) (Figure 4. 2c).  
Plasma samples were diluted as described in Figure 4.1 and incubated with a range of 
concentrations (1x10-7 to 4x10-13M) of tetanus toxoid-conjugated meningococcal polysaccharide 
from serogroups A, C, W-135 and Y (TT-MenACWY). Each plasma:TT-MenACWY mixture, plasma 
control only or buffer only control (blank) was then incubated in triplicate on ELISA plates coated 
with TT-MenACWY. Each of the plasma:TT-MenACWY mixtures were aspirated and incubated in 
duplicate on a second set of ELISA plates coated with TT-MenACWY. Subsequent IgG1, IgG2, 
IgG3, IgG4 or IgM antibody binding (492nm) was detected on both sets of ELISA plates. The 
correlation between the absorbance values achieved on the first set and second set of TT-
MenACWY ELISA plates to assess whether the binding equilibrium between antibody subclasses 
to TT-MenACWY had not been significantly disturbed after incubation on the first set of TT-
MenACWY ELISA plates. (Figure 4. 3). The mean R-squared values for each antibody subclass 
was calculated as 0.98±0.02 (IgG1), 0.99±0.01 (IgG2), 0.97±0.03 (IgG3), 0.97±0.02 (IgG4) and 
0.97±0.03 (IgM). Samples with R-squared values <0.9 (binding equilibrium disturbed by more 
than 10%) were excluded from analysis. In total, three samples were excluded.  
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Figure 4. 1 Sample Dilution Factor Calculations for Competitive ELISA Assay 
In preparation for the meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific 
IgG1, IgG2, IgG3 and IgG4 and IgM competitive ELISA assays, the dilution factor required in each 
competitive ELISA assay for each plasma sample (n=14) was assessed by ELISA. In this way, the 
ELISA signal achieved with each plasma sample in each competitive ELISA assay was normalised. 
Plasma samples were taken from individuals at least one month post-vaccination with a 
quadrivalent plain polysaccharide (serogroups A, C, W-135 and Y) meningococcal vaccine 
(Mencevax™). Plasma samples were diluted in duplicate across ELISA plates coated with a 
mixture of TT-conjugated meningococcal polysaccharides from serogroups A, C, W and Y. 
Subsequent IgG1, IgG2, IgG3, IgG4 or IgM antibody binding was detected with either a rabbit 
anti-human IgG1, a rabbit anti-human IgG2, a rabbit anti-human IgG3, a rabbit anti-human IgG4 
or a donkey anti-human IgM antibody (Stratech). a, Typical binding curves for each antibody 
subclass selected from five representative individuals. Each point represents the average 
absorbance achieved at each plasma sample dilution factor for each subclass. The errors bars 
represent the standard deviation. The solid line represents the standard curve model (non-linear 
regression, sigmoidal, 4PL standard curve) used to interpolate the dilution factor of the plasma 
sample required to achieve an absorbance of 1.0 (492nm; dotted line) for each antibody 
subclass. b, The dilution factors required for each plasma sample with each antibody subclass to 
achieve an absorbance of 1.0 (492nm). Each point represents the average dilution factor of the 
plasma from one individual for each competitive ELISA assay. Samples achieving an absorbance 
lower than 1.0 (492nm) at a dilution factor of 1/10 (dotted line) were assigned a value of 1 and 
omitted from the competitive ELISA due to restraints on sample volume. The horizontal line 
represents the mean average dilution factor by antibody subclass.   
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Figure 4. 2 Functional Affinity of Antibody Subclasses to Meningococcal 
Polysaccharides 
The functional affinity (M) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2, IgG3 and IgG4 and IgM antibodies present in the plasma of fourteen 
individuals to the meningococcal polysaccharide (serogroups A, C, W-135 and Y) was assessed 
by competitive ELISA as described in Section 2.5.1.1. a, The functional affinity of IgG1 (n=12), 
IgG2 (n=10), IgG3 (n=6), IgG4 (n=6) and IgM (n=12) antibody to TT-conjugated meningococcal 
polysaccharides in vaccinee plasma. Each point represents the functional affinity of antibody 
subclasses to TT-MenACWY for one individuals. The errors bars represent the geometric mean 
(middle line) with the 95% confidence intervals (top and bottom lines) of an antibody subclass. 
Significant differences between the functional affinity of antibody subclasses were compared by 
t-test analysis. The asterisks indicate the statistical significance of the difference between the 
functional affinity of antibody subclasses (* = P<0.05; ** = P value <0.01). N numbers vary due 
the exclusion factors of samples as described in Figure 4.1 and Figure 4.3. b, Representative 
curves showing inhibition of binding of IgG1, IgG2, IgG3, IgG4 and IgM to TT-MenACWY-coated 
plates following incubation of antibody with a range of concentrations of fluid-phase TT-
MenACWY. Each point represents the average inhibition of antibody binding to the TT-
MenACWY ELISA plate at each concentration of TT-MenACWY incubated with the plasma 
sample. Error bars represent the standard deviation. The solid lines represent the standard curve 
model used to interpolate the concentration of TT-MenACWY resulting in 50% binding inhibition 
to the TT-MenACWY-coated ELISA plate (non-linear regression; sigmoidal, 4PL standard curve). 
The dotted line shows the concentration of 50% inhibition of antibody subclass binding to plates 
was calculated as the functional affinity of antibody (dotted line). c, Table summarising the 
geometric mean and the 95% confidence intervals of the functional affinities of each antibody 
subclasses to TT-MenACWY.   
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Figure 4. 3 Competitive ELISA: Analysis of First and Second Plates 
The functional affinity (M) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2, IgG3 and IgG4 and IgM antibodies present in the plasma of fourteen 
individuals to the meningococcal polysaccharide (serogroups A, C, W-135 and Y) was assessed 
by competitive ELISA as described in Figure 4.2. Plasma samples were diluted as described in 
Figure 4.1 and incubated with a range of concentrations (1x10-7 to 4x10-13M) of tetanus toxoid-
conjugated meningococcal polysaccharide from serogroups A, C, W-135 and Y (TT-MenACWY). 
Each plasma:TT-MenACWY mixture, plasma control only or buffer only control (blank) was then 
incubated in triplicate on ELISA plates coated with TT-MenACWY. Each of the plasma:TT-
MenACWY mixtures were aspirated and incubated in duplicate on a second set of ELISA plates 
coated with TT-MenACWY. Subsequent IgG1, IgG2, IgG3, IgG4 or IgM antibody binding (492nm) 
was detected on both sets of ELISA plates. The correlation between the absorbance values 
achieved on the first set and second set of TT-MenACWY ELISA plates to assess whether the 
binding equilibrium between antibody subclasses to TT-MenACWY had not been significantly 
disturbed after incubation on the first set of TT-MenACWY ELISA plates. a, Representative 
correlations between the absorbance achieved on the first and second set of ELISA plates at 
each concentration of TT-MenACWY incubated with plasma samples. Each point represents the 
absorbance achieved on the first and second set of ELISA plates at each concentration of TT-
MenACWY incubated with plasma samples for IgG1, IgG2, IgG3, IgG4 and IgM antibodies. Solid 
lines represent the model of linear regression fit to each data used to calculate the R-squared 
values for each antibody subclass in each sample. b, The correlation (R-squared values) of the 
absorbance achieved on the first and second set of ELISA plates for IgG1 (n=12), IgG2 (n=11), 
IgG3 (n=6), IgG4 (n=6) and IgM (n=13) antibodies. N numbers vary due the exclusion factors of 
samples as described in Figure 4.1. Each point represents the R-squared calculated for each 
antibody subclasses for one individual. The errors bars represent the geometric mean (middle 
line) with the 95% confidence intervals (top and bottom lines) of R-values for each subclass. ). 
R-squared values lower than 0.9 suggests a greater than 10% disturbance in binding equilibrium 
between antibody subclasses to TT-MenACWY after incubation on the first on TT-MenACWY-
coated ELISA plate. Samples with R-squared < 0.9 were excluded from analysis (asterisked). 
Three samples were excluded in total.  
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4.2.2 Functional Affinity of Purified and Plasma IgG1 to Meningococcal 
Polysaccharides 
 The functional affinities of antibodies of different subclasses were assessed in plasma 
by competitive ELISA. However, other antibody subclasses were present in plasma which may 
impact accurate quantitation of functional affinity by competing for binding and thus interfering 
with absolute antibody concentration. To address this, the functional affinities of IgG1 in a 
plasma sample (pool of 14 individuals previously vaccinated with Mencevax™) and purified non-
specific IgG1 (from the same pooled sample) to TT-MenACWY were compared (Figure 4. 4). The 
functional affinity of plasma IgG1 was calculated as 8.7x10
-11
M and the functional affinity of 
purified IgG1 was calculated as 8.4x10
-11
M. By one-way ANOVA statistical analysis, there was no 
significant difference between the functional affinities of plasma IgG1 and purified IgG1 
antibodies to TT-conjugated meningococcal polysaccharides. These data concluded that the 
other antibody subclasses present in plasma in addition to the antibody subclass being assessed 
do not impact on the functional affinity of the antibody subclass. 
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Figure 4. 4 Functional Affinity of Purified and Plasma IgG1 to Meningococcal 
Polysaccharides  
The functional affinity (M) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2, IgG3 and IgG4 and IgM antibodies present in the plasma of fourteen 
individuals to the meningococcal polysaccharide (serogroups A, C, W-135 and Y) was assessed 
by competitive ELISA as described in Figure 4.2. In the competitive ELISA, other antibody 
subclasses are present in plasma in addition to the antibody subclass being assessed which may 
impact accurate quantitation of functional affinity by competing for binding and thus interfering 
with absolute antibody concentration. To address this, the functional affinities of IgG1 in a 
plasma sample (pool of 14 individuals previously vaccinated with Mencevax™) and purified non-
specific IgG1 (from the same pooled sample) to TT-MenACWY were compared. a, Plasma or 
purified non-specific IgG1 were incubated with a range of concentrations TT-MenACWY. Each 
sample:TT-MenACWY mixture was then incubated in triplicate on ELISA plates coated with TT-
MenACWY. Subsequent IgG1 antibody binding (492nm) was detected. The concentration (M) of 
TT-MenACWY inhibiting 50% IgG1 binding was interpolated by fitting the data with a non-linear 
regression; sigmoidal, 4PL standard curve. Each point represents the average inhibition of IgG1 
binding to the TT-MenACWY ELISA plate at each concentration of TT-MenACWY incubated with 
plasma IgG1 (red crosses) or purified IgG1 (open squares). Error bars represent the standard 
deviation. b, Summary table of the functional affinities (M) and standard deviations of plasma 
IgG1 and purified IgG1 antibodies to TT-MenACWY. By one-way ANOVA statistical analysis, there 
was no significant difference between the functional affinities of plasma IgG1 and purified IgG1 
antibodies to TT-conjugated meningococcal polysaccharides showing that the other antibody 
subclasses present in plasma in addition to the antibody subclass being assessed do not impact 
on the functional affinity of the antibody subclass.  
Sample Functional Affinity (M) Standard Deviation 
Plasma IgG1 8.725E-11 1.212E-11 
Purified IgG1 8.351E-11 1.527E-11 
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4.2.3 Functional Affinity and KD of Two Anti-FH Antibodies 
To validate the use of this assay, the functional affinity of two anti-human FH antibodies 
(OX-24 and MBI-7) to human FH (variant H402) was measured by competitive ELISA (Figure 4. 
5); the KD of both antibodies had been determined previously using SPR. Human FH (variant 
H402) was purified from human plasma by affinity chromatography and competitive ELISA run 
as before. The functional affinity of antibody OX-24 was calculated as 2.2x10
-10
M and the 
functional affinity of antibody MBI-7 was calculated as 1.1x10
-9
M.  
 
4.3 Interaction of Human and Rabbit C1q with Antibody Subclasses 
 There is evidence that human antibody subclasses differentially activate human and 
rabbit complement. It is hypothesised that this contributes to the poor correlation between SBA 
titres when either human or rabbit serum is used as the source of complement (Findlow et al., 
2009; Gill et al., 2011a; Griffiss and Goroff, 1983; Mandrell et al., 1995; Santos et al., 2001; 
Zollinger and Mandrell, 1983). To test this hypothesis, the interaction of human and rabbit C1q 
to different antibody subclasses was investigated by ELISA and SPR. In preparation for these 
assays, human antibody subclasses and human and rabbit C1q were purified as described below. 
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Figure 4. 5 Functional Affinity and KD of Two Anti-FH Antibodies 
The functional affinity (M) of meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
specific IgG1, IgG2, IgG3 and IgG4 and IgM antibodies present in the plasma of fourteen 
individuals to the meningococcal polysaccharide (serogroups A, C, W-135 and Y) was assessed 
by competitive ELISA as described in Figure 4.2. To validate the use of the competitive ELISA 
assay, the functional affinity of two anti-human FH antibodies (OX-24 and MBI-7) to human FH 
(variant H402), which had been previously assessed by surface plasmon resonance, was 
measured by competitive ELISA. a, Firstly, human FH was affinity purified for use in the 
completive ELISA as described in Section 2.2.7. The purity the purified human FH was assessed 
by SDS-PAGE. 200ng of the purified antibody was run through a 9% polyacrylamide gel under 
non-reducing (NR) and reducing conditions (R) and stained with coomassie Brilliant Blue dye. 
Under non-reducing (NR) conditions FH appeared as a single band of 146.6kDa. Under reduced 
conditions (R) FH appeared as a single band of 150.4kDa. No contaminating proteins were 
detected in the human FH preparation. b, By western blot analysis probing with a mouse anti-
human FH antibody (OX-24), the 146.6kDa band (NR) and the 150.4kDa band (R) were confirmed 
as FH. c, A summary table detailing the KD and functional affinity of OX-24 and MBI-7 antibodies 
to human FH as measured by surface plasmon resonance and competitive ELISA, respectively.  
Antibody 
Method 
Surface Plasmon 
Resonance (KD) 
Competitive ELISA 
(Functional Affinity) 
OX-24 1.2x10
‐10 
M 2.2x10
‐10
M 
MBI-7 2.0x10
‐9 
M 1.1x10
‐9
M 
c 
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4.3.1 Isolation of Antibody Subclasses 
Non-specific human IgG1, IgG2, IgG3, IgG4, IgM and non-specific rabbit IgG antibodies 
were purified to homogeneity by affinity chromatography. To assess purity and calculate protein 
mass, each antibody preparation was run through a 9% polyacrylamide gel under reducing 
conditions and stained with coomassie Brilliant Blue dye (Figure 4. 6). Using the molecular 
weight marker (MwM) as the standard, the molecular weights (kDa) of each antibody heavy 
chain (HC) were interpolated as described in Chapter 2: Section 2.4.1.1. The molecular weights 
of rabbit IgG HC was calculated as 51.7kDa, human IgG1 HC as 51.0kDa, IgG2 HC as 49.4kDa, 
IgG3 HC as 61.1kDa, IgG4 HC as 51.5kDa and IgM HC as 86.9kDa. By western blot, no 
contamination of the purified non-specific human IgG subclasses with other IgG subclasses could 
be detected (Figure 4. 7).  
Human anti-meningococcal polysaccharide (serogroups A, C, W and Y) antibody (anti-
MenACWY) and human IgG (non-specific) antibody were affinity purified from plasma using 
meningococcal polysaccharide-conjugated Sepharose or Protein G, respectively, and used in the 
C1q-binding assay. The human anti-meningococcal polysaccharide (serogroups A, C, W and Y) 
antibody was purified from the plasma of 14 adult individuals taken at least one month post 
vaccination with a plain meningococcal polysaccharide (serogroups A, C, W and Y) vaccine 
(Mencevax™). The non-specific human IgG was purified from human plasma taken from three 
individuals. The antibody composition of both antibody preparations was measured by ELISA. 
The composition of the non-specific IgG purified from human plasma was calculated as 72.3% 
IgG1, 16.2% IgG2, 8.5% IgG3 and 3.1% is IgG4 (Figure 4. 8). The antibody subclass composition 
of the anti-MenACWY antibody was 23.4% IgG1, 37.3% IgG2, 4.0% IgG3, 3.1% IgG4 and 30.0% 
IgM (Figure 4. 8).  
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Figure 4. 6 Coomassie Stain of Human IgM, IgG1, IgG2, IgG3, IgG4 and Rabbit IgG 
Antibodies 
Human IgM, IgG1, IgG2, IgG3, IgG4 and rabbit IgG antibodies were affinity purified from plasma. 
The purity and composition of each antibody preparation was assessed by SDS-PAGE. 200ng of 
each antibody preparation was run though a 9% polyacrylamide gel under reducing conditions 
and stained with coomassie Brilliant Blue dye. Molecular weight markers (MwM) were run either 
side of the gel and used to interpolate the molecular weight (kDa) of each protein band. The 
molecular weight of the heavy chain of each antibody preparation was calculated as 51.7kDa 
(rabbit IgG), 51.0kDa (human IgG1), 49.4kDa (human IgG2), 61.1kDa (human IgG3), 51.5kDa 
(human IgG4) and 86.9kDa (human IgM). No contaminating proteins could be detected in any 
antibody preparation.  
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Figure 4. 7 Western Blot Analysis of Human IgG1, IgG2, IgG3 and IgG4 Antibody 
Preparations 
Human IgG1, IgG2, IgG3 and IgG4 antibodies were affinity purified from plasma. By western blot, 
each IgG subclass preparation was assessed for contamination with any other of the IgG 
subclasses. 200ng of each antibody preparation was run through four 12.5% polyacrylamide gels 
under reducing conditions. 10µL human plasma (diluted 1 in 500) was also run on each gel as a 
positive control for each antibody subclass. Once run, gels were transferred onto nitrocellulose 
membrane and probed with either a rabbit anti-human IgG1 (blot a), a rabbit anti-human IgG2 
(blot b), a rabbit anti-human IgG3 (blot c) or a rabbit anti-human IgG4 (blot d) antibody 
(Stratech). In blot a (anti-human IgG1), positive bands were detected in the lanes containing 
purified human IgG1 and plasma only. In blot b (anti-human IgG2), positive bands were detected 
in the lanes containing purified human IgG2 and plasma only. In blot c (anti-human IgG3), 
positive bands were detected in the lanes containing purified human IgG3 and plasma only. In 
blot d (anti-human IgG4), positive bands were detected in the lanes containing purified human 
IgG4 and plasma only. These data confirmed that there was no detectable contamination of each 
IgG subclass preparation with any other of the IgG subclasses.  
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Figure 4. 8 Antibody Subclass Composition of Human IgG and Anti-MenACWY 
Antibody Preparations 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was affinity-
purified from the plasma of fourteen adult individuals. Plasma samples were taken at least one 
month post-vaccination with a quadrivalent plain polysaccharide (serogroups A, C, W-135 and 
Y) meningococcal vaccine (Mencevax™). Non-specific human IgG was affinity-purified from the 
plasma of three adult individuals using a protein G-conjugated Sepharose column. The 
concentration of IgG1, IgG2, IgG3, IgG4 and IgM present in the antibody purified from each 
individual was assessed by running each sample (in duplicate) though a commercial IgM ELISA 
kit and a commercial IgG subclass ELISA kit. The proportion of each antibody subclass in the 
meningococcal polysaccharide specific antibody (solid bars) and purified human IgG (open bars) 
was calculated as the percentage of total antibody concentration (e.g. the concentration of IgG1 
antibody present in the sample over the concentration of IgG1 plus IgG2 plus IgG3 plus IgG4 plus 
IgM present in the sample). The mean proportion of each antibody subclass present in the 
purified meningococcal polysaccharide-specific antibody was calculated as 23% IgG1, 37% IgG2, 
4.0% IgG3, 3.0% IgG4 and 30% IgM. The mean proportion of each antibody subclass present in 
the purified human IgG antibody was calculated as 72% IgG1, 16% IgG2, 8.5% IgG3, 5.4% IgG4 
and 0.0% IgM. Each point represents the average proportion of an antibody subclass present in 
the antibody purified from one individual. The errors bars represent the mean proportion 
(middle line) with the standard deviation (top and bottom lines) of an antibody subclass.  
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4.3.2 Human and Rabbit C1q Binding ELISA 
To investigate the differences in the interaction of human and rabbit C1q to different 
antibody subclasses, binding of human and rabbit C1q to solid-phase human IgG1, IgG2, IgG3, 
IgG4, non-specific IgG, meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific 
antibody and rabbit IgG was measured by ELISA (Figure 4.9). Human serum (4%; Figure 4.9a), 
rabbit serum (4%; Figure4.9b) or buffer only (no serum control) was incubated in duplicate on 
either blank ELISA wells or ELISA wells coated with 30μg/mL of each antibody subclass 
preparation. Subsequent human and rabbit C1q binding to each antibody subclass was detected 
with a sheep anti-human C1q antibody. The absorbance achieved following incubation of serum 
or buffer only (no serum) with each antibody preparation was compared by t-test statistical 
analysis. Significant human C1q binding was detect with human IgG3, human IgG1, human IgG, 
anti-MenACWY and rabbit IgG. Significant rabbit C1q binding was detect with human IgG3, 
human IgG1, human IgG and human IgM. These data highlight important differences in the 
ability of human and rabbit C1q to bind human antibody subclasses. 
 
4.3.3 Isolation of Human and Rabbit C1q 
 In preparation for the SPR assays, human and rabbit C1q was purified to homogeneity 
from serum by cation exchange chromatography and affinity chromatography on natural ligand 
(crosslinked Ig), respectively. The purity and composition of human and rabbit C1q was assessed 
by SDS-PAGE (Figure 4. 10). ). As well as C1q, other protein bands (assumed to aggregates of 
C1q and other contaminants) were also detected in both preparations concluding that further 
purification of both human and rabbit C1q was necessary. Contaminating proteins, aggregates 
and fragments were removed from each preparation by injection over a 24ml Superdex 75 size 
exclusion chromatography column (Figure 4. 11).   
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Figure 4. 9 Human and Rabbit C1q Antibody Binding ELISA 
To investigate the differences in the interaction of human and rabbit C1q to different antibody 
subclasses, binding of human and rabbit C1q to solid-phase human IgG1, IgG2, IgG3, IgG4, non-
specific IgG, meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody and 
rabbit IgG was measured by ELISA. Human IgG1, IgG2, IgG3, IgG4, IgM, non-specific IgG and 
rabbit IgG antibodies were purified from plasma by affinity chromatography (as detailed in 
Section 2.2.2 and Section 2.2.4). The meningococcal polysaccharide (serogroups A, C, W-135 
and Y) specific antibody was affinity-purified from the pooled plasma of fourteen adult 
individuals taken at least one month post-vaccination with a quadrivalent plain polysaccharide 
(serogroups A, C, W-135 and Y) meningococcal vaccine (as detailed in Section 2.2.3). The 
antibody subclass compositions of the non-specific human IgG and meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) specific antibody preparation are detailed in 
Figure 4.8. Human serum (4%; a), rabbit serum (4%; b) or buffer only (a and b; no serum control) 
was incubated in duplicate on either blank ELISA wells or ELISA wells coated with 30μg/mL of 
each antibody subclass preparation. Subsequent human and rabbit C1q binding to each antibody 
subclass was detected with a sheep anti-human C1q antibody. Each bar represents the mean 
average absorbance achieved following incubation of either serum (open bars) or buffer only 
(solid bars) with each antibody preparation. The error bars represent the standard deviation. 
The absorbance achieved following incubation of serum or buffer only (no serum) with each 
antibody preparation was compared by t-test statistical analysis. The asterisks indicate the 
statistical significance of the difference between the average absorbance achieved with serum 
and buffer alone by antibody subclass (**** = P value<0.0001; ** = P value<0.01). a, Significant 
human C1q binding was detect with human IgG3, human IgG1, human IgG, anti-MenACWY and 
rabbit IgG. b, Significant rabbit C1q binding was detect with human IgG3, human IgG1, human 
IgG and human IgM.  
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Figure 4. 10 Isolation of Human and Rabbit C1q – Affinity Chromatography 
Human C1q was purified by cation exchange. ai, Typical chromatograph showing injection of 
human serum through BioRex 70 resin and elution of bound C1q. Rabbit C1q was purified from 
by affinity chromatography. bi, Typical chromatograph showing injection of human serum 
through an immune complex column and elution of bound C1q. The purity and composition of 
human (aii) and rabbit (bii) C1q was assessed by SDS-PAGE. 500ng of human and rabbit C1q was 
run through a 12.5% polyacrylamide gel under non-reducing (NR) and reducing (R) conditions 
and stained with coomassie Brilliant Blue dye. Under non-reducing conditions, human and rabbit 
C1q appeared as two bands corresponding to the a-b and c-c dimers of C1q (labelled). Under 
reducing conditions, human and rabbit C1q appeared as three bands corresponding to the a, b 
and c monomers of C1q (labelled). In both preparations, other protein bands (assumed to 
aggregates of C1q and other contaminants) were also detected. These data showed that further 
purification of both human and rabbit C1q was necessary. 
ai aii 
bii bi 
 
 
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 11 Purification of Human and Rabbit C1q – Size Exclusion Chromatography 
Human C1q was purified by cation exchange by injection of human serum through BioRex 70 
resin. Rabbit C1q was purified from by affinity chromatography by injection of rabbit serum 
through a Sepharose column conjugated with crosslinked Ig (rabbit anti-human IgG bound to 
human IgG). By SDS-PAGE analysis, it was noted that both human and rabbit C1q preparations 
contained both aggregates of C1q and other contaminants (detailed in Figure 4.10). To remove 
these contaminants human and rabbit C1q preparations were injected over a 24ml Superdex 75 
size exclusion chromatography column. Approximately 4-5mg (in 0.5ml buffer) rabbit or human 
C1q was injected over a 24ml Superdex 75 (SD75) column. An overlay of typical chromatographs 
displaying absorbance (mAU) over eluted volume (mL) following injection of human (solid line) 
and rabbit (broken line) C1q preparations are shown. The peak of human C1q elution occurred 
at 14.43ml (or 0.60 column volumes) whereas the peak of rabbit C1q occurred at 13.0ml (0.54 
column volumes). This difference in elution peaks between human and rabbit C1q conclude that 
rabbit C1q is of a larger molecular weight that human C1q. 
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Once contaminating proteins were removed, both human and rabbit C1q preparations 
were run through a 12.5% polyacrylamide gel and stained with coomassie Brilliant Blue to assess 
purity and composition (Figure 4. 12). Under non-reducing conditions human and rabbit C1q 
appeared as two distinct bands, representing the a-b and c-c dimer subunits from which C1q is 
composed. Using the molecular weight marker (ladder) as a standard, the apparent molecular 
weights of the a-b heterodimer subunits of human and rabbit C1q were interpolated as 58.9kDa 
and 59.9kDa, respectively. The apparent molecular weights of the c-c homodimer subunits of 
human and rabbit C1q were interpolated as 42.6kDa and 52.0kDa, respectively. Under reducing 
conditions, human and rabbit C1q appeared a three bands, representing the a, b and c monomer 
subunits of C1q. The apparent molecular weights of the a, b and c chains of human C1q were 
calculated as 29.3kDa, 26.5kDa and 20.1kDa, respectively. The apparent molecular weights of 
the a, b and c chains of rabbit C1q were calculated as 27.3kDa, 25.9kDa and 22.0kDa, 
respectively. With knowledge of the structure of C1q (six a, b and c monomers), the molecular 
weights of human C1q was calculated as 468.5kDa and the molecular weight of rabbit C1q was 
calculated as 483.2kDa. No contaminating proteins were detected in either preparations 
meaning the concentration of human and rabbit C1q could be accurately calculated for the SPR 
assays. 
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Figure 4. 12 Coomassie Stain of Human and Rabbit C1q 
Human C1q was purified by cation exchange by injection of human serum through BioRex 70 
resin (detailed in Figure 4.10). Rabbit C1q was purified from by affinity chromatography by 
injection of rabbit serum through a Sepharose column conjugated with crosslinked Ig (rabbit 
anti-human IgG bound to human IgG). Contaminating proteins, aggregates and fragments from 
both rabbit and human C1q preparations were then removed by injection over a 24ml Superdex 
75 size exclusion chromatography column (detailed in Figure 4.11). The purity and composition 
of each C1q preparation was assessed by SDS-PAGE. 500ng of purified C1q was run through a 
12.5% polyacrylamide gel under non-reducing and reducing conditions and stained with 
coomassie Brilliant Blue dye. Molecular weight markers (MwM) were run either side of the gel 
and used to interpolate the molecular weight (kDa) of each protein band. Under non-reducing 
conditions, human and rabbit C1q appear as two bands corresponding to the a-b (human = 
58.9kDa, rabbit= 59.9kDa) and c-c (human = 42.6kDa, rabbit= 52.0kDa) dimers from which C1q 
is composed. Human and rabbit C1q reduced into three band corresponding to the a (human = 
29.3kDa, rabbit= 27.3kDa), b (human = 26.5kDa, rabbit= 25.9kDa) and c (human = 20.1kDa, 
rabbit= 22.0kDa) monomers from which C1q is composed. No contaminating proteins could be 
detected in any antibody preparation.  
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4.3.4 Assessment of Human and Rabbit C1q Affinity to Antibody Subclasses by 
SPR 
The affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibody was 
measured by SPR as described by Patel et al., (2015). Recombinant Protein L was used to capture 
antibodies to the surface of a CM5 SPR sensor chip via the light chain (Björck, 1988). Protein L 
was amine-coupled to flow cells one and two at 2654RU and 2553.5RU, respectively. Flow cell 2 
was used to capture antibody whilst flow cell 1 was used as the reference surface.  
Human and rabbit C1q was then injected over captured IgG1, IgG2, IgG3, IgG4 and IgM 
antibody at a range of concentrations and binding (RU) measured (Figure 4. 14, Figure 4. 15, 
Figure 4. 16 and Figure 4. 17). The amount of each antibody captured was adjusted in order to 
equalise maximum human and rabbit C1q binding (Figure 4. 13). Unfortunately, protein L-
captured human IgM antibody did not interact with C1q (Figure 4. 13e). As such, human IgM 
was excluded from further SPR affinity analyses. As will be discussed below, it is expected that 
the conformation of human IgM antibody remains planar when bound by protein L and thus the 
C1q binding sites of IgM remain inaccessible. 
The KD of human and rabbit C1q to each antibody preparation was then calculated by 
steady-state analysis (Table 4.1). The KD of human C1q with human IgG1 was calculated as 
136.8nM, IgG2 as 198.1nM, IgG3 as 37.69nM and IgG4 as 358.1nM. The KD of rabbit C1q with 
human IgG1 was calculated as 196.2nM, IgG2 as 231.8nM, IgG3 as 123.1nM, IgG4 as 378.0nM 
and rabbit IgG as 219.3nM. 
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Figure 4. 13 Human C1q Binding to each antibody isotype 
To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3, IgG4 and IgM 
antibodies was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3, IgG4 
and IgM antibodies were purified from human plasma by affinity chromatography (as detailed 
in Figure 4.6). Human and rabbit C1q were purified from serum by affinity chromatography and 
cation exchange chromatography, respectively (as detailed in Figure 4.12). Firstly, the ability of 
human C1q to bind protein L-captured human IgG1, IgG2, IgG3, IgG4 and IgM antibodies was 
assessed. The purified human IgG1, IgG2, IgG3 or IgG4 antibodies were captured to a protein L-
coated CM5 Biacore™ sensor chip. Once captured, either buffer (0nM C1q) human C1q (600nM 
C1q) was injected over each antibody and binding was assessed. Sensograms showing the 
binding achieved (response units (RU)) with either 0nM C1q (broken line) or 600nM C1q (solid 
line) over time (seconds (s)) with protein L-captured human IgG1 (a), IgG2 (b), IgG3 (c), IgG4 (d) 
and IgM (e) are shown. Antibodies were injected at 0s and human C1q was injected between 
160s and 220s for 40 seconds. Chip surfaces were regenerated between 360s and 420s for 180 
seconds. C1q injection of over protein L-captured antibody subclasses produced 99RU (IgG1; a), 
89RU (IgG2; b), 88RU (IgG3; c) and 89RU (IgG4; d). Human C1q did not bind protein L-captured 
human IgM (e).  
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Figure 4. 14 Sensorgrams of Human C1q Binding to Immobilised Antibody Subclasses 
To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibodies 
was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3 and IgG4 antibodies 
were purified from human plasma by affinity chromatography (as detailed in Figure 4.6). Human 
and rabbit C1q were purified from serum by affinity chromatography and cation exchange 
chromatography, respectively (as detailed in Figure 4.12). The purified human IgG1, IgG2, IgG3 
or IgG4 antibodies were captured to a protein L-coated CM5 Biacore™ sensor chip. Once 
captured, human or rabbit C1q was injected over each antibody at a range of different 
concentrations (600-3.125nM). Human and rabbit C1q binding to each antibody subclass was 
assessed at each. Sensograms showing the binding achieved (response units (RU)) at each 
concentration of purified human C1q over time (seconds (s)) with protein L-captured human 
IgG1 (a), IgG2 (b), IgG3 (c) and IgG4 (d) are shown. Human C1q was injected at time zero for 20 
seconds. Each line represents one injection of C1q at the concentration listed in the key for each 
sensogram.  
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Figure 4. 15 Steady state analysis of Human C1q interaction with different Antibody 
Subclasses 
To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibodies 
was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3 and IgG4 antibodies 
were purified from human plasma by affinity chromatography (as detailed in Figure 4.6). Human 
and rabbit C1q were purified from serum by affinity chromatography and cation exchange 
chromatography, respectively (as detailed in Figure 4.12). The purified human IgG1, IgG2, IgG3 
or IgG4 antibodies were captured to a protein L-coated CM5 Biacore™ sensor chip. Once 
captured, human or rabbit C1q was injected over each antibody at a range of different 
concentrations (600-3.125nM). The dissociation constants (KD) of human and rabbit C1q for 
each antibody subclass were interpolated by steady state analysis (i.e. the concentration (nM) 
of C1q achieving 50% of maximum C1q binding for an antibody subclass). Graphs showing the 
binding achieved (response units (RU)) at each concentration of purified human C1q with protein 
L-captured human IgG1 (a), IgG2 (b), IgG3 (c) and IgG4 (d) are shown. Each point represents RU 
at each concentration of purified human C1q. The solid line represents the steady state curve 
fitted to each data set. The red, broken line represents the concentration of C1q achieving 50% 
of maximum C1q binding for an antibody subclass. Inserts, The KD (nM), chi-squared (goodness 
of fit; Chi2) and maximum C1q binding (Rmax) values for human C1q to each antibody 
preparation are detailed. 
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Figure 4. 16 Sensorgrams of Rabbit C1q Binding to Immobilised Antibody Subclasses 
To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibodies 
was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3 and IgG4 antibodies 
were purified from human plasma by affinity chromatography (as detailed in Figure 4.6). Human 
and rabbit C1q were purified from serum by affinity chromatography and cation exchange 
chromatography, respectively (as detailed in Figure 4.12). The purified human IgG1, IgG2, IgG3 
or IgG4 antibodies were captured to a protein L-coated CM5 Biacore™ sensor chip. Once 
captured, human or rabbit C1q was injected over each antibody at a range of different 
concentrations (600-3.125nM). Human and rabbit C1q binding to each antibody subclass was 
assessed at each. Sensograms showing the binding achieved (response units (RU)) at each 
concentration of purified rabbit C1q over time (seconds (s)) with protein L-captured human IgG1 
(a), IgG2 (b), IgG3 (c) and IgG4 (d) are shown. Rabbit C1q was injected at time zero for 40 
seconds. Each line represents one injection of C1q at the concentration listed in the key for each 
sensogram. 
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Figure 4. 17 Steady state analysis of Human C1q interaction with different Antibody 
Subclasses 
A To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibodies 
was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3 and IgG4 antibodies 
were purified from human plasma by affinity chromatography (as detailed in Figure 4.6). Human 
and rabbit C1q were purified from serum by affinity chromatography and cation exchange 
chromatography, respectively (as detailed in Figure 4.12). The purified human IgG1, IgG2, IgG3 
or IgG4 antibodies were captured to a protein L-coated CM5 Biacore™ sensor chip. Once 
captured, human or rabbit C1q was injected over each antibody at a range of different 
concentrations (600-3.125nM). The dissociation constants (KD) of human and rabbit C1q for 
each antibody subclass were interpolated by steady state analysis (i.e. the concentration (nM) 
of C1q achieving 50% of maximum C1q binding for an antibody subclass). Graphs showing the 
binding achieved (response units (RU)) at each concentration of purified rabbit C1q with protein 
L-captured human IgG1 (a), IgG2 (b), IgG3 (c) and IgG4 (d) are shown. Each point represents RU 
at each concentration of purified rabbit C1q. The solid line represents the steady state curve 
fitted to each data set. The red, broken line represents the concentration of C1q achieving 50% 
of maximum C1q binding for an antibody subclass. Inserts, The KD (nM), chi-squared (goodness 
of fit; Chi2) and maximum C1q binding (Rmax) values for rabbit C1q to each antibody preparation 
are detailed. 
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Table 4. 1 Dissociation Constants (KD) of Rabbit and Human C1q for each Antibody 
Subclass 
To investigate the differences in the interaction of human and rabbit C1q to the human IgG 
subclasses, the affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibodies 
was measured by surface plasmon resonance (SPR). Human IgG1, IgG2, IgG3 and IgG4 antibodies 
were purified from human plasma by affinity chromatography (as detailed in Figure 4.6). Human 
and rabbit C1q were purified from serum by affinity chromatography and cation exchange 
chromatography, respectively (as detailed in Figure 4.12). The purified human IgG1, IgG2, IgG3 
or IgG4 antibodies were captured to a protein L-coated CM5 Biacore™ sensor chip. Once 
captured, human or rabbit C1q was injected over each antibody at a range of different 
concentrations (600-3.125nM). Human and rabbit C1q binding to each antibody subclass was 
assessed at each concentration (sensograms for these assays are detailed in Figure 4.14 and 
Figure 4.16). The dissociation constants (KD) of human and rabbit C1q for each antibody subclass 
was calculated by steady state analysis (i.e. the concentration (nM) of C1q achieving 50% of 
maximum C1q binding for an antibody subclass) as detailed in Figure 4.15 and Figure 4.17. The 
KD (nM) and Chi-squared (goodness of fit) values for human and rabbit C1q to each antibody 
preparation is shown in the table below.  
 
 
  
Antibody 
Human C1q Rabbit C1q 
KD; nM Chi Squared KD; nM Chi Squared 
IgG1 136.8 2.1 196.2 0.35 
IgG2 198.1 0.83 231.8 0.11 
IgG3 37.69 2.59 123.1 0.82 
IgG4 358.1 2.64 378 0.15 
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4.4 Discussion 
4.4.1 Interaction of Antibody Subclasses with Meningococcal Polysaccharides 
I have investigated the functional affinity of IgG1, IgG2, IgG3, IgG4 and IgM antibodies 
in plasma to meningococcal polysaccharides (serogroups A, C, W and Y) by competitive ELISA 
(Figure 4. 2). The functional affinity of IgG1 and IgM antibody was significantly higher than IgG2 
and IgG4 antibody. The functional affinity of IgG3 antibody was significantly higher than IgG4 
antibody.  
The functional affinities of IgG1 antibody either in plasma or purified from plasma were 
directly compared to rule out any artefacts caused by antibodies of other subclasses, other than 
the one being assessed (Figure 4. 4). There was no significant difference between the functional 
affinities of plasma IgG1 and purified IgG1 antibodies and it was concluded that the presence of 
other antibody subclasses did not alter functional affinity.  
The functional affinity of two anti-FH antibodies, whose affinity had been previously 
assessed by SPR, was measured by competitive ELISA (Figure 4. 5). Functional affinity and KD 
values correlated well further validating the competitive ELISA as a method to compare the 
relative functional affinity of antibodies to antigen. It may be argued that comparing the affinity 
of a monoclonal antibody to a protein antigen by competitive ELISA and SPR may not be directly 
relevant as a way of validating the use of competitive ELISA to measure the affinity of polyclonal 
antibody to a polysaccharide antigen. In this way, it may be useful to further validate the 
competitive ELISA for this specific purpose by comparing the affinity of purified meningococcal 
polysaccharides (serogroups A, C, W and Y) specific antibody to meningococcal polysaccharides 
by SPR to the values achieved by the competitive ELISA. 
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The affinity of antibodies induced by meningococcal polysaccharide vaccines is thought 
to be important in protection against disease, with antibodies of a higher affinity producing 
higher SBA titres (Hetherington and Lepow, 1992; Schlesinger et al., 1992). A previous study has 
shown that the concentration of meningococcal polysaccharide-specific IgG1 antibody in 
vaccinee plasma positively correlated with overall antibody affinity to meningococcal 
polysaccharides and that the concentration IgG2 antibody negatively correlated with antibody 
affinity (de Voer et al., 2011). This study has shown that meningococcal polysaccharide-specific 
IgG1 antibody, as well as IgM antibody, was of a higher affinity than meningococcal 
polysaccharide-specific IgG2 antibody. These data reveal the mechanism behind the positive 
correlation between concentration of IgG1 antibody and affinity of antibody to meningococcal 
polysaccharides and the mechanism behind the negative correlation between concentration of 
IgG2 antibody and affinity of antibody to meningococcal polysaccharides.  
 
4.4.2 Interaction of Human and Rabbit C1q with different Antibody Subclasses 
 
4.4.2.1 Human and Rabbit C1q Binding ELISA 
The interaction of human and rabbit C1q to various antibody preparations was assessed 
by ELISA (Figure 4. 9). By rank order, human C1q bound most to IgG3 antibody followed by IgG1 
>> IgM > IgG2 > IgG4. The differential ability of IgM and human IgG subclasses to bind C1q are 
well known and mirror the data produced here (Bindon et al., 1988; Brüggemann et al., 1987; 
Kaul and Loos, 1997; Schumaker et al., 1976). In line with the rank order of human C1q binding 
to antibodies, rabbit C1q bound most to IgG3 antibody followed by IgG1 > IgM >> IgG2 > IgG4.  
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Human and rabbit C1q binding to human IgG, rabbit IgG and human anti-MenACWY 
antibody was also assessed in the same ELISA (Figure 4. 9). With these antibody preparations 
included, the rank order of human C1q binding was: IgG3 > human IgG > IgG1 > rabbit IgG > anti-
MenACWY > IgM > IgG2 > IgG4. The rank order of rabbit C1q binding to antibody preparations 
was: IgG3 > human IgG > IgG1 > IgM > rabbit IgG > anti-MenACWY > IgG2 > IgG4. Rabbit IgG 
consists of only one subclass whereas the human IgG and anti-MenACWY antibody are 
composed of multiple antibody subclasses (Figure 4. 8). Although the hinge length of rabbit IgG 
is one residue smaller than IgG2 and IgG4 (eleven versus twelve), both isotypes which interact 
poorly with C1q, it shows intermediate segmental flexibility between that of IgG1 and IgG4 
(Dangl et al., 1988). The extended ‘upper’ hinge region of rabbit IgG accounts for this seemingly 
disproportionate flexibility and enhanced ability to interact with C1q compared to that of IgG2 
and IgG4 (Dangl et al., 1988; Rayner et al., 2012). With all this taken into account, the amount 
of C1q bound to purified human IgG, rabbit IgG and anti-MenACWY antibody preparations in 
this assay is as expected. 
Previous studies show that the bactericidal activity of human IgM towards Neisseria 
meningitidis in the presence of rabbit serum is up to 1000 times greater than with human serum. 
For comparison, the bactericidal activity of human IgG towards Neisseria meningitidis in the 
presence of rabbit serum is only 10 times greater than with human serum (Griffiss and Goroff, 
1983; Mandrell et al., 1995; Santos et al., 2001; Zollinger and Mandrell, 1983). In this study, 
significant rabbit C1q binding was measured with human IgG3, IgG1 and IgM antibodies whereas 
significant human C1q binding was measured with human IgG3 and IgG1 antibodies only (Figure 
4. 9). In this study I have confirmed that human IgM antibody binds rabbit C1q better than 
human C1q, and that this would result in better activation of rabbit complement than human 
complement, and correlates with the functional assays previously described. 
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4.4.2.2 Assessment of Human and Rabbit C1q Affinity to Antibody Subclasses by SPR 
 The affinity of human and rabbit C1q to human IgG1, IgG2, IgG3 and IgG4 antibody was 
measured by SPR using a method previously described by Patel et al., (2015) (Table 4.1). Unlike 
other commonly used immunoglobulin binding proteins that bind to the Fc region, such as 
Protein A and Protein G, Protein L binds to the light chain of antibody (Graille et al., 2001). The 
binding sites of Protein G and Protein A for antibody spans between the CH2 and CH3 domains 
of the Fc region (Deisenhofer, 1981; Kato et al., 1995). This binding site overlaps with the binding 
site of C1q and therefore capable of disrupting C1q binding to antibody making their use in 
studying the affinity of immunoglobulins to C1q inappropriate (Nitsche-Schmitz et al., 2007). In 
contrast, Protein L binds to the light chain of immunoglobulins minimising interference with C1q 
binding (Björck, 1988; Patel et al., 2015). 
 Human C1q was purified from human serum by cation exchange chromatography using 
a method first described by Tenner et al., (Tenner et al., 1981). Rabbit C1q was isolated from 
rabbit serum by affinity chromatography based on a method described by Pohl et al., (Pohl et 
al., 1980). Rabbit C1q could not be isolated by cation exchange chromatography. The exact 
mechanism behind this is unknown but differences in the charge of the two molecules is 
probable (Lowe and Reid, 1974; Reid et al., 1972). By SDS-PAGE analysis, it was shown that rabbit 
C1q is of a larger molecular weight that human C1q (483.2kDa versus 468.5kDa) (Figure 4. 12). 
The a-b heterodimer subunit of human and rabbit C1q were of a similar molecular weight 
(58.9kDa versus 59.9kDa, respectively) whereas the c-c homodimer subunit of rabbit C1q was of 
a greater molecular weight than the c-c homodimer subunit (52.0kDa versus 42.6kDa, 
respectively). When injected over 24ml Superdex 75 size exclusion chromatography column 
rabbit C1q eluted earlier than human C1q, further emphasising the larger molecular weight of 
rabbit C1q (Figure 4. 11). These differences between rabbit and C1q have been previously 
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reported (Lowe and Reid, 1974; Reid et al., 1972; Swanson et al., 1988; Volanakis and Stroud, 
1972). 
 Protein L-bound human IgM antibody did not interact with purified human C1q (Figure 
4. 13). As such, the affinity of human and rabbit C1q to human IgM antibody could not be 
assessed. In solution, IgM exists in a planar conformation obscuring the C1q binding sites within 
the structure of the molecule. When bound to antigen, IgM flexes significantly about its CH2 
region. This altered, ‘staple’ conformation reveals the C1q binding site on the CH3 and CH4 
domains of IgM allowing C1q to associate (Czajkowsky and Shao, 2009; Feinstein and Munn, 
1969; Perkins et al., 1991; Zlatarova et al., 2006). The conformation of IgM bound to Protein L 
has not been studied but based on these data it is predicted to remain planar keeping the C1q 
binding sites inaccessible. The affinity of human and rabbit C1q to human IgM would be of great 
interest for this project as the greatest difference in complement activation between human 
and rabbit complement is seen with IgM (Mandrell et al., 1995; Santos et al., 2001).  
Two methods were attempted to reveal the C1q binding sites on IgM with limited 
success (data not shown). The first method attempted to isolate the IgM monomer fraction by 
partially reducing purified human IgM (pentameric) with 10mM 2-mercaptoethanol as described 
by Ditzel et al., (1993). Following incubation of IgM with 2-mercaptoethanol, approximately 17% 
IgM reduced to monomeric IgM with the remaining IgM reducing to trimeric IgM (27%), dimeric 
IgM (13%), half-monomeric IgM (36%) and other unidentified products (7%). The IgM monomer 
fraction was separated from the other products of reduction by size exclusion chromatography 
by injection through a superose 6 column. The final product (composed of 67% IgM monomer 
and 33% IgM half-monomer) was captured onto the protein L-coated CM5 chip and C1q binding 
was assessed by SPR. Again, no binding of C1q to the protein L-captured IgM monomer and half-
monomer preparation could be detected. It was concluded that this method of isolating 
monomeric IgM was inappropriate as either: the IgM monomer remains planar when bound to 
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protein L, keeping the C1q binding sites inaccessible, or the C1q binding sites of the IgM 
monomer were denatured when incubated with 10mM 2-mercaptoethanol. More appropriate 
methods of isolating monomeric IgM may prove more successful. The second method 
attempted to induce a conformational change of IgM antibody from the ‘planar’ to the ‘staple’ 
conformation by capturing purified anti-TT IgM onto a CM5 chip by coating the chip with TT. In 
this way, the C1q binding site on the CH3 and CH4 domains of IgM will be revealed allowing C1q 
to associate (Czajkowsky and Shao, 2009; Feinstein and Munn, 1969; Perkins et al., 1991; 
Zlatarova et al., 2006). The purified anti-TT IgM bound well to the TT-coated CM5 chip but no 
IgM specific C1q binding could be detected due to high levels of non-specific binding to the TT-
coated reference CM5 chip. Using a more appropriate antigen to capture antigen-specific IgM 
may prove more successful. 
 The amount of each antibody captured to protein L-coated CM5 SPR sensor chip was 
adjusted in order to equalise maximum human and rabbit C1q binding (Figure 4. 13). A much 
greater RU of captured IgG4 antibody was needed to reach an Rmax equivalent to that of IgG3 
antibody. A lower RU of IgG2 than IgG4 antibody and a lower RU of IgG1 than IgG2 antibody was 
required to reach an equal C1q Rmax achieved with IgG3 antibody. C1q is able to bind up to six 
molecules of IgG. The affinity of C1q to antibody and resulting complement activation increases 
with the number IgG molecules engaged (Diebolder et al., 2014; Wright et al., 1980). It has also 
been shown that antigen density also dictates the level of complement activation achieved by 
an antibody subclass (Garred et al., 1989; Giuntini et al., 2016). IgG3 antibody activates 
complement better than IgG1 antibody when bound to a sparsely expressed antigen whereas 
IgG1 antibody activates complement better than IgG3 antibody when bound to a densely 
expressed antigen (Giuntini et al., 2016). The differential densities of antibody subclasses (IgG4 
> IgG2 > IgG1 > IgG3) may have altered their relative affinities to human and rabbit C1q. If this 
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is the case, the relative affinity of IgG4 antibody to C1q will have been increased compared to 
IgG2 < IgG1 < IgG3 antibodies. 
 By rank order, human C1q had the highest affinity to human IgG3 antibody followed by 
IgG1, IgG2 and IgG4 (Table 4.1). These results are in line with previous studies on the difference 
in affinity of human IgG subclasses to human C1q (Bindon et al., 1988; Brüggemann et al., 1987; 
Kaul and Loos, 1997; Patel et al., 2015; Schumaker et al., 1976). By ultracentrifugation analysis, 
Schumaker et al., (1976) reported the affinity of human C1q to monomeric antibody subclasses 
as 85µM (IgG1), 157µM (IgG2), 34µM (IgG3) and 229µM (IgG4). In the study by Patel et al., 
(2015), from which this assay is based upon, the KD of human C1q to human IgG1, IgG2, IgG3 
and IgG4 was calculated as 81nM, 191nM, 88nM and 223nM respectively.  
The rank order of rabbit C1q affinity to human IgG subclasses were the same as seen 
with human C1q (Table 4.1). In general, the KD of rabbit C1q to human IgG subclasses were 
higher than with human C1q indicating an overall lower affinity. The greatest difference in KD 
between human and rabbit C1q was seen with IgG3 (ratio of 1:3.3). The next greatest difference 
in KD was IgG1 (1:1.4) followed by IgG2 (1:1.2) and IgG4 (1:1.1) with an average ratio of 1:1.8. 
No in-depth study comparing the differences between rabbit C1q with human C1q and their 
effects on the interaction with immunoglobulins been carried out previously. It is assumed that 
the differences seen here are as a result of differences in charge, size and binding motifs seen 
between human and rabbit C1q.  
A study assessing the human and rabbit complement-fixing activities of human IgG 
subclasses showed that human IgG1 and IgG3 activated human complement significantly more 
than rabbit complement whereas and human IgG2 activated rabbit complement significantly 
more than human complement (Dangl et al., 1988). These data suggest that human C1q has a 
higher affinity to human IgG1 and IgG3 antibody and a lower affinity to human IgG2 antibody 
than rabbit C1q. The data from this study confirm that human C1q does show greater affinity for 
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human IgG1 and IgG3 antibody than rabbit C1q, but disagree with previous data by showing that 
human C1q has a greater affinity for human IgG2 than rabbit C1q. The difference between the 
affinity of human and rabbit C1q to human IgG2 antibody was small and the ability of human 
IgG2 to activate rabbit complement better than human complement may be as a result of a 
lower activation threshold for rabbit C1q.  
 
4.4.2.3 Conclusions 
In the previous chapter, I showed that rSBA titres significantly correlated with the 
concentration of serogroup-specific IgM antibody (Chapter 3: Table 3.4b and Table 3.6). In stark 
contrast, hSBA titres did not correlate well with the concentration of serogroup-specific IgM 
antibody. As such, I hypothesised that the differential affinity of human and rabbit C1q to human 
antibody subclasses and subsequent differential complement activation accounts for the poor 
correlation between hSBA and rSBA titres. 
 In this chapter, I have highlighted important differences between the interactions of 
human and rabbit C1q with human antibody subclasses, which may explain the mechanism 
behind the poor correlation between hSBA and rSBA titres. These differences were particularly 
apparent with the antibody subclasses IgM and IgG1 (and IgG3), which I have shown significantly 
correlate with rSBA and hSBA titres, respectively. Whether these differences in the interaction 
of human and rabbit C1q with human antibody subclasses results in differential human and 
rabbit complement activation will be investigated in the next chapter. Nevertheless, these data 
further question the use of rabbit serum as the source of complement in SBAs and provide 
significant insight into difficulties and challenges associated with interpretation of rSBA data. 
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Chapter Five – Contribution of Antibody Subclass and 
Complement Pathways to Bactericidal Killing with 
Rabbit or Human Complement 
 
5.1 Introduction 
 
5.1.1 Interaction of Antibody Subclasses with Human and Rabbit Complement 
 The classical pathway of complement activation is activated by IgG and IgM antibodies 
(Müller-Eberhard and Kunkel, 1961). The initiator of the classical pathway of complement is C1q, 
which is activated once bound to the Fc regions of IgM (staple) and multiple IgG antibodies 
(Gaboriaud et al., 2003; Idusogie et al., 2000; Moore et al., 2010; Morgan et al., 1995; Schneider 
and Zacharias, 2012; Thommesen et al., 2000; Xu et al., 1994). The human IgG subclasses differ 
in their ability to interact with C1q and activate complement (Ishizaka et al., 1967; Patel et al., 
2015). Human IgG3 antibody expresses the highest affinity to C1q followed by IgG1, IgG2 and 
IgG4 (Patel et al., 2015; Schumaker et al., 1976). The staple form of IgM shows intermediate 
affinity for C1q in between that of IgG1 and IgG2 (Brüggemann et al., 1987). The difference in 
ability of human IgG subclasses to bind C1q is thought to be determined by combination of hinge 
length and flexibility, Fab steric hindrance, CH2 sequence, glycosylation in addition to antigen 
density and hexamer formation (Brekke et al., 1995; Diebolder et al., 2014; Tan et al., 1990; Xu 
et al., 1994). 
 The ability of human IgM and IgG subclasses to activate rabbit complement is poorly 
understood and it may be hypothesised that differences in the ability of human antibody 
subclasses to activate human and rabbit complement explains the poor correlation between 
hSBA and rSBA titres. Several studies have shown that human IgM antibody has a greatly 
enhanced bactericidal activity in the presence of rabbit serum compared to human serum than 
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other human antibody subclasses assessed (Mandrell et al., 1995; Santos et al., 2001; Zollinger 
and Mandrell, 1983). The concentration of human IgM antibody required for equivalent SBA 
titres is 500-1000 times less in the presence of rabbit serum compared to human serum. In 
contrast, the concentration of human IgG antibody required for equivalent SBA titres is only 10 
times less in the presence of rabbit serum compared to human serum. In a study comparing the 
ability of human IgG subclasses to activate human and rabbit serum, the investigators showed 
that human IgG1 and IgG3 activates human complement better than rabbit complement whilst 
human IgG2 activates rabbit complement better than human (Dangl et al., 1988). Human IgG4 
antibody did not activate human or rabbit complement. 
In the first results chapter of this study, we showed that hSBA titres of immune serum 
correlated best with the concentration of Neisseria meningitidis specific IgG1 antibody 
concentrations. In contrast, rSBA titres of immune serum correlated best with the concentration 
of Neisseria meningitidis specific IgM antibody concentrations. These data suggested an 
important difference in the ability of human antibody subclasses to activate human and rabbit 
complement. In the second results chapter of this study, we showed that human IgG1 antibody 
binds human C1q better than rabbit C1q and that human IgM and IgG2 antibodies binds rabbit 
C1q better than human C1q. These data showed that there is a significant difference between 
the interaction of human subclasses with human and rabbit complement. Whether this 
difference in C1q binding between antibodies translates to a significant difference in the ability 
of antibody subclasses to activate human and rabbit serum will be investigated in this chapter.  
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5.1.2 Human and Rabbit Complement Pathways and Neisseria meningitidis 
Complement-mediated lysis is considered by some to be the most important 
mechanism in the protection against invasive meningococcal disease (Goldschneider et al., 
1969a; Granoff, 2009). Opsonisation by products of complement activation and subsequent 
phagocytosis of Neisseria meningitis in protection is less well defined but thought to play a 
significant role in some individuals (Granoff, 2009). High incidence rates of meningococcal 
disease in those deficient in terminal pathway components (C5, 6, 7, 8 and 9) and not in earlier 
components suggests greater importance of bacteriolysis over phagocytosis (Figueroa and 
Densen, 1991; Humphries et al., 2015; Maslanka et al., 1997).  
Each pathway of complement activation has been implicated in the protection against 
meningococcal disease. Investigations on the relative importance of each complement pathway 
in the clearance of Neisseria meningitidis with human serum show that classical pathway 
activation, driven by antibody, is the most important pathway in the protection against 
meningococcal disease (Agarwal et al., 2014; Drogari-Apiranthitou et al., 2002). In individuals 
with lower concentrations of bactericidal antibody, an active alternative pathway, amplifying 
reduced classical pathway activation, plays an equally significant role in disease prevention 
(Hellerud et al., 2010; Ram et al., 2011). Although the lectin and alternative pathways are directly 
activated on the surface of Neisseria meningitis, in the absence of antibody their individual 
physiological relevance is questionable. 
The importance of each complement pathway in the clearance of Neisseria meningitidis 
with rabbit serum is poorly understood and it may be hypothesised that species-specific 
differences in the interaction of the complement activation pathways with Neisseria 
meningitidis contribute to the poor correlation between hSBA and rSBA titres. Neisseria 
meningitidis is able to modulate the alternative pathway of complement activation by binding 
FH using a number of FH-specific proteins, including the FHbp. The specificity of FHbp to human 
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FH and not rabbit FH suggests that the alternative pathway of rabbit complement will be more 
active towards Neisseria meningitidis than the alternative pathway of human complement 
(Granoff et al., 2009). Further differences between human and rabbit complement activation on 
Neisseria meningitidis by each of the three pathways will be investigated in this chapter. 
 
5.1.3 Chapter Aims 
The aims of this chapter are as follows: 
i. To compare the ability of human IgM and IgG subclasses to activate human and 
rabbit complement. 
ii. To assess the contribution of the different complement cascade pathways to 
bactericidal killing with rabbit or human complement. 
 
5.2 Activation of Human and Rabbit Complement by Different 
Subclasses of Human Antibody 
It is hypothesised that the differential ability of human antibody subclasses to activate 
human and rabbit complement account for the poor correlation between SBA titres in assay 
using human or rabbit serum as the source of complement. In the previous chapter, I have 
shown that human and rabbit C1q (the initiator of the classical pathway of complement 
activation) differentially interact with human antibody subclasses. Whether these differences in 
interaction with human and rabbit C1q result in differences in the activation of human and rabbit 
complement will be investigated in this chapter. 
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5.2.1 Human and Rabbit Complement Deposition ELISA 
Differences in the activation of human and rabbit complement by several purified 
antibody subclasses was measured by ELISA. Human and rabbit C3 deposition was detected as 
a marker of complement activation following the incubation of human or rabbit serum on ELISA 
plates coated with these purified antibody subclasses. Human and rabbit C3 deposition was 
detected using a sheep anti-human C3/C3c antibody. 
In preparation for this ELISA, the cross-reactivity of a polyclonal sheep anti-human 
C3/C3c antibody (antibodies-online) to human and rabbit C3 was assessed by western blot 
(Figure 5.1a) Human and rabbit serum, diluted 1/400 (v/v) in PBS, was run through 7.5% 
polyacrylamide gel under non-reducing conditions, transferred onto a nitrocellulose membrane 
and probed with the polyclonal anti-C3-HRP conjugate antibody. Chemiluminescence was 
detected in both human and rabbit serum proving species cross-reactivity of the anti-C3 
detection antibody and suitability for this and subsequent assays. The C3-positive band present 
in rabbit serum was noticeably larger than with human serum. 
 An active source of human and rabbit complement was required for this ELISA. The 
complement activity of human and rabbit serum was assessed by a classical pathway haemolytic 
assay Figure 5. 1b. The human serum was prepared in house from a pool of three healthy adult 
donors. The frozen rabbit serum was purchased from VHBio (Gateshead, UK). A range of human 
and rabbit serum concentrations (10-0.04%), water only (positive) or buffer only (negative) was 
incubated with antibody sensitised sheep erythrocytes in duplicate. Subsequent haemolysis 
(405nm) at each concentration of rabbit and human serum was measured and percentage 
haemolysis calculated. It was concluded that both the human and rabbit serum were suitable 
sources of active complement for use in this and subsequent assays. 
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Figure 5. 1 Anti-C3 Western Blot and Haemolytic Assay with Human and Rabbit Serum 
Differences in the activation of human and rabbit complement by a number of purified antibody 
subclasses was measured by ELISA. Human and rabbit C3 deposition was detected as a marker 
of complement activation following the incubation of human or rabbit serum on ELISA plates 
coated with a number of purified antibody subclasses. Human and rabbit C3 deposition was 
detected using a sheep anti-human C3/C3c antibody. a, the cross-reactivity of the sheep anti-
human C3/C3c antibody to human and rabbit C3 was assessed by western blot. 10µL of human 
(NHS) or rabbit (BRS) serum (diluted 1 in 400) was run through a 12.5% polyacrylamide gel under 
conditions, transferred to a nitrocellulose membrane and probed with the sheep anti-human 
C3/C3c antibody. A single C3-positive band was detected with both human and rabbit serum 
above the 190kDa marker proving the cross-reactivity of the sheep anti-human C3/C3c antibody 
to both human and rabbit C3. Rabbit C3 had a greater apparent molecular weight than human 
C3. b, The complement activity of the human and rabbit serum used in subsequent functional 
assays was assessed by classical pathway haemolytic assay as describe in Section 2.8.1. A range 
of human and rabbit serum concentrations (10-0.04%), water only (positive) or buffer only 
(negative) was incubated with antibody sensitised sheep erythrocytes in duplicate. Subsequent 
haemolysis (405nm) at each concentration of rabbit and human serum was measured and 
percentage haemolysis calculated. Each point represents the average percentage haemolysis 
achieved following incubation of erythrocytes with each concentration of human (open circles) 
or rabbit (open squares) serum. The error bars represent standard deviation. The dotted lines 
represent the non-linear regression model fit to each data set (sigmoidal, 4PL standard curve). 
It was concluded that both the human and rabbit serum were suitable sources of complement 
for use in subsequent functional assays. 
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5.2.1.1 Complement Deposition ELISA Development 
 An ELISA was set up to assess the optimal concentration of human and rabbit serum for 
use in the Human and Rabbit Complement Deposition ELISA (Figure 5.2). A range of 
concentrations of human or rabbit serum (10-0.001%) in the presence or absence of 0.01M EDTA 
(to inhibit complement activity) was incubated in duplicate on ELISA wells coated with 10μg/mL 
non-specific human IgG3. Human IgG3 was chosen due its superior ability to activate 
complement compared to the other subclasses (Bindon et al., 1988). The non-specific human 
IgG3 was affinity purified from human plasma was described in Section 2.2.4. Subsequent 
human and rabbit C3 deposition (absorbance 492nm) was then detected with a sheep anti-
human C3/C3c antibody. The concentration of human and rabbit serum resulting in maximum 
absorbance and 50% maximum absorbance was interpolated by fitting the data with a non-
linear regression; sigmoidal, 4PL standard curve. The concentration of human serum resulting in 
maximum absorbance and 50% maximum absorbance was 0.48% and 0.19%, respectively 
(Figure 5.2b). The concentration of rabbit serum resulting in maximum absorbance and 50% 
maximum absorbance was 8.5% and 0.79%, respectively (Figure 5.2a). Minimal C3 deposition 
was detected in the presence of 0.01M EDTA. The optimal concentration of human and rabbit 
serum for use in the Human and Rabbit Complement Deposition ELISA was decided as 0.5% and 
10%, respectively. 
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Figure 5. 2 Complement Activation of a Titration of Human and Rabbit Serum with 
Solid-Phase IgG3 
Differences in the activation of human and rabbit complement by a number of purified antibody 
subclasses was measured by ELISA. Human and rabbit C3 deposition was detected as a marker 
of complement activation following the incubation of human or rabbit serum on ELISA plates 
coated with a number of purified antibody subclasses. Human and rabbit C3 deposition was 
detected using a sheep anti-human C3/C3c antibody. Firstly, an assay was set up to assess the 
suitable concentration of human (b) and rabbit (a) serum to be used in subsequent functional 
ELISAs. A range of concentrations of human or rabbit serum (10-0.001%) in the presence (open 
squares) or absence (open circles) of 0.01M EDTA (to inhibit complement activity) was incubated 
in duplicate on ELISA wells coated with 10μg/mL human IgG3. Human IgG3 was chosen due its 
superior ability to activate complement compared to the other subclasses (Bindon et al., 1988). 
Subsequent human and rabbit C3 deposition (absorbance 492nm) was then detected with a 
sheep anti-human C3/C3c antibody. Each point represents the mean average absorbance 
achieved with each antibody subclass in the presence of either human (b) or rabbit serum (a). 
The error bars represent the standard deviation. The concentration of human and rabbit serum 
resulting in maximum absorbance and 50% maximum absorbance was interpolated by fitting 
the data with a non-linear regression; sigmoidal, 4PL standard curve. The concentration of 
human serum resulting in maximum absorbance and 50% maximum absorbance was 0.48% and 
0.19%, respectively. The concentration of rabbit serum resulting in maximum absorbance and 
50% maximum absorbance was 8.5% and 0.79%, respectively. Minimal C3 deposition was 
detected in the presence of 0.01M EDTA. 
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 An ELISA was set up to assess the optimal coating concentration of purified human IgG3 
for use in the Human and Rabbit Complement Deposition ELISA (Figure 5.3). ELISA plates were 
coated in a range of concentrations human IgG3 (100-0.002µg/mL) and incubated with either 
human serum or rabbit serum in the presence or absence of 0.01M EDTA (to inhibit complement 
activity) in duplicate. Subsequent human and rabbit C3 deposition (absorbance 492nm) was 
then detected with a sheep anti-human C3/C3c antibody. The coating concentration of human 
IgG3 resulting in maximum absorbance and 50% maximum absorbance was interpolated by 
fitting the data with a non-linear regression; sigmoidal, 4PL standard curve. The coating 
concentration of human IgG3 resulting in maximum rabbit C3 absorbance and 50% maximum 
rabbit C3 absorbance was 8.5μg/mL and 2.9μg/mL, respectively (Figure 5.3a). The coating 
concentration of human IgG3 resulting in maximum human C3 absorbance and 50% maximum 
human C3 absorbance was 3.3μg/mL and 1.3μg/mL, respectively (Figure 5.3b). Minimal C3 
deposition was detected in the presence of 0.01M EDTA. The optimal coating concentration of 
antibody for use in the Human and Rabbit Complement Deposition ELISA was decided 10μg/mL. 
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Figure 5. 3 Human and Rabbit Complement Activation with a Titration of Solid-Phase 
IgG3  
Differences in the activation of human and rabbit complement by a number of purified antibody 
subclasses was measured by ELISA. Human and rabbit C3 deposition was detected as a marker 
of complement activation following the incubation of human or rabbit serum on ELISA plates 
coated with a number of purified antibody subclasses. Human and rabbit C3 deposition was 
detected using a sheep anti-human C3/C3c antibody. Firstly, an assay was set up to assess the 
suitable ELISA well coating concentration of human antibody subclasses to be used in 
subsequent functional ELISAs. ELISA plates were coated in a range of concentrations human IgG3 
(100-0.002µg/mL) and incubated with either human serum (0.5%; b) or rabbit serum (10%; a) in 
the presence (open squares) or absence (open circles) of 0.01M EDTA (to inhibit complement 
activity) in duplicate. Human IgG3 was chosen due its superior ability to activate complement 
compared to the other subclasses (Bindon et al., 1988). Subsequent human and rabbit C3 
deposition (absorbance 492nm) was then detected with a sheep anti-human C3/C3c antibody. 
Each point represents the mean average absorbance achieved with each coating concentration 
of human IgG in the presence of either human (b) or rabbit serum (a). The error bars represent 
the standard deviation. The coating concentration of human IgG3 resulting in maximum 
absorbance and 50% maximum absorbance was interpolated by fitting the data with a non-
linear regression; sigmoidal, 4PL standard curve. a, The coating concentration of human IgG3 
resulting in maximum rabbit C3 absorbance and 50% maximum rabbit C3 absorbance was 
8.5μg/mL and 2.9μg/mL, respectively. b, The coating concentration of human IgG3 resulting in 
maximum human C3 absorbance and 50% maximum human C3 absorbance was 3.3μg/mL and 
1.3μg/mL, respectively. Minimal C3 deposition was detected in the presence of 0.01M EDTA. 
a b 
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5.2.1.2 Human and Rabbit Complement Activation by Immunoglobulins 
 The ability of non-specific human IgG1, IgG2, IgG3, IgG4, IgM, human IgG, MenACWY-
specific antibody and non-specific rabbit IgG (one subclass only) antibody to activate human and 
rabbit complement was assessed by ELISA (Figure 5. 4). Non-specific human IgG1, IgG2, IgG3, 
IgG4, IgM, human IgG and rabbit IgG was affinity purified from the pooled plasmas of three 
(human) and one (rabbit) individuals as described in Section 2.2.4 and Section 2.2.2. Human 
MenACWY-specific antibody was affinity purified from the pooled plasma of 14 adult individuals 
previously vaccinated with Mencevax ™ (plain polysaccharides from meningococcal serogroups 
A, C, W-135 and Y) as described in Section 2.2.3. The antibody subclass composition of human 
IgG and anti-MenACWY antibody preparations was previously determined as described in 
Chapter 4: Figure 4.8. Human serum (0.5%), rabbit serum (10%) or buffer only (assay blank) was 
incubated in duplicate on wells or ELISA wells coated with 10μg/mL of each antibody subclass 
preparation. Subsequent human and rabbit C3 deposition (absorbance 492nm) was then 
detected with a sheep anti-human C3/C3c antibody. The absorbance achieved following 
incubation of serum (minus blank) with each antibody preparation was compared by t-test 
statistical analysis. In the presence of human serum, the rank order of complement activation 
was IgG3>> IgG1>>>> IgM; IgG2; IgG4 (Figure 5.4a). In the presence of rabbit serum, the rank 
order of complement activation was IgG3>>> IgM; IgG1; IgG2> IgG4 (Figure 5.4b). These data 
show that human IgM is a more potent activator of rabbit complement that it is for human 
complement. 
  
 
 
183 
 
 
C
3
 D
e
p
o
s
it
io
n
(A
b
s
o
r
b
a
n
c
e
 4
9
2
n
m
)
Ig
G
1
Ig
G
2
Ig
G
3
Ig
G
4
Ig
M
H
u
m
a
n
 I
g
G
R
a
b
b
it
 I
g
G
A
n
ti
-A
C
W
Y
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
H u m a n  S e ru m
C
3
 D
e
p
o
s
it
io
n
(A
b
s
o
r
b
a
n
c
e
 4
9
2
n
m
)
Ig
G
1
Ig
G
2
Ig
G
3
Ig
G
4
Ig
M
H
u
m
a
n
 I
g
G
A
n
ti
-A
C
W
Y
R
a
b
b
it
 I
g
G
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
R a b b it  S e ru ma b
 
 
 
 
 
 
 
 
 
Figure 5. 4 Human and Rabbit Complement Activation by Antibody Subclasses 
Differences in the activation of human and rabbit complement by a number of purified antibody 
subclasses was measured by ELISA. Human IgG1, IgG2, IgG3, IgG4, IgM, non-specific IgG and 
rabbit IgG antibodies were purified from plasma by affinity chromatography (as detailed in 
Section 2.2.2 and Section 2.2.4). The meningococcal polysaccharide (serogroups A, C, W-135 
and Y) specific antibody was affinity-purified from the pooled plasma of fourteen adult 
individuals taken at least one month post-vaccination with a quadrivalent plain polysaccharide 
(serogroups A, C, W-135 and Y) meningococcal vaccine (as detailed in Section 2.2.3). The 
antibody subclass compositions of the non-specific human IgG and meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) specific antibody preparation are detailed in 
Figure 4.8. Human serum (0.5%; a), rabbit serum (10%; b) or buffer only (blank) was incubated 
in duplicate on wells or ELISA wells coated with 10μg/mL of each antibody subclass preparation. 
Subsequent human and rabbit C3 deposition (absorbance 492nm) was then detected with a 
sheep anti-human C3/C3c antibody. Each point represents the mean average absorbance (minus 
the mean average absorbance of each blank) achieved with each antibody subclass in the 
presence of either human (a) or rabbit serum (b). The error bars represent the standard 
deviation. The absorbance achieved following incubation of serum (minus blank) with each 
antibody preparation was compared by t-test statistical analysis. a, In the presence of human 
serum, the rank order of complement activation was IgG3>> IgG1>>>> IgM; IgG2; IgG4. b, In the 
presence of rabbit serum, the rank order of complement activation was IgG3>>> IgM; IgG1; 
IgG2> IgG4.  
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5.2.2 Anti-Meningococcal Polysaccharide Complement Deposition Assay 
 In the Human and Rabbit Complement Deposition ELISA, antibody subclasses were 
directly coated to ELISA plates. As these antibodies are not bound to their antigen, they will not 
be arranged in a manner conducive to activating complement. To address this, an assay was 
designed to capture antigen-specific antibody to ELISA plates coated with antigen; thereby 
simulating the mechanism of complement activation in vivo. Briefly, purified meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM antibodies were 
captured onto ELISA plates coated with tetanus toxoid-conjugated meningococcal 
polysaccharides from serogroups A, C, W-135 and Y. Polysaccharide-specific antibody subclasses 
IgG3 and IgG4 could not be isolated in sufficient quantities for this and subsequent assays. C3 
deposition was detected as a marker of activation after incubation of human and rabbit serum 
with each polysaccharide-bound antibody preparation.  
 
5.2.2.1 Isolation of Anti-MenACWY IgG1, IgG2 and IgM Antibody 
In preparation for the Anti-Meningococcal Polysaccharide Complement Deposition 
Assay, meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was 
affinity-purified from the pooled plasma of fourteen adult individuals (as detailed in Section 
2.2.3). Plasma samples were taken at least one month post-vaccination with a quadrivalent plain 
polysaccharide (serogroups A, C, W-135 and Y) meningococcal vaccine (Mencevax™). The 
purified meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was 
separated by antibody subclass by affinity chromatography by injection of the purified antibody 
over a series of columns packed with Sepharose conjugated to antibody subclass-specific 
proteins (as detailed in Section 2.2.2 and Section 2.2.4). The purity and composition of each 
purified antibody was assessed by SDS-PAGE (Figure 5.5). Each antibody preparation was run 
though a 10% polyacrylamide gel under reducing conditions and stained with coomassie Brilliant 
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Blue dye (Figure 5.5a). No contaminating proteins could be detected in any antibody 
preparation. By western blot, antibody subclass preparation was assessed for contamination 
with other antibody subclasses (Figure 5.5b-d). Each antibody preparation was run through 
three 10% polyacrylamide gels under reducing conditions. Once run, gels were transferred onto 
nitrocellulose membrane and probed with either a rabbit anti-human IgG1 (Figure 5.5b), a rabbit 
anti-human IgG2 (Figure 5.5c) or a donkey anti-human IgM (Figure 5.5d) antibody. It was 
concluded that there was no detectable contamination of each meningococcal polysaccharide 
(serogroups A, C, W-135 and Y) specific antibody subclass preparation with any other of the 
antibody subclasses tested.  
 
5.2.2.2 Preparation and Assessment of Anti-MenACWY Antibody-Depleted Human Serum 
A source of human serum with minimal antibody specific to meningococcal 
polysaccharides from serogroups A, C, W and Y is required for the Anti-Meningococcal 
Polysaccharide Complement Deposition Assay. To produce a suitable source of human 
complement for these assays, human serum was depleted of meningococcal polysaccharide-
specific antibody by injection over a TT-conjugated meningococcal polysaccharide (serogroups 
A, C, W-135 and Y) conjugated Sepharose column as described in Section 2.5.4.1.  
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Figure 5. 5 SDS-PAGE Analysis of Anti-MenACWY IgG1, IgG2 and IgM Antibodies 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was affinity-
purified from the pooled plasma of fourteen adult individuals (as detailed in Section 2.2.3). 
Plasma samples were taken at least one month post-vaccination with a quadrivalent plain 
polysaccharide (serogroups A, C, W-135 and Y) meningococcal vaccine (Mencevax™). The 
purified meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific antibody was 
separated by antibody subclass by affinity chromatography by injection of the purified antibody 
over a series of columns packed with Sepharose conjugated to antibody subclass-specific 
proteins (as detailed in Section 2.2.2 and Section 2.2.4). The purity and composition of each 
purified antibody was assessed by SDS-PAGE. a, 200ng of each antibody preparation was run 
though a 10% polyacrylamide gel under reducing conditions and stained with coomassie Brilliant 
Blue dye. No contaminating proteins could be detected in any antibody preparation. By western 
blot, antibody subclass preparation was assessed for contamination with other antibody 
subclasses. 200ng of each antibody preparation was run through three 10% polyacrylamide gels 
under reducing conditions. Once run, gels were transferred onto nitrocellulose membrane and 
probed with either a rabbit anti-human IgG1 (blot b), a rabbit anti-human IgG2 (blot c) or a 
donkey anti-human IgM (blot d) antibody (Stratech). In blot b (anti-human IgG1), a positive band 
was detected in the lane containing purified human IgG1 only. In blot c (anti-human IgG2), a 
positive band was detected in the lane containing purified human IgG2 only. In blot d (anti-
human IgM), a positive band was detected in the lane containing purified human IgM only. These 
data confirmed that there was no detectable contamination of each meningococcal 
polysaccharide (serogroups A, C, W-135 and Y) specific antibody subclass preparation with any 
other of the antibody subclasses tested.  
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The reactivity of human serum and the meningococcal polysaccharide-specific antibody-
depleted human serum was assessed by ELISA (Figure 5.6a). A titration of serum was incubated 
in duplicate on an ELISA plate coated with meningococcal polysaccharides from serogroups A, 
C, W-135 and Y. Subsequent IgG binding was detected using a donkey anti-human IgG antibody. 
By two-way ANOVA multiple comparison significantly more IgG binding was detected with 
human serum compared to the meningococcal polysaccharide-specific antibody-depleted 
human serum confirming efficient depletion of meningococcal polysaccharide-specific antibody. 
To ensure anti-MenACWY antibody depletion of human serum had not altered 
complement activity, the lytic activity of non-depleted and anti-MenACWY depleted human 
serum was assessed by classical pathway haemolytic assay (Figure 5. 6b). Haemolysis of 
sensitised sheep erythrocytes (2%) was measured following a thirty-minute incubation with 10-
0.26% non-depleted and depleted serum. Two-way ANOVA statistical analysis showed that 
there was no significant difference in haemolytic activity between human serum and 
meningococcal polysaccharide-specific antibody-depleted human serum.  
 An assay was set up to check whether depletion of anti-MenACWY-TT antibody had 
successfully reduced endogenous complement activity of human serum with MenACWY-TT 
antigens. C3 deposition, following incubation of a titration (20-0.3%) of unmodified human 
serum, anti-MenACWY-TT depleted serum and rabbit serum with MenACWY-TT antigens, was 
measured by ELISA (Figure 5. 6c). By two-way ANOVA multiple comparison significantly more C3 
deposition was detected with human serum compared to rabbit serum and the meningococcal 
polysaccharide-specific antibody-depleted human serum confirming efficient depletion of 
meningococcal polysaccharide-specific antibody. From these assays, it was concluded that 
human serum was successfully depleted of the exogenous meningococcal polysaccharide 
specific antibody without altering complement activity and thus was an acceptable source of 
complement for the Anti-Meningococcal Polysaccharide Complement Deposition Assay.  
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Figure 5. 6 Assessment of Anti-MenACWY Antibody-Depleted Human Serum 
a, Differences in the activation of human and rabbit complement by antigen-bound human 
antibody subclasses was measured by ELISA as described in Figure 5.7. A source of human serum 
with minimal antibody specific to meningococcal polysaccharides from serogroups A, C, W and 
Y is required for these assays. To produce a suitable source of human complement for these 
assay, human serum was depleted of meningococcal polysaccharide-specific antibody by 
injection over a TT-conjugated meningococcal polysaccharide (serogroups A, C, W-135 and Y) 
conjugated Sepharose column as described in Section 2.5.4.1. a, The reactivity of human serum 
(open circles) and the meningococcal polysaccharide-specific antibody-depleted human serum 
(open squares) was assessed by ELISA. A titration of serum was incubated in duplicate on an 
ELISA plate coated with meningococcal polysaccharides from serogroups A, C, W-135 and Y. 
Subsequent IgG binding (absorbance 492nm) was detected using a donkey anti-human IgG 
antibody. Each point represents the mean average absorbance achieved as each dilution of 
serum. The error bars represent the standard deviation. By two-way ANOVA multiple 
comparison significantly more IgG binding was detected with human serum compared to the 
meningococcal polysaccharide-specific antibody-depleted human serum confirming efficient 
depletion of meningococcal polysaccharide-specific antibody. b, To ensure meningococcal 
polysaccharide-specific antibody-depletion of human serum had not altered complement 
activity, the complement activity of human serum and meningococcal polysaccharide-specific 
antibody-depleted human serum was assessed by haemolytic assay as described in Section 
2.8.1. A range of serum concentrations (10-0.25%) was incubated with antibody sensitised sheep 
erythrocytes in duplicate. Subsequent haemolysis at each concentration serum was measured 
and percentage haemolysis calculated. Each point represents the average percentage 
haemolysis achieved following incubation of erythrocytes with each concentration of serum. 
Two-way ANOVA statistical analysis showed that there was no significant difference in 
haemolytic activity between human serum and meningococcal polysaccharide-specific 
antibody-depleted human serum. c, Complement activation of human serum (open circles), the 
meningococcal polysaccharide-specific antibody-depleted human serum (crosses) and rabbit 
serum (open squares) by meningococcal polysaccharide was assessed by ELISA. A titration of 
serum was incubated in duplicate on an ELISA plate coated with meningococcal polysaccharides 
from serogroups A, C, W-135 and Y. Subsequent C3 deposition (absorbance 492nm) was 
detected using a goat anti-human C3/C3c antibody. Each point represents the mean average 
absorbance achieved as each dilution of serum. The error bars represent the standard deviation. 
By two-way ANOVA multiple comparison significantly more C3 deposition was detected with 
human serum compared to rabbit serum and the meningococcal polysaccharide-specific 
antibody-depleted human serum confirming efficient depletion of meningococcal 
polysaccharide-specific antibody.  
a b c 
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5.2.2.3 Human and Rabbit Complement Activation by Antigen-bound Immunoglobulins 
Differences in the activation of human and rabbit complement by antigen-bound human 
antibody subclasses was measured by ELISA (Figure 5.7). Purified meningococcal polysaccharide 
(serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM antibodies were incubated in 
duplicate at a range of concentration (40-0.04µg/mL) on ELISA plates coated with 20µg/mL 
tetanus toxoid-conjugated meningococcal polysaccharides from serogroups A, C, W-135 and Y. 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibodies were affinity-purified from the pooled plasma of fourteen adult individuals (as 
detailed in Figure 5.5). Tetanus toxoid-conjugated meningococcal polysaccharide-specific 
antibody-depleted human serum (Figure5.7a; 0.5%) or rabbit serum (Figure5.7b; 10%) was then 
added in duplicate to each concentration of antigen-bound meningococcal polysaccharide 
specific IgG1, IgG2 and IgM antibodies. Subsequent human and rabbit C3 deposition 
(absorbance 492nm) was then detected with a sheep anti-human C3/C3c antibody. By two-way 
ANOVA multiple comparison statistical analysis comparing human C3 deposition with each 
antibody subclass, the rank order of activation was IgG1>>> IgM> IgG2. By two-way ANOVA 
multiple comparison statistical analysis comparing rabbit C3 deposition with each antibody 
subclass, the rank order of activation was IgM> IgG1>> IgG2. These data show that human IgM 
is a more potent activator of rabbit complement that it is for human complement. 
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Figure 5. 7 Human and Rabbit Complement Activation by MenACWY-bound IgG1, IgG2 
and IgM Antibodies 
Differences in the activation of human and rabbit complement by antigen-bound human 
antibody subclasses was measured by ELISA. Purified meningococcal polysaccharide (serogroups 
A, C, W-135 and Y) specific IgG1 (open squares), IgG2 (crosses) and IgM (open circles) antibodies 
were incubated in duplicate at a range of concentration (40-0.04µg/mL) on ELISA plates coated 
with 20µg/mL tetanus toxoid-conjugated meningococcal polysaccharides from serogroups A, C, 
W-135 and Y. Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 
and IgM antibodies were affinity-purified from the pooled plasma of fourteen adult individuals 
(as detailed in Figure 5.5). Tetanus toxoid-conjugated meningococcal polysaccharide-specific 
antibody-depleted human serum (a; 0.5%) or rabbit serum (b; 10%) was then added in duplicate 
to each concentration of antigen-bound meningococcal polysaccharide specific IgG1, IgG2 and 
IgM antibodies. Subsequent human and rabbit C3 deposition (absorbance 492nm) was then 
detected with a sheep anti-human C3/C3c antibody. Each point represents the mean average 
absorbance achieved with each antigen-bound antibody subclass in the presence of either 
human (a) or rabbit serum (b). The error bars represent the standard deviation. By two-way 
ANOVA multiple comparison statistical analysis comparing human C3 deposition with each 
antibody subclass, the rank order of activation was IgG1>>> IgM> IgG2. By two-way ANOVA 
multiple comparison statistical analysis comparing rabbit C3 deposition with each antibody 
subclass, the rank order of activation was IgM> IgG1>> IgG2.  
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5.2.3 Complement Activation by Anti-MenACWY Antibody Subclasses Bound to 
Neisseria Meningitidis serogroup W-135 (strain 102/98)  
The ability of anti-MenACWY IgG1, IgG2 and IgM antibodies to activate human 
complement when bound to Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria 
was assessed by SBA and complement deposition assay as described in Section 2.9 and Section 
2.10.3. The IgG-depleted serum was prepared as described by Brookes et al., (2013). Only one 
serogroup of bacteria was used in these assays due to time restraints. Neisseria meningitidis 
serogroup W-135 (strain 102/98) was chosen as the focus in the following and subsequent 
assays due to its current relevance. The global incidence of invasive meningococcal disease 
caused by serogroup W-135 has significantly increased in the past 5 years (Ladhani et al., 2015; 
Mustapha et al., 2016). 
Firstly, binding of the anti-MenACWY IgG1, IgG2 and IgM antibodies to Neisseria 
meningitidis serogroup W-135 (strain 102/98) bacteria was assessed by flow cytometry (Figure 
5.8). Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibodies were affinity-purified from the pooled plasma of fourteen adult individuals (as 
detailed in Figure 5.5). A serial dilution of each antibody preparation (diluted to 250-3.9µg/mL) 
was incubated with Neisseria Meningitidis serogroup W-135 (strain 102/98) in duplicate. The 
bacteria were also incubated with either buffer only (negative control; -ve) or heat-inactivated 
mouse anti-meningococcal polysaccharide (serogroups A, C, W-135 and Y) serum (positive 
control; +ve). The positive control serum was obtained from a mouse previously immunised with 
the plain meningococcal polysaccharides of serogroups A, C, W-135 and Y. Subsequent IgG1, 
IgG2 and IgM binding (fluorescence) to Neisseria Meningitidis serogroup W-135 (strain 102/98) 
was detected with a goat anti-human IgG/IgM FITC conjugated antibody (Jackson 
ImmunoResearch). It was concluded that each of the purified meningococcal polysaccharide-
specific antibodies were able to bind to Neisseria Meningitidis serogroup W-135 (strain 102/98).  
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Figure 5. 8 Anti-MenACWY IgG1, IgG2 and IgM Antibody Binding to Neisseria 
Meningitidis Serogroup W (strain 102/98) 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibodies were affinity-purified from the pooled plasma of fourteen adult individuals (as 
detailed in Figure 5.5). Plasma samples were taken at least one month post-vaccination with a 
quadrivalent plain polysaccharide (serogroups A, C, W-135 and Y) meningococcal vaccine 
(Mencevax™). Binding of the purified meningococcal polysaccharide-specific IgM (a), IgG1 (b) 
and IgG2 (c) antibodies was assessed by flow cytometry. A serial dilution of each antibody 
preparation (diluted to 250-3.9µg/mL) was incubated with Neisseria Meningitidis serogroup W-
135 (strain 102/98) in duplicate. The bacteria were also incubated with either buffer only 
(negative control; -ve) or heat-inactivated mouse anti-meningococcal polysaccharide 
(serogroups A, C, W-135 and Y) serum (positive control; +ve). The positive control serum was 
obtained from a mouse previously immunised with the plain meningococcal polysaccharides of 
serogroups A, C, W-135 and Y. Subsequent IgG1, IgG2 and IgM binding (fluorescence) to 
Neisseria Meningitidis serogroup W-135 (strain 102/98) was detected with a goat anti-human 
IgG/IgM FITC conjugated antibody (Jackson ImmunoResearch). Each histogram represents the 
fluorescence achieved following incubation of the bacteria with each concentration of purified 
meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgM (a), IgG1 (b) and IgG2 
(c) antibody and positive and negative controls. The fluorescence of 10,000 bacteria for each 
sample was analysed in the fluorescence channel. It was concluded that each of the purified 
meningococcal polysaccharide-specific antibodies were able to bind to Neisseria Meningitidis 
serogroup W-135 (strain 102/98).  
IgM IgG1 IgG2 
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After confirming that purified meningococcal polysaccharide-specific antibody 
subclasses could bind Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria, survival 
of Neisseria meningitidis serogroup W bacteria, incubated with 25% IgG-depleted human serum 
in the presence or absence of the purified anti-MenACWY antibody subclasses, was assessed by 
SBA (Figure 5. 9a). Meningococcal polysaccharide-specific IgG1 (7.8µg/ml), IgG2 (7.8µg/ml) and 
IgM (500µg/ml) antibodies were incubated with live Neisseria Meningitidis serogroup W-135 
(strain 102/98) in duplicate. The bacteria were also incubated with either buffer only (serum and 
HI serum) or heat-inactivated mouse anti-meningococcal polysaccharide serum (positive). Once 
incubated, IgG-depleted human serum (25%; prepared as described by Brookes et al., 2013) or 
25% heat-inactivated IgG-depleted human serum (HI serum) was added to each preparation of 
bacteria. Each preparation of bacteria was grown on a blood agar plate overnight and the 
number of colony forming units (CFU) was counted for each. By one-way ANOVA, no significant 
difference in bacterial growth was detected in the presence of 25% IgG-depleted human serum 
and purified anti-MenACWY IgG1 (7.8µg/ml), IgG2 (7.8µg/ml) or IgM (500µg/ml) antibody when 
compared to 25% IgG-depleted human serum alone. Significantly increased bacterial growth 
was detected when incubated with 25% IgG-depleted HI human serum alone (P<0.0001) and 
significantly reduced bacterial growth was detected when incubated with 25% IgG-depleted 
human serum and HI immune sera (1/2 dilution) (P<0.001) when compared to incubation with 
25% IgG-depleted human serum alone. From these data it was concluded that the purified 
meningococcal polysaccharide-specific antibody subclasses had no bactericidal activity towards 
Neisseria Meningitidis serogroup W-135 (strain 102/98) bacteria. 
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The deposition of C3 on Neisseria meningitidis serogroup W-135 (strain 102/98) 
bacteria, incubated with 5% IgG-depleted human serum in the presence or absence of purified 
anti-MenACWY antibody subclasses, was assessed by flow cytometry (complement deposition 
assay; Figure 5. 9b). Meningococcal polysaccharide-specific IgG1 (3.1µg/ml), IgG2 (3.1µg/ml) 
and IgM (200µg/ml) antibodies were incubated with killed Neisseria Meningitidis serogroup W-
135 (strain 102/98). The bacteria were also incubated with either buffer only (serum and no 
serum) or heat-inactivated mouse anti-meningococcal polysaccharide serum (positive). Once 
incubated, IgG-depleted human serum (5%) or buffer (no serum) was added to each preparation 
of bacteria. Subsequent complement deposition (median fluorescence) was detected using a 
rabbit anti-human C3c FITC-conjugated antibody (Abcam).By one-way ANOVA, no significant 
difference in C3 deposition was detected in the presence of 5% IgG-depleted human serum and 
purified anti-MenACWY IgG1 (3.1µg/ml), IgG2 (3.1µg/ml) or IgM (200µg/ml) antibody when 
compared to 5% IgG-depleted human serum alone. Significantly increased C3 deposition was 
detected when incubated with 5% IgG-depleted human serum and HI immune serum (1/5 
dilution) (P<0.0001) when compared to incubation with 5% IgG-depleted human serum alone. 
From these data it was concluded that the purified meningococcal polysaccharide-specific 
antibody subclasses could not induce complement deposition on Neisseria Meningitidis 
serogroup W-135 (strain 102/98) bacteria. 
 
  
 
 
195 
 
 
C
F
U
S
e
ru
m
H
I 
S
e
ru
m
P
o
s
it
iv
e
Ig
G
1
 +
 S
e
ru
m
Ig
G
2
 +
 S
e
ru
m
Ig
M
 +
 S
e
ru
m
0
5 0
1 0 0
1 5 0
h S B A
* * * *
* * *
N S
M
e
d
ia
n
F
lu
o
r
e
s
c
e
n
c
e
  
(F
IT
C
)
S
e
ru
m
N
o
 S
e
ru
m
P
o
s
ti
v
e
Ig
G
1
 +
 S
e
ru
m
Ig
G
2
 +
 S
e
ru
m
Ig
M
 +
 S
e
ru
m
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
*
* * * *
N S
C o m p le m e n t D e p o s itio n  A s s a ya b
 
 
 
 
 
 
 
Figure 5. 9 Complement Activation by Anti-MenACWY Antibody Subclasses Bound to 
Neisseria Meningitidis Serogroup W-135 (strain 102/98)  
The ability of anti-MenACWY IgG1, IgG2 and IgM antibodies to activate human complement 
when bound to Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria was assessed 
by serum bactericidal assay (hSBA; a) and flow cytometry (complement deposition assay; b) 
Meningococcal polysaccharide (serogroups A, C, W-135 and Y) specific IgG1, IgG2 and IgM 
antibodies were affinity-purified from the pooled plasma of fourteen adult individuals (as 
detailed in Figure 5.5). a, Meningococcal polysaccharide-specific IgG1 (7.8µg/ml), IgG2 
(7.8µg/ml) and IgM (500µg/ml) antibodies were incubated with live Neisseria Meningitidis 
serogroup W-135 (strain 102/98) in duplicate. The bacteria were also incubated with either 
buffer only (serum and HI serum) or heat-inactivated mouse anti-meningococcal polysaccharide 
serum (positive). Once incubated, IgG-depleted human serum (25%; prepared as described by 
Brookes et al., 2013) or 25% heat-inactivated IgG-depleted human serum (HI serum) was added 
to each preparation of bacteria. Each preparation of bacteria was grown on a blood agar plate 
overnight and the number of colony forming units (CFU) was counted for each. Each bar 
represents the average CFU achieved with each preparation and the error bars represent the 
standard deviation. The significant difference between the number of CFU for bacteria 
incubated with serum only and the other preparations was assessed by t-test statistical analysis. 
The asterisks indicate the statistical significance of the difference between the average CFU 
between complement deposition of bacteria incubated with serum only control and the other 
preparations (* = P value<0.05; *** = P value<0.001; **** = P value<0.0001; NS = not significant). 
b, Meningococcal polysaccharide-specific IgG1 (3.1µg/ml), IgG2 (3.1µg/ml) and IgM (200µg/ml) 
antibodies were incubated with killed Neisseria Meningitidis serogroup W-135 (strain 102/98). 
The bacteria were also incubated with either buffer only (serum and no serum) or heat-
inactivated mouse anti-meningococcal polysaccharide serum (positive). Once incubated, IgG-
depleted human serum (5%) or buffer (no serum) was added to each preparation of bacteria. 
Subsequent complement deposition (median fluorescence) was detected using a rabbit anti-
human C3c FITC-conjugated antibody (Abcam). Each bar represents the average median 
fluorescence achieved with each preparation and the error bars represent the standard 
deviation. The significant difference between complement deposition of bacteria incubated with 
serum only control and the other preparations was assessed by t-test statistical analysis.  
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5.3 Human and Rabbit Complement Pathways and Neisseria 
Meningitidis 
The importance of each complement pathway in the clearance of Neisseria meningitidis 
with rabbit serum is poorly understood and it may be hypothesised that species-specific 
differences in the interaction of the complement activation pathways with Neisseria 
meningitidis contribute to the poor correlation between hSBA and rSBA titres. The activities of 
each pathway of complement activation in human and rabbit serum towards Neisseria 
meningitidis serogroup W-135 (strain 102/98) were compared using a series of pathway-specific 
inhibitors. 
 
5.3.1 Assessment of Complement Inhibitors  
5.3.1.1 Cross-Reactivity with Human and Rabbit Serum 
To assess the activity of the classical, alternative and lectin pathways of human and 
rabbit complement towards Neisseria meningitidis serogroup W (strain 102/98), three pathway-
specific blocking antibodies were incubated with either human or rabbit serum prior to 
incubating with Neisseria meningitidis serogroup W (strain 102/98) bacteria. The specificity of 
these antibodies was factor B (FB; alternative pathway blocking antibody; kindly gifted by Dr. 
Córdoba of the Centro de Investigaciones Biológicas, Madrid), C1q (Pathway Diagnostics) and 
MBL (R&D Systems). The cross-reactivity of these pathway-specific blocking antibodies to 
human and rabbit serum was assessed by western blot (Figure 5.10). 
When probed with the blocking anti-FB antibody, chemiluminescence was detected in 
both human and rabbit serum proving species cross-reactivity of the anti-FB antibody (Figure 5. 
10a). A single FB-positive band was detected in human serum at a molecular weight of 100kDa 
and at 84.4kDa in rabbit serum. When probed with the blocking anti-C1q antibody, 
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chemiluminescence was detected only with human serum (Figure 5. 10b). A single C1q-positive 
band was detected in human serum at a molecular weight of 49.3kDa corresponding to the a-b 
chain of human C1q. When probed with the blocking anti-MBL antibody, chemiluminescence 
was detected in both human and rabbit serum proving species cross-reactivity of the anti-MBL 
antibody (Figure 5. 10c). The predominant MBL-positive band detected in human and rabbit 
serum was at a molecular weight of 32kDa and at 31.4kDa, respectively. 
 
5.3.1.2 Validation of Complement Inhibition 
The concentration of an anti-C1q antibody required to block complement activation by 
the classical pathway was assessed by haemolytic assay (Figure 5. 11). The concentration of 
human (Figure 5. 11a) and rabbit (Figure 5. 11c) serum required for 80% haemolysis of sensitised 
sheep erythrocytes was calculated as 2.9% and 13.1%, respectively. Approximately, 15nM anti-
C1q antibody was sufficient to block the haemolytic activity of 2.9% human serum (Figure 5. 
11b). No inhibition of haemolytic activity of 13.1% rabbit serum was seen with the anti-C1q 
antibody at any concentration assessed (Figure 5. 11d). 
 The concentration of an anti-FB antibody required to block complement activation by 
the alternative pathway was assessed by haemolytic assay (Figure 5. 12). The concentration of 
0.01M EGTA human serum required for 80% haemolysis of rabbit erythrocytes was calculated 
as 39.8% (Figure 5. 12a). Approximately, 300nM anti-FB antibody was sufficient to block the 
haemolytic activity of 39.8% human serum (Figure 5. 12b). 
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Figure 5. 10 Western Blot Analysis of Complement Pathway Inhibitors 
To assess the activity of the classical, alternative and lectin pathways of human and rabbit 
complement towards Neisseria meningitidis serogroup W (strain 102/98), three pathway-
specific blocking antibodies were incubated with either human or rabbit serum prior to 
incubating with Neisseria meningitidis serogroup W (strain 102/98) bacteria. The specificity of 
these antibodies was factor B (FB; alternative pathway blocking antibody; kindly gifted by Dr. 
Córdoba of the Centro de Investigaciones Biológicas, Madrid), C1q (Pathway Diagnostics) and 
MBL (R&D Systems). The cross-reactivity of these pathway-specific blocking antibodies to 
human and rabbit serum was assessed by western blot. 10µL of human or rabbit serum (diluted 
1 in 400) was run through a 12.5% polyacrylamide gel under non-reducing (blots a and b) or 
reducing conditions (blot c), transferred to a nitrocellulose membrane and probed with either 
the mouse anti-human FB blocking antibody (blot a), the mouse anti-human C1q blocking 
antibody (blot b) or the mouse anti-human MBL blocking antibody (blot c). Both the anti-FB 
blocking antibody and the anti-MBL blocking antibody were shown to be reactive to both human 
and rabbit FB and MBL, respectively. In contrast, the anti-C1q blocking antibody was shown to 
be reactive to human C1q only and did not bind rabbit C1q. 
 
  
a b c 
 
 
199 
 
 
H u m a n  S e ru m  (% )
H
a
e
m
o
ly
s
is
 (
%
)
0 .0 1 0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
a C 1 q (n M )
0 5 1 0 1 5 2 0 2 5
0
2 0
4 0
6 0
8 0
1 0 0
H
a
e
m
o
ly
s
is
 (
%
)
R a b b it  S e r u m  (% )
H
a
e
m
o
ly
s
is
 (
%
)
0 .1 1 1 0 1 0 0
0
5 0
1 0 0
1 5 0
A n ti-C 1 q  (n M )
H
a
e
m
o
ly
s
is
 (
%
)
0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0
0
5 0
1 0 0
1 5 0
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 11 Inhibition of Haemolytic Activity of Human and Rabbit Serum with an Anti-
C1q Antibody 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. The concentration of the mouse anti-human C1q blocking 
antibody (Pathway Diagnostics) required to block the classical pathway of complement 
activation in human (b) and rabbit (d) serum was assessed by haemolysis assay as described in 
Section 2.8.1.2. Firstly, the concentration of human and rabbit serum resulting in 80% 
haemolysis of antibody-sensitised sheep erythrocytes was assessed. A range of serum 
concentrations (10-0.25%) was incubated with antibody-sensitised sheep erythrocytes in 
duplicate. Subsequent haemolysis at each concentration human (a) or rabbit (c) serum was 
measured and percentage haemolysis calculated. Each point represents the average percentage 
haemolysis achieved following incubation of erythrocytes with each concentration of serum. 
The error bars represent the standard deviation. The concentration of human and rabbit serum 
resulting in 80% haemolysis was interpolated by fitting the data with a non-linear regression; 
sigmoidal, 4PL standard curve. The concentration of human and rabbit serum required for 80% 
haemolysis was calculated as 2.9% and 13.1%, respectively. Next, human (2.9%; b) and rabbit 
(13.1%; d) serum was incubated with range of concentrations of the mouse anti-human C1q 
blocking antibody followed by antibody-sensitised sheep erythrocytes in duplicate. Subsequent 
haemolysis at each concentration of the mouse anti-human C1q blocking antibody was 
measured and percentage haemolysis calculated. Each point represents the average percentage 
haemolysis achieved following incubation of erythrocytes with each human (b) and rabbit (d) 
serum pre-incubated with each concentration of the mouse anti-human C1q blocking antibody. 
The error bars represent the standard deviation.   
a b 
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Figure 5. 12 Inhibition of Haemolytic Activity of Human Serum with an Anti-FB 
Antibody 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. The concentration of the mouse anti-human FB blocking 
antibody required to block the alternative pathway of complement activation in human serum 
was assessed by haemolysis assay as described in Section 2.8.2.1. a, Firstly, the concentration 
of human serum resulting in 80% haemolysis of rabbit erythrocytes (in the presence of 0.01M 
EGTA) was assessed. A range of serum concentrations (100-11%) was incubated with rabbit 
erythrocytes (in the presence of 0.01M EGTA) in duplicate. Each point represents the average 
percentage haemolysis achieved following incubation of erythrocytes with each concentration 
of serum. The error bars represent the standard deviation. The concentration of human serum 
resulting in 80% haemolysis was interpolated by fitting the data with a non-linear regression; 
sigmoidal, 4PL standard curve. The concentration of human serum required for 80% haemolysis 
was calculated as 39.8%. b, Next, human (39.8%) serum was incubated with range of 
concentrations of the mouse anti-human FB blocking antibody followed by rabbit erythrocytes 
(in the presence of 0.01M EGTA) in duplicate. Subsequent haemolysis at each concentration of 
the mouse anti-human FB blocking antibody was measured and percentage haemolysis 
calculated. Each point represents the average percentage haemolysis achieved following 
incubation of erythrocytes with each human serum pre-incubated with each concentration of 
the mouse anti-human FB blocking antibody. The error bars represent the standard deviation. 
The mouse anti-human FB blocking antibody, at a concentration of 250nM, was sufficient to 
block the haemolytic activity of human serum. 
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The concentration of an anti-MBL antibody required to block complement activation by 
the lectin pathway was assessed by ELISA (Figure 5. 13). A titration of human serum was 
incubated on an ELISA plate coated with 200µg/mL mannan and subsequent C3 deposition 
detected (Figure 5. 13a). The concentration of human serum required for 80% C3 deposition 
was calculated as 2%. Human serum (2%) was incubated on an ELISA plates coated with 
200µg/mL mannan in the presence of a titration of the anti-MBL antibody (Figure 5. 13b). 
Approximately, 200nM (30µg/mL) anti-MBL antibody was sufficient to block human lectin 
pathway complement activation. 
The impact of 250nM mouse anti-human FB, 250nM mouse anti-human MBL and 15nM 
mouse anti-human C1q blocking antibodies as well as 1.94µM purified human FH and 0.01M 
EDTA on the activity of the classical (Figure 5.14a) and alternative (Figure 5.14b) pathways of 
complement activation in human serum was assessed using a commercial WeissLab ELISA. 
Reconstituted lyophilised human serum diluted 1 in 101 (classical pathway) or 1 in 18 
(alternative pathway) as the positive control, heat inactive human serum diluted 1 in 101; 
(classical pathway) or 1 in 18 (alternative pathway) as the negative control and human serum 
diluted 1 in 101 (classical pathway) or 1 in 18 (alternative pathway) alone or pre-incubated 
with either 250nM mouse anti-human FB, 250nM mouse anti-human MBL, 15nM mouse anti-
human C1q blocking antibodies, 1.94µM purified human FH or 0.01M EDTA was incubated in 
duplicate on a plate either pre-coated with purified human IgM antibody (classical pathway) or 
LPS (alternative pathway). A buffer only control was also included in each assay.  
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Figure 5. 13 Lectin Pathway Inhibition with an Anti-MBL Antibody 
a, The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. The concentration of the mouse anti-human MBL blocking 
antibody (R&D Systems) required to block the lectin pathway of complement activation in 
human serum was assessed by ELISA as described in Section 2.5.6. a, Firstly, the concentration 
of human serum resulting in 80% maximal C3 deposition (absorbance 492nm) was calculated. A 
range of serum concentrations (10-0.015%) was incubated on an ELISA plate coated with 
200µg/mL mannan in duplicate. Subsequent C3 deposition at each concentration of human 
serum was detected with a sheep anti-human C3/C3c antibody. Each point represents the 
average absorbance achieved at each concentration of human serum. The error bars represent 
the standard deviation. The concentration of human serum resulting in 80% maximal C3 
deposition was interpolated by fitting the data with a non-linear regression; sigmoidal, 4PL 
standard curve. The concentration of human serum required for 80% maximal C3 deposition 
was calculated as 2.0%. b, Next, human (2.0%) serum was incubated with range of 
concentrations of the mouse anti-human MBL blocking antibody and added to an ELISA plate 
coated with 200µg/mL mannan in duplicate. Subsequent C3 deposition at each concentration of 
the mouse anti-human MBL blocking antibody was detected with a sheep anti-human C3/C3c 
antibody. Each point represents the average absorbance achieved at each concentration the 
mouse anti-human MBL blocking antibody. The error bars represent the standard deviation. The 
mouse anti-human MBL blocking antibody, at a concentration of 250nM, was sufficient to block 
lectin pathway of complement activation in human serum. 
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Subsequent C5b-9 deposition (absorbance 405nm) was detected with an anti-human 
C5b-9 antibody. The absorbance (405nm) achieved with human serum in the presence of each 
inhibitor was compared to the absorbance achieved with human serum alone by t-test statistical 
analysis. Compared to human serum alone, significantly reduced C5b-9 deposition was detected 
with the buffer only control, the negative control, 0.01M EDTA and 15nM of the mouse anti-
human C1q blocking antibody (Figure 5.14a). Compared to human serum alone, significantly 
reduced C5b-9 deposition was detected with the buffer only control, the negative control, 
0.01M EDTA, 250nM of the mouse anti-human FB blocking antibody and 1.94µM purified human 
FH (Figure 5.14b). It was concluded that the alternative pathway inhibitors (anti-FB and human 
FH) and lectin pathway inhibitor (anti-MBL) did not significantly impact on the classical pathway 
of human complement activation. In addition, it was concluded that the classical pathway 
inhibitor (anti-C1q) and lectin pathway inhibitor (anti-MBL) did not significantly impact on the 
alternative pathway of human complement activation. 
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Figure 5. 14 Inhibition Classical and Alternative Pathway Activity – WeissLab Assay 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. The impact of 250nM mouse anti-human FB, 250nM 
mouse anti-human MBL and 15nM mouse anti-human C1q blocking antibodies as well as 
1.94µM purified human FH and 0.01M EDTA on the activity of the classical (a) and alternative 
(b) pathways of complement activation in human serum was assessed using a commercial 
WeissLab ELISA. Reconstituted lyophilised human serum diluted 1 in 101 (a) or 1 in 18 (b) as the 
positive control, heat inactive human serum diluted 1 in 101 (a) or 1 in 18 (b) as the negative 
control and human serum (diluted 1 in 101 (a) or 1 in 18 (b); positive) alone or pre-incubated 
with either 250nM mouse anti-human FB, 250nM mouse anti-human MBL, 15nM mouse anti-
human C1q blocking antibodies, 1.94µM purified human FH or 0.01M EDTA was incubated in 
duplicate on a plate either pre-coated with purified human IgM antibody (a) or LPS (b). A buffer 
only control was also included in each assay. The classical pathway assay buffer (a) consisted of 
veronal buffered saline (VBS) with 5mM MgCl2, and the alternative pathway assay buffer 
consisted of VBS with 10mM EGTA and 5mM MgCl2 (b). Subsequent C5b-9 deposition 
(absorbance 405nm) was detected with a anti-human C5b-9 antibody. Each bar represents the 
mean average absorbance achieved with each sample. The error bars represent the standard 
deviation. The absorbance (405nm) achieved with human serum in the presence of each 
inhibitor was compared to the absorbance achieved with human serum alone by t-test statistical 
analysis. The asterisks indicate the statistical significance of the difference between the average 
absorbance achieved with human serum alone and other conditions (*** = P value<0.001; **** 
= P value<0.0001; * = P value<0.05). a, Compared to human serum alone, significantly reduced 
C5b-9 deposition was detected with the buffer only control, the negative control, 0.01M EDTA 
and 15nM of the mouse anti-human C1q blocking antibody. b, Compared to human serum alone, 
significantly reduced C5b-9 deposition was detected with the buffer only control, the negative 
control, 0.01M EDTA, 250nM of the mouse anti-human FB blocking antibody and 1.94µM 
purified human FH.   
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5.3.2 Complement Deposition Assay 
 The activity of the classical, alternative and lectin pathways of human and rabbit 
complement towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed 
by flow cytometry using three pathway-specific blocking antibodies (Figure 5. 15). Killed 
Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria was incubated in 5% IgG-
depleted human serum (prepared as described by Brookes et al., 2013) or 5% rabbit serum in 
the absence (complement) or presence of 250nM mouse anti-human FB, 250nM mouse anti-
human MBL and 15nM mouse anti-human C1q (human serum only) blocking antibodies as well 
as 1.94µM purified human FH. Bacteria were also incubated in buffer only as the negative 
control for the assay (bacteria only). Subsequent complement deposition (median fluorescence) 
was detected using a rabbit anti-human C3c FITC-conjugated antibody (Abcam). No source of 
serogroup W-135-specific antibody was introduced to the bacteria at any point during this assay. 
The significant difference between complement deposition on the bacteria incubated 
with complement only and other preparations of bacteria were compared by t-test analysis. 
Compared to bacteria incubated with 5% IgG-depleted human serum alone significantly reduced 
complement deposition was detected in the presence of the mouse anti-human FB and mouse 
anti-human C1q blocking antibodies. (Figure 5. 15a). Anti-C1q and anti-FB antibody inhibited 
human complement activation by 98% and 31%, respectively. Addition of an anti-MBL antibody 
and human FH to IgG-depleted human serum had no significant impact on C3 deposition. 
Compared to bacteria incubated with 5% rabbit serum alone significantly reduced complement 
deposition was detected in the presence of mouse anti-human FB and mouse anti-human MBL 
blocking antibodies as well as purified human FH (Figure 5. 15b).  
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Figure 5. 15 Human and Rabbit C3 Deposition on Neisseria meningitidis Serogroup W-
135 (strain 102/98) with Complement Pathway Inhibitors 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. a, Killed Neisseria meningitidis serogroup W-135 (strain 
102/98) bacteria was incubated in 5% IgG-depleted human serum (prepared as described by 
Brookes et al., 2013) in the absence (complement) or presence of 250nM mouse anti-human FB, 
250nM mouse anti-human MBL and 15nM mouse anti-human C1q blocking antibodies as well 
as 1.94µM purified human FH. Bacteria were also incubated in buffer only as the negative 
control for the assay (bacteria only). Subsequent complement deposition (median fluorescence) 
was detected using a rabbit anti-human C3c FITC-conjugated antibody (Abcam). Each bar 
represents the average median fluorescence achieved with each preparation and the error bars 
represent the standard deviation. The significant difference between complement deposition 
on the bacteria incubated with complement only and other preparations of bacteria were 
compared by t-test analysis. The asterisks indicate the statistical significance of the difference 
between the average fluorescence achieved between complement deposition of bacteria 
incubated with complement only and the other preparations (**** = P value<0.0001; NS = not 
significant). Compared to bacteria incubated with 5% IgG-depleted human serum alone 
significantly reduced complement deposition was detected in the presence of the mouse anti-
human FB and mouse anti-human C1q blocking antibodies. b, Killed Neisseria meningitidis 
serogroup W-135 bacteria was incubated in 5% rabbit serum in the absence (complement) or 
presence of 250nM mouse anti-human FB and 250nM mouse anti-human MBL blocking 
antibodies as well as 1.94µM purified human FH. Bacteria were also incubated in buffer only as 
the negative control for the assay (bacteria only). Subsequent complement deposition (median 
fluorescence) was detected using a goat anti-rabbit C3c FITC-conjugated antibody (Acris). Each 
bar represents the average median fluorescence achieved with each preparation and the error 
bars represent the standard deviation. Compared to bacteria incubated with 5% rabbit serum 
alone significantly reduced complement deposition was detected in the presence of mouse anti-
human FB and mouse anti-human MBL blocking antibodies as well as purified human FH. NB. No 
source of serogroup W-135-specific antibody was introduced to the bacteria at any point during 
this assay.   
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5.3.3 Opsonophagocytic Assay 
 The activity of the classical, alternative and lectin pathways of human and rabbit 
complement towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed 
by opsonophagocytic assay using three pathway-specific blocking antibodies (Figure 5. 16). 
Killed BCECF-stained Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria were 
incubated in 5% IgG-depleted human serum (prepared as described by Brookes et al., 2013) or 
5% rabbit serum in the absence (complement) or presence of 250nM mouse anti-human FB, 
250nM mouse anti-human MBL and 15nM mouse anti-human C1q (human serum only) blocking 
antibodies as well as 1.94µM purified human FH. Bacteria were also incubated in buffer only as 
the negative control for the assay (bacteria only). Bacteria were then incubated with N,N-
dimethylformamide differentiated HL60 cells (MOI=40). The amount of BCECF-AM-stained 
Neisseria meningitidis serogroup W-135 (strain 102/98) phagocytosed by differentiated HL60 
cells was detected in the fluorescein channel. No source of serogroup W-135-specific antibody 
was introduced to the bacteria at any point during this assay. 
 The significant difference between phagocytosis of the bacteria incubated with 
complement only and other preparations of bacteria were compared by t-test analysis. 
Compared to bacteria incubated with 5% IgG-depleted human serum alone significantly reduced 
phagocytosis was detected in the presence of the 250nM mouse anti-human FB and 15nM 
mouse anti-human C1q blocking antibodies (Figure 5. 16a). Compared to bacteria incubated 
with 5% rabbit serum alone significantly reduced phagocytosis was detected in the presence of 
250nM mouse anti-human FB and 250nM mouse anti-human MBL blocking antibodies as well 
as 1.94µM purified human FH (Figure 5. 16b).   
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Figure 5. 16 Human and Rabbit Complement Opsonophagocytic Assay with Neisseria 
Meningitidis Serogroup W-135 (strain 102/98) and Complement Pathway Inhibitors 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. a, Killed BCECF-stained Neisseria meningitidis serogroup 
W-135 (strain 102/98) bacteria were incubated in 5% IgG-depleted human serum (prepared as 
described by Brookes et al., 2013) in the absence (complement) or presence of 250nM mouse 
anti-human FB, 250nM mouse anti-human MBL and 15nM mouse anti-human C1q blocking 
antibodies as well as 1.94µM purified human FH. Bacteria were also incubated in buffer only as 
the negative control for the assay (bacteria only). Bacteria were then incubated with N,N-
dimethylformamide differentiated HL60 cells. Subsequent phagocytosis (fluorescence) of the 
bacteria by the HL60 cells was assessed by flow cytometry. Each bar represents the average 
median fluorescence achieved with each preparation and the error bars represent the standard 
deviation. The significant difference between phagocytosis of the bacteria incubated with 
complement only and other preparations of bacteria were compared by t-test analysis. The 
asterisks indicate the statistical significance of the difference between the average fluorescence 
achieved between phagocytosis of bacteria incubated with complement only and the other 
preparations (** = P value<0.01; *** = P value<0.001; **** = P value<0.0001; NS = not 
significant). Compared to bacteria incubated with 5% IgG-depleted human serum alone 
significantly reduced phagocytosis was detected in the presence of the 250nM mouse anti-
human FB and 15nM mouse anti-human C1q blocking antibodies. b, Killed BCECF-stained 
Neisseria meningitidis serogroup W-135 (strain 102/98 ) bacteria was incubated in 5% rabbit 
serum in the absence (complement) or presence of 250nM mouse anti-human FB and 250nM 
mouse anti-human MBL blocking antibodies as well as 1.94µM purified human FH. Bacteria were 
also incubated in buffer only as the negative control for the assay (bacteria only). Bacteria were 
then incubated with N,N-dimethylformamide differentiated HL60 cells. Subsequent 
phagocytosis (fluorescence) of the bacteria by the HL60 cells was assessed by flow cytometry. 
Each bar represents the average median fluorescence achieved with each preparation and the 
error bars represent the standard deviation. The significant difference between phagocytosis of 
the bacteria incubated with complement only and other preparations of bacteria were 
compared by t-test analysis. Compared to bacteria incubated with 5% rabbit serum alone 
significantly reduced phagocytosis was detected in the presence of 250nM mouse anti-human 
FB and 250nM mouse anti-human MBL blocking antibodies as well as 1.94µM purified human 
FH. NB. No source of serogroup W-135-specific antibody was introduced to the bacteria at any 
point during this assay.  
a b 
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5.3.4 Serum Bactericidal Assay 
 The activity of the classical, alternative and lectin pathways of human and rabbit 
complement towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed 
by SBA using three pathway-specific blocking antibodies (Figure 5. 17). Live Neisseria 
meningitidis serogroup W-135 (strain 102/98) bacteria was incubated in 25% IgG-depleted 
human serum in the absence (C') or presence of 250nM mouse anti-human FB, 250nM mouse 
anti-human MBL and 15nM mouse anti-human C1q blocking antibodies as well as 1.94µM 
purified human FH. Bacteria were also incubated in 25% heat-inactivated IgG-depleted human 
serum only as the negative control for the assay (HI C'). Each preparation of bacteria was grown 
on a blood agar plate overnight and the number of colony forming units (CFU) was counted for 
each. The significant difference between the number of CFU for bacteria incubated with serum 
only and the other preparations was assessed by t-test statistical analysis.  
Compared to bacteria incubated with 25% IgG-depleted human serum only, a 
significantly higher number of CFUs were measured in the presence of 15nM mouse anti-human 
C1q blocking antibody or heat-inactivated serum. No source of serogroup W-135-specific 
antibody was introduced to the bacteria at any point during this assay (Figure 5. 17a). Compared 
to bacteria incubated with 25% rabbit serum only, a significantly higher number of CFUs were 
measured in the presence of 250nM mouse anti-human FB blocking antibody, heat-inactivated 
serum and 1.94 human FH (Figure 5. 17b).  
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Figure 5. 17 Growth of Neisseria meningitidis Serogroup W-135 (strain 102/98) with 
Human and Rabbit Serum in the Presence of Complement Pathway Inhibitors 
The activity of the classical, alternative and lectin pathways of human and rabbit complement 
towards Neisseria meningitidis serogroup W bacteria (strain 102/98) was assessed using three 
pathway-specific blocking antibodies. a, Live Neisseria meningitidis serogroup W-135 (strain 
102/98) bacteria was incubated in 25% IgG-depleted human serum in the absence (C') or 
presence of 250nM mouse anti-human FB, 250nM mouse anti-human MBL and 15nM mouse 
anti-human C1q blocking antibodies as well as 1.94µM purified human FH. Bacteria were also 
incubated in 25% heat-inactivated IgG-depleted human serum only as the negative control for 
the assay (HI C'). Each preparation of bacteria was grown on a blood agar plate overnight and 
the number of colony forming units (CFU) was counted for each. Each bar represents the average 
CFU achieved with each preparation and the error bars represent the standard deviation. The 
significant difference between the number of CFU for bacteria incubated with serum only and 
the other preparations was assessed by t-test statistical analysis. The asterisks indicate the 
statistical significance of the difference between the average CFU between complement 
deposition of bacteria incubated with serum only and the other preparations (** = P value<0.01; 
*** = P value<0.001). Compared to bacteria incubated with 25% IgG-depleted human serum 
only, a significantly higher number of CFUs were measured in the presence of 15nM mouse anti-
human C1q blocking antibody or heat-inactivated serum. b, Live Neisseria meningitidis 
serogroup W-135 (strain 102/98) bacteria was incubated in 25% rabbit serum in the absence (C') 
or presence of 250nM mouse anti-human FB and 250nM mouse anti-human MBL blocking 
antibodies as well as 1.94µM purified human FH. Bacteria were also incubated in 25% rabbit 
serum only as the negative control for the assay (HI C'). Each preparation of bacteria was grown 
on a blood agar plate overnight and the number of colony forming units (CFU) was counted for 
each. Each bar represents the average CFU achieved with each preparation and the error bars 
represent the standard deviation. The significant difference between the number of CFU for 
bacteria incubated with serum only and the other preparations was assessed by t-test statistical 
analysis. Compared to bacteria incubated with 25% rabbit serum only, a significantly higher 
number of CFUs were measured in the presence of 250nM mouse anti-human FB blocking 
antibody, heat-inactivated serum and 1.94 human FH. NB. No source of serogroup W-135-
specific antibody was introduced to the bacteria at any point during this assay.  
b a
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The impact of 1.94µM purified human FH on the growth of Neisseria meningitidis 
serogroup W-135 (strain 102/98) in the presence of either 25% IgG-depleted human serum or 
25% rabbit serum was assessed by serum bactericidal assay (Figure 5.19). Live Neisseria 
meningitidis serogroup W-135 (strain 102/98) bacteria were incubated with heat-inactivated 
mouse anti-meningococcal polysaccharide serum (diluted 1 in 2, 1 in 4 or 1 in 8) or buffer only 
(HI t=0). The bacteria were then incubated with either 25% IgG-depleted human serum only or 
25% IgG-depleted human serum supplemented with 1.94µM purified human FH. Each 
preparation of bacteria was then grown on a blood agar plate overnight and the number of 
colony forming units (CFU) was counted for each. By t-test analysis, there no significant 
difference between the number of CFUs incubated with either 25% IgG-depleted human serum 
only or 25% IgG-depleted human serum supplemented with 1.94µM purified human FH at any 
dilution of the heat-inactivated mouse anti-meningococcal polysaccharide serum (Figure 5.19a). 
By t-test analysis, there was a significant increase in the number of CFUs with 25% rabbit serum 
supplemented with 1.94µM purified human FH compared to 25% rabbit serum only with the 
heat-inactivated mouse anti-meningococcal polysaccharide serum diluted 1 in 2 and 1 in 4 (* = 
P value<0.05; Figure 5.19b). 
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Figure 5. 18 Growth of Neisseria meningitidis Serogroup W-135 (strain 102/98) with 
Human or Rabbit Serum and Human FH 
The impact of 1.94µM purified human FH on the growth of Neisseria meningitidis serogroup W-
135 (strain 102/98) in the presence of either 25% IgG-depleted human serum (a) or 25% rabbit 
serum (b) was assessed by serum bactericidal assay. a, Neisseria meningitidis serogroup W-135 
(strain 102/98) bacteria were incubated with heat-inactivated mouse anti-meningococcal 
polysaccharide serum (diluted 1 in 2, 1 in 4 or 1 in 8) or buffer only (HI t=0). The bacteria were 
then incubated with either 25% IgG-depleted human serum only (grey bars) or 25% IgG-depleted 
human serum supplemented with 1.94µM purified human FH (black bars). Each preparation of 
bacteria was then grown on a blood agar plate overnight and the number of colony forming 
units (CFU) was counted for each. Each bar represents the average CFU achieved with each 
preparation and the error bars represent the standard deviation. By t-test analysis, there no 
significant difference between the number of CFUs incubated with either 25% IgG-depleted 
human serum only or 25% IgG-depleted human serum supplemented with 1.94µM purified 
human FH at any dilution of the heat-inactivated mouse anti-meningococcal polysaccharide 
serum. b, Neisseria meningitidis serogroup W-135 (strain 102/98) bacteria were incubated with 
heat-inactivated mouse anti-meningococcal polysaccharide serum (diluted 1 in 2, 1 in 4 or 1 in 
8) or buffer only (HI t=0). The bacteria were then incubated with either 25% rabbit serum only 
(grey bars) or 25% rabbit serum supplemented with 1.94µM purified human FH (black bars). 
Each preparation of bacteria was then grown on a blood agar plate overnight and the number 
of colony forming units (CFU) was counted for each. Each bar represents the average CFU 
achieved with each preparation and the error bars represent the standard deviation. By t-test 
analysis, there was a significant increase in the number of CFUs with 25% rabbit serum 
supplemented with 1.94µM purified human FH compared to 25% rabbit serum only  with the  
heat-inactivated mouse anti-meningococcal polysaccharide serum diluted 1 in 2 and 1 in 4 (* = 
P value<0.05). 
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5.4 Discussion 
 
5.4.1 Interaction of Antibody Subclasses with Human and Rabbit Complement 
 The first aim of this study was to compare the ability of human IgM and IgG subclasses 
to activate human and rabbit complement. Firstly, complement activation after incubation of 
either human or rabbit serum with different solid-phase antibody subclasses was measured by 
ELISA. C3 deposition was detected as a marker of complement activation using an anti-
human/rabbit C3 HRP-conjugated antibody. The anti-C3 antibody was determined to be cross-
reactive to both human and rabbit C3 by western blot (Figure 5. 1a). Purified antibody 
subclasses were immobilised in two ways: either directly coated onto ELISA plates or by binding 
antigen-specific antibodies to ELISA plates coated directly with meningococcal polysaccharides 
from serogroups A, C, W and Y.  
Human IgG1, IgG2, IgG3, IgG4, IgM, anti-MenACWY IgG/IgM, human IgG and rabbit IgG 
antibody preparations were directly coated to ELISA plates, incubated with either human or 
rabbit serum and subsequent complement activation (C3 deposition) was detected (Figure 5. 4). 
By rank order of complement activation IgG3 antibody activated human complement to the 
greatest extent followed by IgG1 > IgM > IgG2 > IgG4. By rank order of complement activation 
IgG3 antibody activated rabbit complement to the greatest extent followed by IgM > IgG1 > IgG2 
> IgG4. The differential ability of these antibody preparations to activate human and rabbit 
complement correlate with their ability to bind human and rabbit C1q as shown in Chapter 4: 
Figure 4.9 and Chapter 4: Figure 4.17. As discussed in Chapter 4: Section 4.4.2, the differential 
ability of IgM and human IgG subclasses to activate human complement are well known and 
mirror these data (Bindon et al., 1988; Brüggemann et al., 1987; Kaul and Loos, 1997; Schumaker 
et al., 1976). I have extended these observations to include comparison with rabbit serum and 
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highlighted significant differences with the ability of human antibody subclasses to activate 
human complement. 
 In vivo, the classical pathway of complement is activated upon the binding of C1q to 
antigen-bound immunoglobulins (Bindon et al., 1988; Brüggemann et al., 1987; Kaul and Loos, 
1997; Schumaker et al., 1976). In the case of IgM, binding to antigen reveals the C1q binding site 
on the CH3 and CH4 domains of IgM allowing C1q to associate, activating complement 
(Czajkowsky and Shao, 2009; Feinstein and Munn, 1969; Perkins et al., 1991; Zlatarova et al., 
2006). In the case of IgG, binding to antigen arranges the Fc region in such a way to facilitate the 
formation of hexamers that generate an efficient dock for C1q to bind at a high affinity, 
activating complement (Diebolder et al., 2014). As such, directly coating antibody to ELISA plates 
could be considered an artificial surface and not conducive to activating complement in the 
physiological manner. To address this, an assay was designed to capture antigen-specific 
antibody to ELISA plates coated with antigen; thereby simulating the mechanism of complement 
activation in vivo. Anti-MenACWY IgG1, IgG2 and IgM antibodies were purified human plasma 
taken from 14 individuals (50mL/person) vaccinated with meningococcal polysaccharides from 
serogroups A, C, W and Y. Antibody preparations were assessed for purity by SDS-PAGE (Figure 
5. 5). By coomassie stain, each antibody preparation (reduced) appeared as two bands 
corresponding to the heavy and light chains of antibody (Figure 5. 5a). No contamination of each 
antibody preparation with other antibody subclasses was detected by western blot (Figure 5. 
5b). Each antibody preparation was bound to ELISA plates coated with meningococcal 
polysaccharides from serogroups A, C, W and Y, incubated with either human or rabbit serum 
and subsequent complement activation was detected and compared between species. Anti-
MenACWY IgG3 and IgG4 antibodies were not isolated at sufficient quantities for this assay. By 
order of complement activation: human IgG1 activated human complement more than IgM 
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followed by IgG2 (Figure 5. 7a). In contrast, human IgM antibody activate rabbit serum more 
than IgG1 followed by IgG2 (Figure 5. 7b). 
 These data confirm the differences in the abilities of human antibody subclasses to 
activate human and rabbit complement previously suggested by other studies and further 
define the mechanisms responsible for differential bactericidal activities of human and rabbit 
complement against Neisseria meningitidis (Griffiss and Goroff, 1983; Mandrell et al., 1995; 
Santos et al., 2001; Zollinger and Mandrell, 1983). The data from this study have confirmed that 
human IgM is a more potent subclass in its ability to activate rabbit complement than it is to 
activate human complement and human IgG1 is a more potent subclass in its ability to activate 
human complement than it is to activate rabbit complement. Again, these data further question 
the use of rabbit serum as the source of complement in SBAs and provide significant insight into 
difficulties and challenges associated with interpretation of rSBA data. 
 
5.4.1.1 Complement Activation by Anti-MenACWY Antibody Subclasses Bound to Neisseria 
meningitidis 
 Complement activation by purified anti-MenACWY IgG1, IgG2 and IgM antibodies 
incubated with Neisseria meningitidis serogroup W-135 (strain 102/98) bacterium in the 
presence of human serum was investigated by SBA and complement deposition assay (Figure 5. 
9). Despite binding to the bacterium, no significant C3b deposition nor inhibition of bacterial 
growth could be detected with each of the purified anti-MenACWY antibody subclasses. As such, 
the differential ability of these human antibody subclasses to activate human and rabbit 
complement, when bound to Neisseria meningitidis serogroup W-135 (strain 102/98), could not 
be compared.  
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5.4.2 Human and Rabbit Complement Pathways and Neisseria Meningitidis 
The second aim of this project was to assess the contribution of the different 
complement cascade pathways to bactericidal killing with rabbit or human complement. The 
impact of blocking each pathway of complement activation in human and rabbit serum on 
complement activation, subsequent opsonisation and phagocytosis and survival of Neisseria 
meningitidis serogroup W-135 (strain 102/98) was assessed. Furthermore, the consequences of 
adding purified human FH to both human and rabbit serum on complement activation with 
Neisseria meningitidis serogroup W-135 (strain 102/98) was also assessed. These assays were 
performed with Neisseria meningitidis serogroup W-135 (strain 102/98) only and further work 
comparing the interaction of each pathway of human and rabbit complement activation with 
other important serogroups (A, B, C and Y) would be of interest. 
The ability of an anti-C1q antibody to block classical pathway activation in human and 
rabbit serum was assessed using a classical pathway haemolytic assay and WeissLab 
complement screen assay (Figure 5. 11 and Figure 5. 14a). Human complement activation by 
the classical pathway was effectively blocked by the anti-C1q antibody. However, the anti-C1q 
antibody was not cross-reactive with rabbit C1q and did not block rabbit complement activation 
by the classical pathway. Specificity of the anti-C1q blocking antibody to human C1q and not to 
rabbit C1q was confirmed by western blot (Figure 5. 10b). Classical pathway inhibition of human 
complement significantly reduced complement deposition on, and subsequent phagocytosis of, 
Neisseria meningitidis serogroup W-135 (strain 102/98) as well as increasing survival in human 
serum (Figure 5. 15a, Figure 5. 16a and Figure 5. 17a). Direct C1q binding and classical pathway 
activation on Gram-negative bacteria has been described although, its importance in the 
absence of bactericidal antibody is probably minimal (Agarwal et al., 2014; Drogari-Apiranthitou 
et al., 2002; Mintz et al., 1995; Tenner et al., 1984). However, these data show that the classical 
pathway of human complement is responsible for the majority of complement activation on 
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Neisseria meningitidis. Further work investigating the contribution of rabbit classical pathway of 
complement activation with Neisseria meningitidis is required. 
 The ability of an anti-FB antibody to block alternative pathway activation in human 
serum was assessed using an alternative pathway haemolytic assay and WeissLab complement 
screen assay (Figure 5. 12 and Figure 5. 14b). The cross-reactivity of a known blocking anti-FB 
antibody with human and rabbit FB was confirmed by western blot (Figure 5. 10a). The ability 
of the anti-FB antibody to block alternative pathway activation in rabbit serum was not assessed 
here but has been shown in a previous study (Subías et al., 2014). Alternative pathway inhibition 
had a significantly greater impact on complement activation and subsequent phagocytosis of 
Neisseria meningitidis serogroup W-135 (strain 102/98) in presence of rabbit serum than with 
human serum (Figure 5. 15b and Figure 5. 16b). Whereas alternative pathway inhibition 
significantly increases the growth of Neisseria meningitis in rabbit serum, no impact on bacterial 
growth was seen when blocking the alternative pathway of human serum (Figure 5. 17). These 
data suggest that the alternative pathway of rabbit complement contributes more to 
complement activation towards Neisseria meningitidis serogroup W-135 (strain 102/98) than 
the alternative pathway of human complement. The FHbp, expressed by Neisseria meningitidis, 
is able to effectively downregulate the alternative pathway of complement activation by binding 
FH (Borrow et al., 2001a; Jodar et al., 2000; Maslanka et al., 1997; Zollinger and Mandrell, 1983). 
FHbp is specific for human FH and cannot bind rabbit FH (Granoff et al., 2009). As such, Neisseria 
meningitidis cannot regulate the alternative pathway of rabbit complement. These data confirm 
that the alternative pathway of human complement is effectively blocked by the bacterium thus 
explaining why further inhibition had only a small impact on complement activation compared 
to alternative pathway inhibition of rabbit complement. 
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 The ability of an anti-MBL antibody to block lectin pathway activation in human serum 
was assessed by functional ELISA (Figure 5. 13b). The cross-reactivity of the anti-MBL antibody 
with human and rabbit MBL was confirmed by western blot (Figure 5. 10c). The ability of the 
anti-MBL antibody to block lectin pathway activation in rabbit serum was not assessed and 
further work characterising this function of this antibody is required. Lectin pathway inhibition 
reduced complement activation and subsequent phagocytosis of Neisseria meningitidis 
serogroup W-135 (strain 102/98) significantly more in the presence of rabbit serum than with 
human serum (Figure 5. 15b and Figure 5. 16b). These data suggest that the lectin pathway of 
rabbit complement contributes more to complement activation towards Neisseria meningitidis 
serogroup W-135 (strain 102/98) than the lectin pathway of human complement. Despite 
reducing rabbit C3 deposition on bacterium by roughly 40%, lectin pathway inhibition did not 
impact on bacterial growth (Figure 5. 17b). MBL, the initiator of the lectin pathway of 
complement, has been shown to directly bind to Neisseria meningitidis following incubation 
with human serum (Estabrook et al., 2004; Sprong et al., 2004). It is unclear whether 
complement activation by the lectin pathway plays a significant role in the clearance of Neisseria 
meningitidis. One study showed no difference between complement deposition of Neisseria 
meningitidis following incubation with serum taken from either MBL sufficient or deficient 
individuals suggesting a minimal role of the lectin pathway (Hellerud et al., 2010). Other studies 
have shown significantly reduced complement activation when the lectin pathway was inhibited 
or absent (Jack et al., 2001; Sprong et al., 2003). The data from this study show little impact on 
complement activation when the lectin pathway in inhibited agreeing a limited role for the lectin 
pathway in the clearance of Neisseria meningitidis. It must be noted that MBL deficient children 
do show an increased risk to meningococcal disease highlighting the importance of either the 
ability of MBL to activate complement or promote phagocytosis of Neisseria meningitidis in early 
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life (Hibberd et al., 1999; Jack et al., 1998; Jack et al., 2001; van Helden and Hoal-van Helden, 
1999). 
Addition of purified human FH to rabbit serum significantly decreased the bactericidal 
activity of HI immune serum towards Neisseria meningitidis serogroup W-135 (strain 102/98) to 
levels comparable to human serum (with or without additional human FH) (Figure 5. 18). In the 
absence of bactericidal antibody, the addition of FH to rabbit serum increased the growth of 
Neisseria meningitidis serogroup W-135 (strain 102/98) as well as decreasing complement 
deposition and phagocytosis of the bacterium (Figure 5. 15b, Figure 5. 16b and Figure 5. 17b). 
A study has shown that human FH, bound to Neisseria meningitidis, is able to regulate both 
human and rabbit complement activity (Granoff et al., 2009). The data from this study confirm 
that human FH can regulate rabbit complement activity towards Neisseria meningitidis in SBAs 
normalising SBA titres to similar levels seen with human serum. In the absence or presence of 
bactericidal antibody, addition of FH to human serum did not significantly impact on the growth 
of Neisseria meningitidis, complement deposition on nor phagocytosis of the bacterium (Figure 
5. 15a, Figure 5. 16a and Figure 5. 17a). These data suggest the level of FH present in HI immune 
serum and human complement is sufficient to fully saturate the FHbp expressed by the bacteria 
in each assay. 
It is concluded that, in the absence of bactericidal antibody, human complement 
activation is primarily driven by the classical activation with minimum input from the alternative 
and lectin pathways. Furthermore, the alternative pathway of rabbit complement plays a much 
more significant role in complement activation towards Neisseria meningitidis serogroup W-135 
(strain 102/98) than the alternative pathway of human complement. However, it cannot be 
concluded whether rabbit complement activation on Neisseria meningitidis is initiated by the 
classical, alternative or lectin pathway. Further work is needed to distinguish between the 
contributions of each pathway in rabbit complement.   
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Chapter Six – Discussion  
 
6.1 Interaction of Human and Rabbit Complement with Antibody 
Subclasses 
 The SBA measures bactericidal activity of sera towards Neisseria meningitis and is used 
to assess the efficacy of new meningococcal vaccines for licensure (Goldschneider et al., 1969a; 
WHO, 1976, 2006). It is generally considered that individuals with an SBA titre greater than four 
are protected against invasive meningococcal disease (Goldschneider et al., 1969a; 
Goldschneider et al., 1969b; Gotschlich et al., 1969a).  
The standard protocol for the SBA uses BRS as the source of complement due to the 
high frequency of endogenous bactericidal activity present in human serum (Maslanka et al., 
1997). The use of BRS in SBAs is controversial as SBA titres achieved with rabbit serum are 
significantly higher than with human serum (Borrow et al., 2001a; Jodar et al., 2000; Maslanka 
et al., 1997; Zollinger and Mandrell, 1983). As such, individuals lacking bactericidal activity (SBA 
titre≤4) when assessed by hSBAs often achieve bactericidal titres greater than 4 when assessed 
by rSBA resulting in a high rate of false positives. A further concern is that rSBA titres correlate 
poorly with hSBA titres (Brookes et al., 2013; Gill et al., 2011a; Santos et al., 2001; Zollinger and 
Mandrell, 1983).  
One reason that rSBA titres are significantly higher than hSBA titres may be due to 
species-specific differences between the interaction of Neisseria meningitis and complement 
regulators. However, these species-specific differences in the ability of Neisseria meningitis to 
regulate human and rabbit complement are constant and do not account for the poor 
correlation between the two assays. I hypothesised that the differential ability of human 
antibody subclasses to activate human and rabbit complement is responsible for the lack of 
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specificity for the rSBA in predicting hSBA titres. The main focus of this project was to investigate 
the differences between the interaction of human antibody subclasses with human and rabbit 
complement and the implications for the use of rabbit serum as a source of complement in SBAs. 
 Firstly, the relationship between the concentration of Neisseria meningitidis serogroup 
A, C W and Y polysaccharide-specific IgG1, IgG2 and IgM antibody present in immune plasma 
with hSBA and rSBA titres was assessed (Chapter 3: Table 3.4 and Table 3.6). Serum antibody 
concentrations were measured either one or four months post vaccination with a plain 
(Mencevax™) or TT-conjugated (Nimenrix™) quadrivalent polysaccharide vaccine. In infants and 
children, the primary antibody subclass response to both vaccines was IgM and IgG1 with 
minimal levels of IgG2 (Chapter 3: Table 3.3 and Table 3.5). This differed significantly to the 
polysaccharide-specific antibody subclass composition in a cohort of adults where the primary 
antibody subclass response to vaccination was in the order IgG2, IgG1 and IgM (Chapter 3: 
Figure 3.1). In cohorts receiving the TT-conjugated quadrivalent polysaccharide vaccine, hSBA 
titres correlated best with the serum concentration of polysaccharide-specific IgG1 antibody 
whereas rSBA correlated best with the serum concentration of polysaccharide-specific IgM 
antibody. To further define these species-specific differences, the interaction of the human 
antibody subclasses IgG1, IgG2, IgG3, IgG4 and IgM with human and rabbit complement was 
investigated at the level of C1q and activated fragments of C3 (Chapter 4: Figure 4.9 and Chapter 
5: Figure 5.4). In both assays, the rank of order of antibody subclasses to fix human complement 
was IgG3>IgG1>IgM>IgG2>IgG4 whereas the rank order of antibody subclasses to fix rabbit 
complement was IgG3>IgM>IgG1>IgG2>IgG4. The affinity of purified human and rabbit C1q to 
human IgG1, IgG2, IgG3 and IgG4 antibody was assessed by SPR (Chapter 4: Table 4.1). The rank 
order of both human and rabbit C1q affinity to human IgG subclasses was IgG3>IgG1>IgG2>IgG4. 
In general, rabbit C1q displayed lower affinities for the four subclasses compared to human C1q. 
The greatest difference in KD between human and rabbit C1q was seen with IgG3 (ratio of 1:3.3) 
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followed by IgG1 (1:1.4), IgG2 (1:1.2) and IgG4 (1:1.1). Although the affinity of human and rabbit 
C1q to human IgM antibody could not be established in this project, we hypothesise a higher 
affinity of rabbit C1q. Finally, the ability of purified human polysaccharide-specific IgG1, IgG2 
and IgM antibody to fix human and rabbit complement when bound to meningococcal 
polysaccharides was investigated by ELISA (Chapter 5: Figure 5.7). As before, the rank order of 
subclasses to fix human complement was IgG1>IgM>IgG2 whereas the rank order of antibody 
subclasses to fix rabbit complement was IgM>IgG1>IgG2. 
These data define important differences in the ability of human antibody subclasses to 
fix human and rabbit complement. Specifically, it appears that polysaccharide-specific IgM 
antibody contributes significantly more to bactericidal titres in SBAs using BRS as the source of 
complement and that polysaccharide-specific IgG1 antibody contributes significantly more to 
bactericidal titres in SBAs using human serum as the source of complement. As such, it is likely 
that individuals with higher concentrations of serogroup-specific IgM antibody in response to 
meningococcal vaccination positively skews rSBA titres compared to hSBA titres. These data also 
suggest that polysaccharide-specific IgG3 antibody contributes significantly more to bactericidal 
titres in SBAs using human serum as the source of complement. However, the IgG3 response to 
TT-conjugated quadrivalent polysaccharide vaccine is minimal and unlikely to greatly impact on 
differences between hSBA and rSBA titres (Chapter3: Figure 3.1). 
SBA titres are usually assessed one month post vaccination during the early stages of 
immune response to vaccination. As higher anti-polysaccharide IgM titres result in 
disproportionally higher rSBA titres compared to hSBA titres, it may be concluded that rSBA 
titres measured at one month post vaccination are misleadingly high and further question the 
relevance of BRS as the source of complement in SBAs in the licensure of new meningococcal 
vaccines. 
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6.1.1 Antibody Response to Plain versus TT-Conjugated Quadrivalent 
Meningococcal Polysaccharide Vaccines 
 In contrast to the antibody response to the TT-conjugated quadrivalent meningococcal 
polysaccharide vaccine, the antibody responses to the plain quadrivalent meningococcal 
polysaccharide vaccine correlated poorly with SBA titres (Chapter3: Table 3.3).  
Higher affinity antibody responses to meningococcal vaccines are associated with higher 
SBA titres (Hetherington and Lepow, 1992; Schlesinger et al., 1992). In this way, it is thought 
that lower affinity antibodies contribute little to SBA titres. Furthermore, it is likely that the 
standard ELISA developed to measure the concentration of serogroup-specific antibody detects 
antibodies of both high and low affinity (Granoff et al., 1998). If this is this case, the inclusion of 
low-affinity antibody in the quantitation of serogroup-specific antibody may explain the poor 
correlation between antibody concentration and SBA titres following vaccination with the plain 
quadrivalent meningococcal polysaccharide vaccine.  
These data also suggest that the significantly higher SBA titres achieved with the TT-
quadrivalent meningococcal polysaccharide vaccine compared to the plain vaccine may not only 
be explained by the increase in concentration of antibody, but also by increased affinity 
maturation of the antibody secreted; a characteristic of TD antigens. Correlations may be 
improved with a modification to the ELISA that can distinguish between high and low-affinity 
antibodies. As shown in a previous study, this may be achieved by diluting samples in a buffer 
containing ammonium thiocyanate (Granoff et al., 1998). This will allow only antibodies only of 
the highest affinity to bind to the meningococcal polysaccharide-coated ELISA plates. 
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6.1.2 Anti-Meningococcal Polysaccharide Complement Deposition Assay 
 A functional assay was set up to measure the ability of purified vaccine-specific antibody 
to activate complement when bound to antigen (Chapter 5: Figure 5.7). However, this assay 
could easily be modified to measure the ability of vaccine-specific antibody present in vaccinee 
sera to activate complement when bound to antigen. In this way, the Meningococcal 
Complement Deposition ELISA may be used as simple assay to measure the efficacy of vaccines 
thus avoiding the numerous variables and issues present in the SBAs. For example, the 
Meningococcal Complement Deposition ELISA overcomes the issue of finding a suitable source 
of human complement lacking endogenous activity towards Neisseria meningitidis. This is 
achieved by depletion of vaccine antigen-specific antibody by affinity chromatography which 
can be completed on a large scale with multiple human donors (Chapter 5: Figure 5.6). For this 
assay to be used as a reliable correlate of protection, several steps of validation must be 
performed including calculating a suitable threshold for complement activation and dilution 
factor of vaccinee sera for an individual to be considered protected against disease. It may be 
necessary to include a positive control, known to contain a protective level of complement 
activating vaccine antigen-specific antibody, in each assay for comparison. 
 
6.1.3 Bactericidal Activity of Purified Polysaccharide-Specific Antibodies 
 The bactericidal activity of purified polysaccharide-specific human IgG1, IgG2 and IgM 
antibody was investigated by SBA and complement deposition assay (Chapter 5: Figure 5.9). To 
our surprise these antibodies did not fix complement to Neisseria meningitidis. The mechanism 
behind the inability of these purified polysaccharide-specific antibody subclasses to activate 
complement, once bound to the bacteria, is unknown.  
IgG-depleted human serum was used as the source of complement in these assays, 
prepared as described by Brookes et al., (2013). Briefly, IgG was removed by injection of human 
 
 
225 
 
 
serum through a Protein G Sepharose column. In addition to removing IgG, the serum was also 
depleted of C1q and C5 which were eluted from the Protein G column using a high salt buffer 
and added back to the IgG-depleted serum. The final concentration of C5 and C1q in the IgG-
depleted serum was comparable to the pre-depleted serum. The concentration of FH, properdin 
and C3 in the IgG-depleted serum was assessed and were unaffected. The concentrations of 
other components were not measured. One reason for the negative killing data may be that 
other components are also depleted during the process of IgG depletion that are necessary for 
full complement activation with purified polysaccharide-specific antibody. In contrast to the 
purified anti-polysaccharide antibodies, immune serum significantly activated complement on 
the surface of Neisseria meningitidis. Immune serum may be replenishing this ‘component’ that 
is removed during the process of IgG depletion, which is not present in purified antibody. 
 Personal communications from Dr Stephen Taylor (Public Health England, Porton Down, 
Salisbury, UK), revealed that this phenomenon has been noted previously and it appears that 
the inability of purified antibody to activate complement when bound to Neisseria meningitidis 
is consistent only with antibody specific to polysaccharide. In contrast, antibodies specific to 
proteins expressed by Neisseria meningitidis activate complement significantly better than 
polysaccharide-specific antibodies when bound to the bacteria in equal concentrations (data not 
published). The mechanisms responsible for the differential ability of purified anti-
polysaccharide and anti-protein antibody to activate complement on Neisseria meningitidis 
have not yet been investigated. It is possible that polysaccharide-specific antibody activates 
complement relatively more superficially compared to protein-specific antibody resulting in 
reduced bactericidal activity. Similar antigen-specific differences in the bactericidal activity of 
antibody have been previously described for the Gram-negative bacteria Escherichia coli 
(Howard and Glynn, 1971). 
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 Meningococcal polysaccharide conjugate vaccines are effective and have reduced the 
burden of disease in countries where they have been successfully introduced. In the UK, routine 
meningococcal polysaccharide serogroup C conjugate vaccination was introduced in 1999 and 
the number of confirmed cases of meningococcal disease caused by serogroup C has decreased 
from 883 in 1999/2000 to just 28 in 2014/2015 (Gov.uk, 2015). Furthermore, I have shown that 
the concentration of polysaccharide-specific IgG1 and IgM antibodies present in immune serum 
correlates well with bactericidal titres (Chapter 3: Table3.4 and Table 3.6). Therefore, 
polysaccharide-specific antibodies must be bactericidal and convey protection against invasive 
meningococcal disease. It appears that polysaccharide-specific antibodies are not bactericidal 
alone but do contribute to bactericidal titres when present in immune serum (Chapter 5: Figure 
5.9) (Elias et al., 2013; Lieberman et al., 1996; Maslanka et al., 1998). In contrast, protein-specific 
antibodies are bactericidal alone and when present in immune serum. As such, it may be 
concluded that the missing ‘component’ removed from the IgG-depleted complement that is 
required for polysaccharide-specific antibodies to be bactericidal is protein-specific antibody 
(Figure 6. 1). It is therefore hypothesised that polysaccharide-specific antibody has a synergistic 
effect on the bactericidal activity of protein-specific antibody. 
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Figure 6. 1 Bactericidal Activity of Purified Polysaccharide-Specific Antibodies 
The concentration of meningococcal polysaccharide-specific IgG1 and IgM antibody significantly 
correlates with the bactericidal of immune serum towards Neisseria meningitidis. However, 
purified polysaccharide-specific antibody is poorly bactericidal. Purified meningococcal protein-
specific antibody is significantly more bactericidal than polysaccharide-specific antibody. It is 
concluded that protein-specific antibody is necessary for polysaccharide-specific antibody to fix 
complement effectively on the surface of Neisseria meningitidis. Polysaccharide-specific 
antibody has a synergistic effect on the bactericidal activity of protein-specific antibody.  
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These data suggest that prior exposure to Neisseria meningitidis is necessary for 
successful immunisation with meningococcal polysaccharide conjugate vaccines and may 
explain why some individuals with seemingly large antibody responses to vaccination achieve 
poor bactericidal titres (Chapter 3: Figure 3.9 and Figure 3.13) (King et al., 1996; Mitchell et al., 
1996). Whilst meningococcal polysaccharide conjugate vaccines are effective, these data also 
suggest that protein-based meningococcal vaccines will produce higher bactericidal titres even 
in those individuals with no previous exposure to the bacteria. However, due to the variable 
nature of these antigens it is predicted that meningococcal protein vaccines will have 
significantly reduced strain coverage compared to meningococcal polysaccharide conjugate 
vaccines (Vogel et al., 2013). A vaccine consisting of both meningococcal proteins and 
polysaccharides will most likely produce higher bactericidal titres than the polysaccharide only 
counterparts. 
 
6.2 Interaction of Human and Rabbit Complement Pathways with 
Neisseria Meningitidis 
 SBAs using rabbit serum as the source of complement commonly produce much higher 
titres in those using human serum (Borrow et al., 2001a; Jodar et al., 2000; Maslanka et al., 1997; 
Zollinger and Mandrell, 1983). Previous studies have shown species-specific interaction of 
complement regulators with Neisseria meningitidis. Specifically, the outer membrane protein 
FHbp binds human FH but not rabbit FH (Granoff et al., 2009). As such, the alternative pathway 
of human complement, and not rabbit complement, is actively regulated by the bacteria. The 
relative contribution of rabbit complement pathways to complement activation on Neisseria 
meningitidis has not previously been investigated, but is hypothesised that the alternative 
pathway of rabbit complement contributes significantly more to complement activation than 
the alternative pathway of human complement.  
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The contribution of the lectin, alternative and classical pathways to complement 
activation on Neisseria meningitidis serogroup W-135 (strain 102/98) in the presence of human 
serum and BRS was invested using a series of pathway-specific inhibitors (Chapter 5: Figure 5.15, 
Figure 5.17 and Figure 5.18). Blocking the alternative pathway of rabbit complement 
significantly reduced complement activation. In contrast, blocking the alternative pathway of 
human complement had little impact on complement activation thus confirming that the 
alternative pathway of rabbit complement contributes significantly more to complement 
activation on Neisseria meningitidis serogroup W-135 (strain 102/98) than the alternative 
pathway of human complement. 
It has been previously shown that human FH bound to Neisseria meningitidis is able to 
regulate both human and rabbit complement (Granoff et al., 2009). We have shown that the 
addition of human FH to the source of rabbit complement reduces the SBA titre of vaccinee sera 
to levels comparable to when human serum is used (Chapter 5: Figure 5.19). The addition of 
human FH to rabbit complement in SBAs will somewhat normalised hSBA and rSBA titres, 
significantly reduce the number of false positives and ultimately improve the scrutiny of clinical 
trials assessing the efficacy of new meningococcal vaccines. The same effect may also be 
achieved with the addition of an alternative pathway inhibitor such as the anti-FB antibody used 
in this study (Subías et al., 2014). In a similar vein, human FH transgenic animals have resulted 
in the development of suitable animal models that may be used to assess the potential of new 
meningococcal vaccines pre-clinically (Granoff et al., 2009; Vu et al., 2012). Whilst the addition 
of human FH to rabbit serum may improve the specificity of the rSBA, it does not address the 
issue of the differential ability of human antibody subclasses to activate human and rabbit 
complement as investigated in this study. One potential solution to this is currently being 
explored by the Taylor Group at PHE. Endogenous bactericidal activity to Neisseria meningitidis 
is removed from human serum by fully depleting IgG by injecting serum over protein G (Brookes 
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et al., 2013). This means that large volumes of human serum can be prepared for use in SBAs, 
removing the requirement for use of rabbit serum.  
With the inclusion of FHbp in the recent generation of protein-based meningococcal 
vaccine antigens, FHbp has been studied extensively (Gorringe and Pajon, 2012; Jiang et al., 
2010; McNeil et al., 2013). Neisseria meningitidis expresses many other proteins that interact 
with the complement system of the host. These include PorB2, PorB3 and NspA which also bind 
FH, NalP which cleaves C3 into an inactive C3b-like fragment and a C3a-like fragment, and PorA 
which binds the classical and lectin pathway regulator C4BP (Giuntini et al., 2015; Jarva et al., 
2005; Lewis et al., 2010; Lewis et al., 2013). It is known that FHbp is specific for human FH and 
does not bind rabbit FH and that NalP cannot inactivate rabbit C3 (Del Tordello et al., 2014; 
Granoff et al., 2009). This species-specific complement regulation is thought to account for the 
far higher bactericidal activity of rabbit serum compared to human serum. The species-
specificity of the other FH binding proteins (PorB2, PorB3 and NspA) and the C4BP binding 
protein (PorA) has not been investigated but would be of great interest in understanding the 
differences between hSBA and rSBA titres. 
Single nucleotide polymorphisms present in genes coding for FH and FHR-3 are 
associated with increased susceptibility to meningococcal disease (Consortium, 2010). FHR-3 is 
a truncated homologue of FH lacking both co-factor and decay accelerator activity. FHR-3 
competes with FH for FHbp binding and it is thought that the relative serum levels of each either 
increase or protect against risk of disease (Caesar et al., 2014). Relatively higher levels of FHR-3 
binding to FHbp than FH will reduce survival of Neisseria meningitis is serum decreasing an 
individual’s susceptibility to disease. Whether FHR-3 competes with FH for binding to PorB2, 
PorB3 and NspA has not been investigated but may be vital in the understanding of protection 
against meningococcal disease. 
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6.3 Conclusions 
 In this project, I investigated the mechanisms responsible for differential bactericidal 
activities of human and rabbit complement against Neisseria meningitidis. We have described 
two predominant mechanisms responsible: the differential ability of human antibody subclasses 
to fix human and rabbit complement and species-specific differences in the interaction of each 
pathway of complement activation with Neisseria meningitidis (Figure 6. 2). Species-specific 
differences in the interaction of each pathway of complement activation with Neisseria 
meningitidis is responsible for the greatly elevated bactericidal titres achieved in SBAs using BRS 
as the complement source compared to those achieved using human serum. The differential 
ability of human antibody subclasses to fix human and rabbit complement is responsible for the 
poor correlation between hSBA and rSBA titres. The data from this project further question the 
use of rabbit serum as the source of complement in SBAs and provide significant insight into 
difficulties and challenges associated with interpretation of rSBA data. 
This study is of particular importance and relevance due to the recent increase in the 
incidence of invasive meningococcal disease caused by the hypervirulent serogroup W sequence 
type 11 complex. In the UK, the number of confirmed cases of meningococcal disease caused by 
serogroup W has increased from 22 in 2009/2010 to 176 in 2014/2015 despite an overall 
decrease in meningococcal disease (Ladhani et al., 2015; Ladhani et al., 2016). In 2014/2015, 
serogroup W accounted for 24.3% of invasive meningococcal infections compared to just 2.6% 
in 2009/2010. As a countermeasure, two quadrivalent meningococcal conjugate polysaccharide 
vaccines (Nimenrix™ and Menveo™) were introduced into the 2015 vaccination schedule (Lloyd 
et al., 2015). It is likely that other regions (such as South America, Europe, South Africa, China 
and United States), experiencing a similar increase in the incidence of meningococcal serogroup 
W disease, will also introduce quadrivalent vaccines into their public vaccinations programmes 
(Ladhani et al., 2015; Mustapha et al., 2016).  
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Figure 6. 2 Mechanisms Responsible for Differential Bactericidal Activities of Human 
and Rabbit Complement against Neisseria meningitidis. 
Bactericidal titres achieved in SBAs using rabbit serum (rSBA) as the source of complement are 
significantly higher than and correlate poorly with bactericidal titres achieved in SBAs using 
human serum (hSBA) as the source of complement. Two mechanisms are proposed for the 
differential bactericidal activities of human and rabbit complement against Neisseria 
meningitidis. a, The outer membrane protein FHbp of Neisseria meningitidis binds human FH 
but not rabbit FH. As such, the alternative pathway human complement and not rabbit 
complement is regulated reducing hSBA titres in relation to rSBA titres. b, rSBA and hSBA titres 
correlate poorly due to the differences between the ability of human antibody subclasses to 
activate human and rabbit complement. A greater IgG2 and IgM antibody response to 
meningococcal vaccines produces disproportionately increased rSBA titres compared to hSBA 
titres whereas a greater IgG1 and IgG3 antibody to meningococcal vaccines produces 
disproportionately increased hSBA titres compared to rSBA titres.  
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